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Cell migration and invasion play a key role in the breast cancer progression and are 
considered hallmarks of cancer. Migration requires the reorganization of the actin 
cytoskeleton, a process known to be regulated by Rho family GTPases via interaction with 
downstream effector proteins. p21-activated kinase (PAKs) are a family of six 
serine/threonine protein kinases, which are activated by the RhoGTPases Rac1 and/or Cdc42. 
PAKs have been implicated in many cellular process including cytoskeleton organization, 
cell motility, cell cycle progression, cell migration and cell survival. Overexpression of PAK 
isoforms has been found in different human cancer tissues including breast. Therefore, PAKs 
may provide a therapeutic target for the prevention breast cancer progression and metastasis. 
Whilst much is known about the biology of PAK1 less is known about the more recently 
described family member PAK6. Although, there is some evidence to suggest PAK6 is 
overexpressed in cancer cell lines relatively little is known about the role of PAK6 in cancer 
progression. This study detected endogenous PAK6 expression in multiple breast cancer cell 
lines. Moreover, in MDA-MB-231 cells expression of activated PAK6 induced cell rounding, 
whilst PAK6 deficient cells exhibit an elongated phenotype. Interestingly, this study has also 
found that treatment with Panobinostat reduces PAK6 expression and phenocopies the cell 
morphology observed for PAK6 knockdown cells. Furthermore, through 
immunoprecipitation and mass spectrometry analysis, interactions between PAK6 and 
unconventional RhoGTPases in breast cancer cells were identified in addition to interactions 
between PAK6 and regulators of cellular contractility. Taken together our results suggest that 
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1. Chapter 1: Introduction 	  
1.1. Breast cancer 	  
Breast cancer is a complex and heterogeneous disease and despite the recent advances in the 
understanding of the mechanisms of breast cancer progression and novel therapeutics, it 
remains the most common cause of cancer morbidity in women worldwide (Siegel et al., 
2012, Jemal et al., 2011). Approximately, 10-15% of diagnosed breast cancer patients 
develop distant metastasis within three years (Weigelt et al., 2005). Multiple factors can 
influence the development of breast cancer and these include obesity, excessive alcohol 
consumption, limited physical activity and/or the use of oral contraceptives and hormonal 
therapy for menopause treatment (Marchbanks et al., 2012, Shin et al., 2010, Hortobagyi et 
al., 2005, Parkin and Fernández, 2006, Youlden et al., 2012). In addition, genetics can also 
play a prominent role as a risk factor for breast cancer. In 65%-80% of hereditary breast 
cancers, there are mutations in the tumour suppressor genes BRCA-1 and BRCA-2 that 
increase the risk of developing the disease (Ripperger et al., 2008).  
Breast cancer subtypes can be defined by the expression of different combinations of 
markers. The expression of progesterone receptor (PR) and estrogen receptor (ER) is 
commonly referred to as hormone receptor positive disease. Some patients exhibit ERBB2-
amplification (also known as human epidermal receptor-2 (HER2)). Alternatively, some 
patients are classified as triple negative as they lack the expression of PRs, ERs and HER2 
(Lorusso and Ruegg, 2012). An increased understanding of the biology of breast cancer has 
resulted in the identification of a number of potential molecular targets and the development 
of novel therapeutics. These include tyrosine kinase inhibitors (TKIs) directed towards 
different targets such as HER1, HER2, c-MET, FGF receptor (FGFR), IGF receptor (IGFR), 
intracellular signalling pathways (PI3K, AKT, ERK) as well as angiogenesis inhibitors 
(Higgins and Baselga, 2011). Some of these drugs are already being used in the clinic to treat 
patients with breast cancer; for example, the anti-HER2 agents trastuzumab and lapatinib 
(Higgins and Baselga, 2011). 
Despite trastuzumab being an effective treatment in early stage HER2 breast cancer, the 
majority of patients with advanced HER2 breast cancers develop trastuzumab resistance. 
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Trastuzumab resistance promotes epithelial to mesenchymal transition (EMT) transforming 
HER2+ disease into a triple negative breast cancer that requires additional treatment options 
(Higgins and Baselga, 2011). Although advances in the treatment of breast cancer have 
significantly enhanced the survival of patients, further treatment options for metastatic breast 
cancer are required, particularly, the identification of new therapeutic strategies that target 
metastatic recurrence and chemoresistance. 
1.1.1. Breast Cancer Progression 
  
Normal human breast glands contain a branching ductal-lobular system, which consists of 
two epithelial cell types. The outer layer of myoepithelial cells and the inner layer of luminal 
epithelial cells are separated from the interstitial stroma by an intact basement membrane 
(BM) (Figure 1.1) (Adriance et al., 2005). Myoepithelial cells form a natural border to 
separate proliferating epithelial cells from the BM and underlying stroma (Deugnier et al., 
2002). The disruption of both the BM and the myoepithelial cell layer promote breast tumour 
invasion progression and metastasis (Man and Sang, 2004, Man, 2007, Gudjonsson et al., 
2002). 
Breast tumours are mainly found to be epithelial in origin and arise from the terminal ductal 
lobular unit. The disease progresses from an atypical epithelial hyperplasia into either ductal 
carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). In-situ carcinoma is defined as 
the presence of proliferating tumour cells that have undergone malignant transformation but 
remain at their site of origin, confined by a basement membrane (Polyak, 2007, Sakorafas 
and Tsiotou, 2000, Sakorafas et al., 2008). Invasive breast cancer (IBC) is described as a loss 
of myoepithelial cell layer and breakdown of the basement membrane. At this stage the 
tumour cells invade surrounding stroma, intravasate local vasculature and migrate to distant 
sites; this process is termed as metastasis (Richie and Swanson, 2003). 
 
 







Figure 1.1: A cross-section of normal mammary gland duct. Normal breast ducts are 
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The development of primary tumour and subsequent metastasis is now thought to involve the 
acquisition of multiple genetic alterations including both gene activation and inactivation 
over time (Weigelt et al., 2005). Moreover, more recently the tumour microenvironment has 
been implicated in driving cancer progression (Yoder et al., 2007). Taken together, these data 
reveal the extreme complexity involved in breast cancer progression and the need to gain a 
better understanding of the mechanisms that contribute to the development of various stages 
of the disease, including invasion, migration and metastasis.  
1.2. Carcinoma Metastasis  	  
Metastatic disease is the most prevalent cause of cancer related mortality due to its systemic 
nature and the resistance of tumour cells to existing treatments. Tumour progression towards 
metastasis includes a serious of changes in cell behaviour, driven by oncogenic 
transformation. Although there are many cellular processes that require cell migration, this 
study has focused on breast cancer cell migration. Breast cancer has the potential to spread to 
almost any region of the body and the most common secondary site is bone, followed by lung 
and liver (Weigelt et al., 2005). However, since the treatment opportunities for advanced 
metastatic breast cancer are limited, it is the late stage of the disease that accounts for the 
highest number of breast cancer deaths. 
 
Primary tumours initiate as a consequence of multiple mutations and epigenetic changes 
altering key genes that affect cell proliferation and survival. In order for cells to metastasise, 
there are a number of key cellular step changes required including the detachment from the 
primary tumour, local invasion, intravasation into the blood or lymphatic system, 
dissemination and extravasation, and subsequent outgrowth at distal, secondary sites (Figure 
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Figure 1.2: Metastatic cascade of breast cancer. A) A section of normal mammary 
gland duct. B) In situ carcinomas where the abnormal cells are epigenetically and 
phenotypically transformed. C) Invasive carcinoma here breakdown of the basement 
membrane causes tumor cells to invade to surrounding tissues and migrate to distant 
organs; leading to micro metastases. D) Schematic representative magnification of 
epithelial carcinoma as a multistage process involving (1) aberrant growth and 
proliferation to form a primary tumour. (2) Tumour cells eventually acquire a migratory 
phenotype and invade through the basement membrane. (3) Tumour cells entering blood 
or lymphatic vessels by intravasation. (4) Tumour cells extravasate (5) Tumour cells 
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The ability of the disseminated cells to survive and proliferate at new sites is dependent on 
key interactions between the tumour cells and their microenvironment (Chambers et al., 
2002). Improving knowledge of the basic biology at each step contributing to the metastatic 
process is crucial for improved therapeutic strategies (Figure 1.2).   
As illustrated in Figure 1.2, the cancer cells must first break away from the primary tumour, 
often undergoing epithelial mesenchymal transition (EMT). One of the key features of 
metastasis is that tumour cells transform from non-invasive cells to migrating, metastatic 
cancer cells. This transition process is initiated when the cells acquire the ability to dissociate 
from intercellular adhesions and become motile (Friedl and Wolf, 2003), which is usually 
driven by complex regulatory signalling cascades that transiently and/or permanently alter 
the expression of multiple proteins that act to reorganise the cytoskeletal network (Yamazaki 
et al., 2005). Down regulation of E-cadherin via aberrant transcriptional regulators, such as 
Snail and Twist is a hallmark of tumour progression leading to EMT by disturbing cell-cell 
adhesion (Hanahan, 2000, Vandewalle et al., 2005, Brabek et al., 2010, Hanahan and 
Weinberg, 2011). Such changes may then allow the cells to implement a more motile 
phenotype (Yilmaz and Christofori, 2010).  
 
In order to spread, the cancer cells must invade through the basement membrane (Hotary et 
al., 2006, Ihara et al., 2011), which involves the production of extracellular proteases 
(Deryugina and Quigley, 2006). Matrix metalloprotease (MMPs) are the most prominent 
protease that permits cancer cells to metastasise and whilst basement membrane and extra 
cellular matrix ECM degradation is their primary function, MMPs also regulate the pathways 
associated with cell growth and angiogenesis (Kessenbrock et al., 2010, Wolf et al., 2007). 
Previous reports have suggested that there is an increase in the expression of MMP9 in breast 
cancer tissues compared with normal breast tissues (Scorilas et al., 2001, Wu and Frost, 
2006, Wu et al., 2008, Bottino et al., 2014). Moreover, a meta-analysis study demonstrated 
that MMP9 overexpression could act as a biomarker suggesting unfavorable results on both 
overall survival (OS) and relapse-free survival (Song et al., 2013).  
Once the basement membrane has been penetrated, cancer cells can invade locally and 
disseminate from the primary tumour and enter the stroma (Valastyan and Weinberg, 2011). 
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Thus, this allows the malignant cells to migrate to a different site. 
1.3. The importance of cell migration  
 
Cell migration is a critical process in all-multicellular organisms and plays a significant role 
in carcinoma metastasis (Chaffer and Weinberg, 2011). Thus, fundamental mechanisms 
underlying cell migration are likely to provide suitable targets for effective therapeutic 
approaches for treating disease. Over the past few years, improvement has been made in 
understanding cell migration, including the establishment of polar structures and the 
mechanisms involved in regulating the dynamic process of actin and microtubule 
polymerisation (Ridley et al., 2003, Zigmond, 1996). 
Cancer cells can migrate through the ECM via two methods, either as individual cells 
(termed as single cells migration) or as a collective group (termed as collective migration). 
Single cell migration has two alternative mechanisms described as mesenchymal or 
amoeboid migration (Figure 1.3). The cells moving via mesenchymal type migration have a 
characteristic elongated morphology and extended long protrusions at their front. Molecules 
such as MMPs are recruited to aid in developing a pathway through the dense ECM 
meshwork (Brabek et al., 2010). In contrast, during amoeboid migration, cells have a 
rounded shape. This type of cell migration requires the activation of the Rho/ROCK pathway 
and subsequent phosphorylation of myosin light chain-2 (MLC-2) (Brabek et al., 2010, Sahai 
and Marshall, 2003, Webb and Horwitz, 2003).  
Three hallmarks characterize collective cell migration. First, the cells remain functionally 
and physically connected, which means that cells maintain their cell-cell junctions and 
migrate in cell clusters, files and sheets as shown in Figure 1.3, either separated or still in 
connection with their originating tissue (Sahai, 2005). Second, multicellular polarity and the 
organization of the actin cytoskeleton produce protrusion force and traction for migration. 
Third, in most modes of collective migration, moving cell groups structurally modify the 
tissue along the migration path, either by causing secondary ECM modification, involving 
the deposition of a basement membrane or by clearing the track. Cells invading collectively 
can adopt different morphologies, which depend on the number of cells, cell type and the 
structure of the tissue that is being invaded (Friedl and Alexander, 2011, Geiger and Peeper, 
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2009). In cancer, collective cell migration and invasion is found in different cancer types, 
including high and intermediate differentiated types of lobular breast cancer, melanoma, 
large cell lung cancer, prostate cancer, and most prominently in squamous cell carcinoma. In 
the most type of collective invasion, there are leader cells producing MMPs, which show 
similar characteristics to mesenchymal migration type cells and form the leading edge of 
multicellular strands, generating a forward traction and pericellular proteolysis of the invaded 
tissue. High-resolution multimodal microscopy has revealed that the guiding cells use β1-
integrin which mediated focal adhesions and at their leading edges expression of MT1-MMP 
to cleave collagen fibers and orient them in a way that generates tube like microtracks into 
which the collective mass migration of follower cells can occur. There is also described a less 
frequent type of collective invasion, where cells with strong epithelial polarity in soft tissues 
aggregate in a tip of multiple cells that protrude along the tissue space but change position, 
therefore lacking clear defined leader cells (Friedl and Alexander, 2011, Friedl et al., 1995, 
Wolf et al., 2007, Friedl and Wolf, 2008). 
 
A variety of intracellular signalling molecules are associated with cell migration, including 
mitogen activated protein kinase (MAPK) cascades, phospholipases, lipid kinases, 
serine/threonine or tyrosine kinases and scaffold proteins. Invasive cell migration requires the 
coordinated regulation of both actin cytoskeletal rearrangements and regulation of adhesive 
interactions with the microenvironment processes that are known to be regulated by Rho 
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Figure 1.3: Mechanisms of single cell or collective cell migration. Cells can migrate either 
individually or collectively via different mechanisms. Single cell migration can be separated 
into amoeboid cell movement involving rounded and highly contractile cells or mesenchymal 
cells, which have an elongated shape and use protease degradation. In collective cell 
migration a group of cells migrate in either a small cluster, file or a sheet. Figure is adapted 




	   25	  
1.4. RhoGTPases: family members and regulation  	  
RhoGTPases form a distinct family within the Ras-like protein superfamily, which also 
includes the Ras, Rab, Ran and Arf families (Vega and Ridley, 2008). Rho members differ 
from other Ras-like GTPases due to the presence of a Rho-specific insert domain. 
RhoGTPases are ubiquitously expressed. In mammals, 20 members have been identified and 
divided into eight different subfamilies: the RhoA, B and C subfamily, the Cdc42, the RhoJ 
and RhoQ subfamily, the Rac1, 2, 3 and RhoG subfamily, the RhoV and RhoU subfamily, 
the RhoD and RhoF subfamily, the RhoH subfamily, the Rnd1, 2 and 3 subfamily, and 
finally the RhoBTB 1 and 2 subfamily (Figure1.4). Out of these subfamilies, Rnd, RhoU, 
RhoH, RhoBTB and RhoV, have characteristics that make them atypical compared to the 
classical RhoGTPase Rho, Rac, Cdc42 and RhoD/RhoF subfamilies (Aspenström et al., 
2007, Ridley, 2013).  
The RhoGTPase subfamilies can be classified into two distinct types of RhoGTPases, the 
classical and the atypical RhoGTPase. Most classical Rho family members, including the 
Rho, Rac, Cdc42, RhoF and RhoD subfamilies, act as molecular switches to control signal 
transduction pathways through cycling between a GDP-bound inactive form and a GTP-
bound active form (Vega and Ridley, 2008). The RhoGTPases cycle is regulated by three 
groups of proteins; the Guanine nucleotide exchange factors (GEFs) stimulate the exchange 
of GDP for GTP to activate a GTPase, the GTPase activating proteins (GAPs) negatively 
regulate the switch by converting the proteins to the GDP-bound inactive conformation, and 
guanine nucleotide dissociation inhibitors (GDIs) bind to some but not all RhoGTPases, and 
prevent their interaction with the membrane by hiding the prenyl group as well as inhibiting 
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Figure 1.4: RhoGTPase family tree. RhoGTPases are a family of 20 proteins, divided into 
8 subfamilies. These families can be classified as classical or atypical, depending on their 





	   27	  
 
 
Figure 1.5: Regulation of RhoGTPase activity. RhoGTPases cycle between an inactivate 
GDP bound and an active GTP bound form. RhoGTPases are activated via GEFs and 
inactivated via GAPs. The binding of GDIs, which sequester the GTPase in the cytoplasm, 
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Consequently, GEFs, GAPs and GDIs play key roles in regulating classical Rho GTPases. 
However, the atypical members of the GTPase family infrequently shadow the simple 
scheme illustrated above and there is little evidence for the existence of GEFs or GAPs for 
atypical RhoGTPases. These proteins are permanently bound to GTP (Aspenström et al., 
2007, Chardin, 2006, Wennerberg, 2004), and their functions are likely to be regulated by 
protein:protein interactions, including types of domains that are absent in classical Rho 
proteins.  
Once activated, RhoGTPases interact with cellular target protein effectors to stimulate a 
variety of intracellular response (Bishop and Hall, 2000). More than 40 effectors, 80 GEFs 
and 80 GAPs have been described for the mammalian Rho family (Raftopoulou and Hall, 
2004, Tcherkezian and Lamarche-Vane, 2007, Ridley, 2016). RhoGTPases are also involved 
in regulating the dynamics of the actin cytoskeleton and provide a key signalling link through 
which spreading, adhesion and migration are organised and regulated (Lawson and Burridge, 
2014). 
1.4.1. RhoGTPases family members are regulators for     
cytoskeleton dynamics and cell migration 	  
The Rho family GTPases Cdc42, RhoA and Rac1 are well characterised in their ability to 
control actin polymerisation dynamics, and this is a fundamental requirement for cell 
migration. The actin cytoskeleton is responsible for regulating changes in cell shape as well 
as the generation of forces required for cells to migrate (Hall, 1998). In initial Rho GTPase 
studies, Swiss 3T3 cells were microinjected with activated RhoA to induce changes in cell 
morphology (Paterson et al., 1990). Subsequently, it was demonstrated that in fibroblasts, 
active mutants of RhoA and Rac1 prompt the generation of stress fibres or lamellipodia 
respectively (Ridley, 1992a, Ridley, 1992b). Lamellipodia that are generated by Rac1 can be 
recognised by their flat and broad morphology. Further studies revealed a role for Cdc42 in 
the induction of filopodia (Kozma et al., 1995, Nobes and Hall, 1995), which are 
characterised as finger like projections. Thus, RhoA, Rac1 and Cdc42 are central in 
remodelling actin during cell movement (Figure 1.6). As cell migration is a pre-requisite for 
cancer cell invasion, these RhoGTPases have been linked with cancer cell metastasis 
(Ellenbroek and Collard, 2007). 
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Although Rac1, Cdc42 and RhoA localise to lamellipodia protrusions (Machacek et al., 
2009), the subsequent response is dependent on their activation status, which may include 
cross talk between the proteins. Cdc42 can directly control Rac1 activation through PIX and 
Tiam1, which are both Rac GEFs (Li et al., 2003, Cau and Hall, 2005, Pegtel et al., 2007). 
Rac1 can inhibit the activation of RhoA via PAK induced inhibition of RhoAGEFs, including 
GEF-H1. Indeed, Rac1 and RhoA are mutually inhibitory proteins, with each able to inhibit 
the activity of the other (Sanz-Moreno et al., 2008, Machacek et al., 2009). The activation of 
ROCK through RhoA can activate LIM kinase (LIMK). While Rac and Cdc42, can activate 
LIMK via PAK activation, activated LIMK phosphorylates and inhibits the activation of 
cofilin, a protein that can promote actin depolymerization (Edwards et al., 1999, Stanyon and 
Bernard, 1999). This suggests that Rac could inhibit cofilin-induced depolymerization. 
However, it is also shown that cofilin is required for and promotes lamellipodium extension 
and cell migration (Aizawa, 1996, Chen et al., 2001), either by severing actin filaments and 
thus providing more barbed ends for actin polymerization and/or by promoting release of 
actin monomers that can then be reincorporated into growing actin filaments at the plasma 
membrane (Ridley, 2001, Zebda et al., 2000). 
The activation of Rac1 or RhoA or ROCK signalling pathways has been correlated with in 
vitro cell migration, as well as in vivo invasion and progression (Sahai et al., 2001, Itoh et al., 
1999, Kaneko et al., 2002). Therefore, pharmacological inhibitors that block RhoA, ROCK 
or MLCK are being developed to interfere with cancer cell invasion (Somlyo et al., 2003, 
Itoh et al., 1999, Kaneko et al., 2002, Sahai et al., 2001). Given their role in driving cell 
migration, it is not surprising that Cdc42, Rac1 and RhoA all contribute to the mechanisms 
by which tumour cells migrate. Indeed, Cdc42, Rac1 and RhoA control the amoeboid or 
mesenchymal phenotype of single cell migration via the reorganisation of the cytoskeleton. 
Cdc42 has a role in both mesenchymal migration to polarise the cell, and amoeboid 
migration through PAK2 to increase MLC phosphorylation and actomyosin contractility 
(Gadea et al., 2008). Furthermore, Cdc42 is a key inducer of the invasive protrusion, 
invadopodia, which are thought to be used by tumour cells to invade through the ECM 
(Murphy and Courtneidge, 2011). In support of this notion, studies have demonstrated that 
the depletion of Cdc42 reduces the metastasis of breast cancer in vivo (Reymond et al., 
2013). The activation of Rac1 promotes mesenchymal migration, which can be induced by 
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adaptor proteins such as NEDD9 or activators such as DOCK3 (Sanz-Moreno et al., 2008). 
Rac1 also inhibits the formation of an amoeboid cell shape by reducing actomyosin 
contractility (Sanz-Moreno et al., 2008). Moreover, cell invasion was also reduced by the 
depletion Rac1. 
In contrast, the amoeboid mechanism of migration is highly dependent on RhoA (Sahai and 
Marshall, 2003, Orgaz et al., 2014). The amoeboid migration occurs via the activation of 
ROCK that stimulate myosin light chain 2 to enhance myosin which induces actin 
contraction (O'Connor and Chen, 2013). The signalling pathways eliciting amoeboid 
migration may also result in the inhibition of mesenchymal migration. Amoeboid migration 
occurs by the activation of ARHGAP22, which is stimulated by ROCK, and in turn, inhibits 
the activation of Rac1 (Sanz-Moreno et al., 2008). Moreover, the inhibition of blebbistatin 
and ROCK by the inhibitor (H1152) results in mesenchymal migration of elongated cells 
(Sanz-Moreno et al., 2008). 
Antagonism between Rac1 and RhoA contributes to their polarising actions on cells (Meili 
and Firtel, 2003, Xu et al., 2003, Burridge and Wennerberg, 2004, Caron, 2003). Rac1 
inhibits RhoA through its activation of p190RhoGAP (Nimnual et al., 2003). In addition, the 
inhibition of Rac1 activity can be dependent on raised RhoA activity, which is associated 
with an increase in actomyosin contractility. RhoA stimulation of ROCK mediated 
phosphorylation and activation of the FilaminA-associated protein FilGAP may contribute to 
the suppression of Rac1 activity (Figure 1.6) (Ohta et al., 2006, Shifrin et al., 2009). 
FilaminA links the cytoplasmic tails of β integrin subunits to actin, and external shear or 
myosin II-dependent force production can result in the dissociation of FilGAP from 
FilaminA (Ehrlicher et al., 2011). FilGAP has been shown to promote mesenchymal-to-
amoeboid transition downstream of ROCK (Saito et al., 2012). Moreover, it is reported that 
RacGAP1 can inhibit Rac at the latter stages of adhesion (Jacquemet et al., 2013). This Rac-
specific GAP is recruited to sites of β1-integrin activation in the lamellipodia of spreading 
cells by a complex involving FilaminA and IQGAP1, which does not have intrinsic GAP 
activity (Jacquemet et al., 2013). 
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Figure 1.6: Rho GTPase regulation of cell migration. During cell migration Rho GTPases 
regulate activities in different areas of the cell. RhoA, Cdc42 and Rac1 are key examples of Rho 
GTPase family members participating in these processes. Both Cdc42 and Rac1 are activated at 
the leading edge of the cell, where Cdc42 establishes the polarity and directionality of cell 
movement, whilst activated Rac induces lamellipodium extension. In this region of the cell, both 
Cdc42 and Rac1 can suppress RhoA activity. RhoA activation initiates the formation of actin 
bundles or stress fibres, containing myosin II, which generate contractile forces via ROCK and 
myosin II. These forces lead to cell body contraction that coupled with the tail retraction allow the 
cell to move forward. Moreover, RhoA can suppress Rac1 activity, preventing the generation of 
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1.4.2. The atypical RhoGTPases family and tumourigenesis  	  
The atypical RhoGTPases do not generally appear to be regulated in the same way as 
classical RhoGTPases which are regulated by GTP–GDP cycling. Instead, the atypical 
RhoGTPases are constitutively GTP-bound, because they either have substitutions in their 
GTPase domain that prevent GTPase activity or possess high intrinsic nucleotide exchange 
activity (Hodge and Ridley, 2016). RhoU and RhoV have a high intrinsic nucleotide 
exchange rate in vitro. Whilst the Rnd (Rnd1, Rnd2 and Rnd3/RhoE), RhoH and RhoBTB 
proteins (RhoBTB1 and RhoBTB2) have amino acid substitutions that prevent them from 
hydrolysing GTP. These amino acid substitutions are at the equivalent amino acids that are 
mutated in Ras oncogenes, and known to prevent/decrease GTP hydrolysis. Furthermore, 
these atypical family members have unique N-terminal and C-terminal extensions to the 
standard G-domain (Borda-d’Agua et al., 2014). The subfamily including RhoF, RhoD, 
RhoQ, RhoJ are also considered to be atypical as they exhibit a high intrinsic exchange 
activity and therefore bound GTP under equilibrium and quiescent conditions (Jaiswal et al., 
2013). During cell migration, there are interactions between atypical and classical Rho-
family GTPases. RhoD, Rnd1, Rnd3, and RhoJ antagonize the Rho-mediated actin 
remodelling during cell migration. RhoG activates Rac by recruiting the ELMO/DOCK 
complex. RhoU promotes cell migration through activation of Rac, whereas RhoH 
antaintergonizes Rac-mediated actin reorganization and cell migration (Figure 1.7). RhoV 
also antagonizes cell migration by promoting PAK degradation. In endothelial cells, Rnd2 
and Rnd3 promote RhoB-induced stress fiber formation. RhoD regulates the reorganization 
of actin through the activation of ZIPK and Arp2/3. RhoF activates mDia and is involved in 
the targeting of active ROCK to the cell cortex (Sadok and Marshall, 2014). In this thesis will 
be focused in RhoU and RhoV in more details. 
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Figure 1.7: Interplay between atypical and classical Rho-family GTPases during cell 
migration. RhoU stimulates cell migration through activation of Rac, whereas RhoH 
antaintergonizes Rac-mediated actin reorganization and cell migration. RhoV also antagonizes 
cell migration by promoting PAK degradation. RhoF activates mDia and is involved in the 
targeting of active ROCK to the cell cortex. RhoD, Rnd1, Rnd3, and RhoJ antagonize the 
Rho-mediated actin remodelling during cell migration. Rnd2 and Rnd3 promote RhoB-
induced stress fiber formation. RhoD regulates the reorganization of actin through the 
activation of Arp2/3 and ZiPK. RhoG activates Rac by recruiting the ELMO/DOCK complex. 
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RhoU (also known as Wrch1) was identified in 2001 as a Wnt-inducible gene (Tao et al., 
2001), whereas RhoV (also known as Chp) was first discovered in 1998 as a p21-activated 
kinase-2 (PAK2) interacting protein (Aronheim et al., 1998). Although RhoU and RhoV 
share sequence similarities with Cdc42, unlike other Rho family members, both have a N-
terminal proline-rich domain that is not present in other Rho family members. This domain 
can bind to SH3 domain-containing proteins such as Nck2 and Grb2, which increase RhoU 
activity (Aspenström et al., 2007, Shutes et al., 2004, Saras et al., 2004). Moreover, RhoU 
and RhoV are modified by palmitoylation but unlike other Rho family members they do 
not undergo isoprenylation (Berzat et al., 2005, Chenette et al., 2005b). Palmitoylation is a 
reversible process, which allows proteins to associate transiently with membranes, 
regulating their localisation and trafficking (Baekkeskov and Kanaani, 2009). RhoU and 
RhoV localisation are affected by inhibitors of protein palmitoylation but not by inhibitors 
of protein prenylation (Berzat et al., 2005, Chenette et al., 2005b).  
 
RhoU and RhoV have been associated with roles in adhesion, migration, cell proliferation 
and transformation. Overexpression of RhoU or RhoV has been revealed to stimulate 
lamellipodial or filopodial extensions and/or integrin based focal adhesions (Aronheim et 
al., 1998, Aspenström et al., 2007, Chuang et al., 2007). RhoU localises to focal adhesions 
in HeLa cells and depletion of RhoU increased focal adhesion formation and inhibited cell 
migration (Chuang et al., 2007). PAK4 and RhoU cooperate to drive adhesion turnover and 
promote cell migration in MDA-MB-231 cells. Loss of RhoU expression reduces cell 
adhesion turnover and migration, whereas overexpression of RhoU rescues the PAK4 
depletion phenotype (Dart et al., 2015). RhoU has also been localised to podosomes and is 
thought to influence integrin signalling in osteoclasts (Brazier et al., 2009). On the other 
hand, RhoU depletion reduced adhesion and migration in T-acute lymphoblastic leukaemia 
cells (Bhavsar et al., 2013). Similarly, neural crest cells were shown to adhere poorly when 
depleted of RhoU and had a rounded morphology (Fort et al., 2011). Therefore, RhoU plays 
an essential role in adhesion of cells to extracellular matrix, which impacts on cell 
migration but its specific function may be cell type specific. 
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RhoU is up regulated by the Wnt signalling pathway. Consequently, RhoU could be involved 
in Wnt-driven oncogenic transformation (Tao et al., 2001). It is reported that RhoU can be up 
regulated or down regulated in some primary tumours (Aspenström et al., 2007, Shutes et al., 
2004) but it is not known whether this correlates with the levels of Wnt signalling. 
Overexpression of RhoU stimulates actin cytoskeletal reorganisation including the formation 
of filopodia and dissolution of stress fibres (Saras et al., 2004). Moreover, RhoU stimulates 
the cell cycle progression and the transformation of fibroblasts when overexpressed (Tao et 
al., 2001, Shutes et al., 2004). Whether this reflects RhoU physiological function or is just a 
consequence of sequence similarity to Cdc42 is not known (Vega and Ridley, 2008).  
Several binding partners for RhoU have been identified including Grb2, NCK, FAK and 
PAR6. In pancreatic cancer cells upon epidermal growth factor (EGF) stimulation, RhoU 
colocalises with the EGF receptor on endosomes in a Grb2-dependent manner (Zhang et al., 
2011). RhoU binds Pyk2 the non-receptor tyrosine kinase. This interaction requires RhoU to 
be in a GTP-bound form and also involves the N-terminal proline-rich extension. Moreover, 
The interaction depends on the presence and activity of Src and has a role in filopodium 
formation in fibroblasts.(Ruusala and Aspenstrom, 2008). RhoU relocates to the plasma 
membrane upon serum stimulation in H1299 non-small cell lung cancer cells. The serum 
stimulation induces Src-mediated tyrosine phosphorylation of RhoU on Tyr254. This 
phosphorylation reduces GTPase activity and the ability of RhoU to interact with 
downstream effectors (Alan et al., 2010). In epithelial cells, RhoU was identified to bind to 
the scaffolding protein Par6 , which is well known for its role in regulating polarity 
downstream of Cdc42. This interaction was recognized affect epithelial cell tight junctions 
assembly and actin organization (Brady et al., 2009, Chen and Zhang, 2013). Much less has 
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The interaction of RhoU with Nck2 could recruit these proteins indirectly and thereby 
promote cell migration (Blasutig et al., 2008). Nck SH2/SH3 adaptors act cooperatively to 
induce actin reorganisation; however, how RhoU proteins contribute to cancer progression 
mechanistically is still unknown. RhoV is abundant in cancer cell lines and others have 
shown that RhoV is up regulated in some human cancers (Aronheim et al., 1998). RhoV 
differs from RhoU at the C-terminus, which lacks a CAAX box and has a unique 32 amino 
acid sequence. Moreover,	  overexpression	  of	  RhoV	  can	  stimulate	  apoptosis	  and	  activation	  of	   Jun	   N-­‐terminal	   kinase	   (JNK)	   signalling	   pathway	   via	   both	   death	   receptor-­‐mediated	  and	   mitochondrial	   apoptotic	   pathways	   as	   determined	   by	   caspase-­‐8	   and	   caspase-­‐9	  activation,	  (Aronheim	  et	  al.,	  1998,	  Shepelev	  et	  al.,	  2011).	  This	  suggests	  a	  potential	  role	  of	   RhoV	   in	   regulating	   apoptosis	   in	   a	   JNK-­‐dependent	   manner,	   but	   the	   association	  between	  RhoV	  and	  cancer	  progression	  remains	  to	  be	  determined.	   
Both RhoU and RhoV bind to some of the PAK family members, which are well known as 
effectors of Rac and Cdc42 (Aronheim et al., 1998, Tao et al., 2001). PAKs regulate cell 
migration and invasion and their overexpression is observed in some human tumours 
(Dummler et al., 2009). Deletion N-terminal of RhoU enhances its ability to bind PAK1 
(Shutes et al., 2004). Overexpression of RhoV prompts downregulation of PAK1 and induces 
lamellipodia possibly through interaction with PAK2 (Aronheim et al., 1998, Weisz 
Hubsman et al., 2007). In MDA-MB231 cells, RhoU bind to PAK4. This interaction is kinase 
independent (Dart et al., 2015). In human embryonic kidney (HEK) cells, RhoV and RhoU 
bind to PAK6. Interaction between PAK6 and RhoV depends on the activation state of the 
GTPase, suggesting that PAK6 is an effector for RhoV. However, the interaction between 
PAK6 and RhoU were weaker (Shepelev and Korobko, 2012).  
The ability of cancer cells to invade and metastasise is an important area of extensive 
research, and the identification of factors, proteins and signalling networks that contribute to 
this process is now required. One group of effector proteins downstream of RhoGTPases and 
contributing heavily to cell migration and metastasis are the family of p21-activated kinases 
(PAKs). 
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1.5. p21 activated kinase (PAK) 	  
1.5.1. PAKs overview  	  
The p21-activated kinases (PAKs) are serine/threonine kinases initially identified in screens 
for Cdc42 and Rac effectors, and there are six PAK isoforms (Manser et al., 1994, King et 
al., 2014). These kinases are highly conserved across a wide range of organisms including 
flies, yeast and humans (Bokoch, 2003). Human PAKs subdivide into two groups; based on 
their structural similarities, sequence homology and regulation. Group I PAKs include 
PAK1-3, and group II PAKs include PAK4-6 (Arias-Romero and Chernoff, 2008, Bokoch, 
2003). 
It is well known that PAKs act as effectors for a wide range of different signalling pathways. 
Activated PAKs can relocalise to the nucleus, where they can manipulate gene transcription 
(Li et al., 2012, Tao et al., 2011, Sells and Chernoff, 1997), or alternatively, localise to the 
leading edge of cells to influence cytoskeletal organisation and thereby contribute to cellular 
motility (Arias-Romero and Chernoff, 2008, Bagrodia et al., 1999). Furthermore, it has been 
shown that PAKs can also function in hormone signalling (Lee et al., 2002, Schrantz et al., 
2004, Rayala et al., 2006), changes in cell morphology (Cau et al., 2001, Manser et al., 1997, 
Zeng et al., 2000) and cell survival or apoptosis (Cotteret et al., 2003, Ong et al., 2011, Ye 
and Field, 2012). 
Depletion of PAK genes in mice has different effects on viability and phenotype; depending 
on which PAK isoform has been silenced. In knockout studies, PAK1, PAK5 and PAK6 
exhibited no obvious developmental requirement, as knockout mice are viable and fertile. 
However, PAK5 and PAK6 double knockout mice have deficits in locomotors activity as 
well as learning and memory but no reduction in their viability or fertility. (Arias-Romero 
and Chernoff, 2008, Nekrasova et al., 2008). In contrast, PAK2 and PAK4 knockout mice are 
embryonically lethal, which suggests essential roles for these two PAK isoforms during 
development (Arias-Romero and Chernoff, 2008, Qu et al., 2003). PAK3 knockout mice are 
viable but exhibit defects in synaptic plasticity, implicating crucial roles for PAK3 in neural 
differentiation (Qu et al., 2003).  
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1.5.2. Domain architecture of PAKs  	  
PAKs exhibit significant sequence homology to the yeast Ste20 protein kinase (Bagrodia et 
al., 1999, Sells and Chernoff, 1997). Outside of the kinase domain, the sequences of PAKs 
and Ste20 protein kinase differ significantly except for a 60 amino acid sequence at the N-
terminal, identified as the p21-GTPase binding domain (GBD) (Sells and Chernoff, 1997). 
All PAKs contain an N-terminal GBD as well as a highly conserved C-terminal catalytic 
serine/threonine kinase domain (Figure 1.8). Group I PAKs have a Cdc42/Rac interactive 
binding region (CRIB) within the GBD, which overlaps with an autoinhibitory domain (AID) 
(Arias-Romero and Chernoff, 2008, Eswaran et al., 2007, Whale, 2011). In contrast, group II 
PAKs were not thought to contain an AID regionally, but more recently a putative AID has 
been identified in PAK4 (Baskaran et al., 2012), and this region is conserved across in all 
group II PAKs (Dart and Wells, 2013). Moreover, all PAK proteins contain a different 
number of proline motifs (PxxP), which are putative binding sites for the SH3 domain 
containing proteins (Jaffer and Chernoff, 2002). The SH3 domain located at the extreme N-
terminal region of PAK1 promotes the binding of the adaptor protein Nck (Bokoch et al., 
1996) and growth factor receptor bound protein 2 (Grb2) (Puto et al., 2003). In addition, 
PAK1 interacts with the PAK-interacting exchange factor (PIX) (Manser et al., 1998), which 
leads to the translocation of a PAK1-Nck complex to the plasma membrane upon receptor 
activation (Lu et al., 1997). The N-terminal sequence to the GBD is smaller in group II PAKs 
compared to that in group I PAKs. PAK5 has been shown to possess an inhibitory region that 
is approximately 120 amino acids in size (Ching et al., 2003). It is reported that in PAK4, 
there is a GEF-H1/Gab1- interacting domain (GID), which binds to PDZ-RhoGEF (Barac et 
al., 2004a, Callow et al., 2005a). PAK4 has also been shown to interact with the integrin 
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The kinase activity of PAK4 is critical, PAK4 mediated phosphorylation of two serine 
residues in the integrin β5 cytoplasmic domain (Li et al., 2010). These phosphorylation 
events help to accelerate integrin αvβ5 turnover within adhesions through inhibition of 
integrin αvβ5 clustering, connections to F-actin and preventing adhesion maturation (Li et al., 
2010), which is dependent on PAK4 kinase activity and promotes cell motility.  
Although there are conserved structural regions within the PAK family of proteins, all of the 
isoforms are structurally different, suggesting that these sequences could provide different 
functional roles, substrate specificity and also allow recognition of specific target sequences 
on binding partners (Arias-Romero and Chernoff, 2008, Rennefahrt et al., 2007, Wells and 
Jones, 2010). However, despite these structural variances, PAK4 and PAK1 can also share a 
number of substrates as shown in Table 1.1.  
PAK6 kinase is unique among PAKs in that this protein possesses an FXXMF motif, which 
links directly to the androgen receptor (AR) ligand-binding domain (LBD) (van de Wijngaart 
et al., 2006). Although PAK6 is similar to PAK1 and binds to the alpha isoform of the 
estrogen receptor (ER) (Lee et al., 2002, Wang et al., 2002), PAK6 is the only PAK family 
member shown to interact with the AR (Yang et al., 2001). Similarities and differences 
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Figure 1.8: PAK family member and structures. There are six members of PAK family 
kinases, which are divided into two groups according to structural similarities and sequence 
homology. All PAKs contain a variable number of proline rich regions, which are putative 
binding sites for SH3 domain containing proteins. Group I PAKs also contains PIX binding 
site in the central region and Nck binding site at the N-terminal (indicated in green and 
yellow, respectively). Specific to PAK4, a β5-integrin binding site (although this region is 
highly homologous among the other PAK family members) and a GEF-H1/Gab1 interacting 
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          Table 1.1: PAK substrates. 
Substrate  Cellular function  PAK  Reference  
Caldesmon  Inhibitor of myosin ATPase activity  PAK1 & 3  (Foster et al., 2000)  
CPI17  Inhibitor of myosin phosphatase  PAK1  (Takizawa et al., 2002) 
Desmin  Intermediate filament protein  PAK1  (Ohtakara et al., 2000) 
FilaminA  Actin cross linking and adhesion protein  PAK1  
(Vadlamudi et al., 
2002a) 
GIT1  GTPase regulation Arf GAP  PAK1  (Zhao et al., 2005) 
GEF-H1  RhoGTPase regulation, RhoA GEF  PAK1 & 4  
(Zenke et al., 2004a) 
(Callow et al., 2005b) 
LIMK1  Actin cytoskeleton dynamics; cofilin kinase  
PAK1, 2 
& 4  
(Dan et al., 2001a) 
(Edwards et al., 1999) 
MLCK  
Regulation of myosin activity 
and actin cytoskeleton 
dynamics  
PAK1 & 2  (Sanders et al., 1999) (Goeckeler et al., 2000) 
Merlin  ERM binding protein  PAK2  (Kissil et al., 2002) 
p41-ARC  Subunit of Arp2/3 complex, actin nucleation  PAK1  
(Vadlamudi et al., 
2002a) 
Paxillin  Focal adhesion scaffold  PAK4  (Wells et al., 2010b) 
PDZ-RhoGEF  RhoGTPase regulation, RhoA GEF  PAK4  (Barac et al., 2004b) 
PIX  RhoGTPase regulation, Rac GEF  PAK1 & 2  
(Shin et al., 2002, ten 
Klooster et al., 2006) 
Raf-1  MEK kinase  PAK1,2, 3&4  
(King et al., 1998, Zang 
et al., 2002) 
Rho-GDI  Inhibitor of RhoGTPase activity  PAK1  
(DerMardirossian et al., 
2004) 
R-MLC  Regulatory chain of myosin motor  PAK2  (Chew et al., 1998) 
SSH-1  Actin cytoskeleton dynamics; cofilin phosphatase  PAK4  (Soosairajah et al., 2005) 
Vimentin  Intermediate filament protein  PAK1  (Goto et al., 2002) 
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1.5.3. Regulation of PAK activity  	  
Group I PAKs have a low basal level of kinase activity, which is enhanced by the binding of 
Cdc42 or Rac1 to the GBD. In the inactive state, the group I PAKs form unphosphorylated 
homodimers whereby the AID binds to the kinase domain and prevents its activity. Active 
Cdc42 or Rac1 binding to GBD of group I PAKs disrupts dimerisation, resulting in 
autophosphorylation at several serine residues and single threonine residue (corresponding to 
Thr423 in PAK1 and Thr402 in PAK2), located within the activation loop of the kinase domain 
which results in kinase activation (Zenke et al., 1999, Arias-Romero and Chernoff, 2008, 
Eswaran et al., 2008, Molli et al., 2009). Distinctively, the PAK3 gene has splice exons that 
have been detected in the GBD/AID region, resulting in four splice variants (Kreis et al., 
2008). These splice variants have not been identified in PAK1/2. The change in GBD/AID 
structure of three PAK3 variants results in increase the kinase activity and modifies the 
GTPase binding. The expression of the new PAK3 (PAK3b, PAK3c, and PAK3cb) splice 
variants in transfected COS7 cells, induces morphological changes of cell shape and leads to 
modifications of focal adhesion structure (Kreis et al., 2008).  
In contrast to group I PAKs, the binding of active Cdc42 has no significant impact on the 
kinase domain of group II PAKs. It is reported that PAK4 has a high basal kinase activity 
that is not affected by the binding of the activated small GTPases, Cdc42 and Rac1(Abo et 
al., 1998). With the exception of PAK5, it was originally thought that group II PAKs had no 
AID present and there has been much speculation over the regulation of PAK4. Recently, 
however, studies have suggested two possible mechanisms of PAK4 activity regulation. The 
first mechanism identifies a potential AID located in the N-terminal domain that is composed 
of amino acids 20-68, which is thought to maintain PAK4 in an inactive conformation until 
the binding of active Cdc42 leads to structural changes causing PAK4 activation (Baskaran et 
al., 2012). In another study, researchers proposed that the PAK4 regulatory domain possesses 
an N-terminal autoinhibitory pseduosubstrate motif, which binds the kinase domain (Ha et 
al., 2012). These reports suggest that PAK4 activity is controlled by the N-terminal AID and 
not by the autophosphorylation of PAK4 at Ser474, which is now suggested to be 
constitutively phosphorylated at this site. Moreover, as this region is highly conserved in all 
group II PAKs it is likely that this process of regulation is also exhibited by PAK5 and 
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PAK6.  
The regulation of PAK kinase activity not only occurs through the interaction of Cdc42 and 
Rac1 GTPases but also via a variety of different proteins and pathways. PAKs activated by 
extracellular signals can contribute to several signalling networks. PAKs can activate 
mitogen-activated protein kinase (Menges et al., 2012) as well as phosphorylating a number 
of regulators of the cytoskeleton, such as LIM domain kinase (LIMK), PAK1 can activate 
LIMK1 (Edwards et al., 1999), and  PAK4 can bind to and phosphorylate LIMK1, which 
stimulates phosphorylation of cofilin (Dan et al., 2001b). Furthermore, the phosphorylation 
of the pro-apoptotic proteins BAD and dynein light chain 1 (DLC1) provide another pathway 
that PAK1 could stimulate to enhance breast cancer cell survival. A number of studies have 
demonstrated that PAK1 and/or PAK2 can directly phosphorylate myosin light-chain (MLC), 
thereby increasing contractility (Zeng et al., 2000).  
The interaction between PAK6 and active Cdc42 does not enhance PAK6 kinase activity 
(Schrantz et al., 2004), but it is likely that this association modulates PAK6 localisation as 
observed for PAK4 (Abo et al., 1998). PAK6 interacts with Rac1(Civiero et al., 2015) and 
the atypical RhoGTPase family member, RhoV, which has 52% sequence homology to 
Cdc42, and RhoV has been implicated in the modulation of cytoskeletal dynamics 
(Aronheim et al., 1998, Shepelev and Korobko, 2012). It has been reported that full-length 
PAK6 exhibits reduced kinase activity when compared to a truncated version of PAK6 
containing only the protein kinase domain (Yang et al., 2001). This suggests that PAK6 may 
also be autoinhibited. PAK6 kinase activity can also be regulated by MAPK signalling 
cascade. Phosphorylation by MAPK at serine 165 activated protein kinase kinase 6 (MKK6) 
activates PAK6 (Kaur et al., 2005). Moreover, autophosphorylation of PAK6 at serine 560 is 
required for MKK6-facilitated activation (Kaur et al., 2005). Furthermore, the results from 
kinase activity studies suggest that the AR may also have a role in regulating PAK6 kinase 
activity in prostate cancer cells (Lee et al., 2002). 
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1.5.4. PAK expression in cancer 
 
Given that PAKs are involved in many cellular activities including proliferation, cell cycle 
regulation and apoptosis, it is likely that this family of kinases may also have roles in 
regulating cancer growth and progression. The overexpression of group I PAKs is detected in 
a wide variety of different cancers. PAK1 is most commonly overexpressed (King et al., 
2014), and increased levels of PAK1 have been detected in human cancer tissue from breast 
(Ong et al., 2011, Holm et al., 2006), lung (Ong et al., 2011), liver (Ching et al., 2007) and 
melanoma (Ong et al., 2013). PAK2 overexpression has been observed in breast (Li et al., 
2011) and lung cancer tissue (Kichina et al., 2010). PAK3 has been found to be present in 
neuroendocrine tumours (Liu et al., 2010).  
Within Group II PAKs, PAK4 is considered to have a ubiquitous expression, with 
particularly elevated levels of PAK4 detected in a number of cancer cell lines and tumour 
type including prostate, breast, and pancreatic (Callow et al., 2002, Kumar et al., 2006). 
PAK5 is found to be expressed predominantly in the brain, where it promotes neurite 
outgrowth (Dan et al., 2002, Pandey et al., 2002), but it is also expressed in colorectal 
cancers (Gong et al., 2009). PAK6 is expressed in prostate and breast cancer cell lines (Kaur 
et al., 2008b). Moreover, PAK6 expression is elevated in prostate cancer tissue and colon 
cancer tissue in comparison to benign samples. Furthermore, PAK6 was overexpressed in 
hepatocellular carcinoma (HCC) (Kaur et al., 2008b, Zhang et al., 2010, Chen et al., 2014). 
In contrast, in clear cell renal cell carcinoma, the intratumoral PAK6 expression was 
significantly lower than that in nontumoral tissues (Liu et al., 2014).  
Generally, much of the attention has been directed towards founding family member PAK1. 
However, the focus is currently shifting towards group II PAK. PAK4 is a pluripotent kinase 
regulating several biological processes ranging from cell motility to survival. To date, it is 
the best characterised of the Group II PAKs with more various roles for this kinase rapidly 
emerging every year. Moreover, there is a significant work linking PAK4 to the critical 
control of the cytoskeleton. As more binding partners and substrates are discovered for group 
II PAK, It will be interesting to learn whether differences in upstream regulators and/or 
spatial control of subcellular localization contribute to PAK isoform. Furthermore, the 
functional importance of these interactions in vivo, especially some of them shared substrate 
specificity with PAK1. Although small molecule inhibitors of PAK4 have yet to prove 
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successful, the continued understanding of group II PAK biology will be a valuable resource 
in strengthening the basis for new therapeutic interventions. The future of group II research is 
an exciting prospect as we expand our knowledge of the roles of this kinase and validate its 
effectiveness as a drug target. 
1.5.5. Group II PAKs: Cancer cell metastasis 
 
PAK proteins have been strongly associated with cytoskeletal dynamics via their regulation 
of actin assembly and consequently are thought to contribute to cell migration (Bokoch, 
2003, Dharmawardhane et al., 1997, Jaffer and Chernoff, 2002). Whilst there is increasing 
evidence of a strong link between PAK4 and cancer cell migration, PAK4 was initially 
identified as a cytoskeletal regulatory kinase, acting in response to a direct interaction with 
Cdc42 (Abo et al., 1998).  One study demonstrated that PAK4 interacts with and 
phosphorylates the GEF, GEF-H1 and this activity may permit PAK4 to interact with 
microtubules, which subsequently affects cellular morphology and motility (Callow et al., 
2005a). Cofilin is a target of LIMK and a key regulator of actin filament disassembly. PAK4 
also interacts with and phosphorylates LIMK, increasing its ability to phosphorylate cofilin 
and thereby inhibiting actin disassembly (Dan et al., 2001b). This interaction between PAK4 
and LIMK has been shown to occur downstream of HGF in prostate cancer cells (Ahmed et 
al., 2008). Moreover, in response to HGF, PAK4 associates with the scaffold protein Gab1 
that drives localisation to the cell periphery, specifically within lamellipodia (Paliouras et al., 
2009), and enhance cell migration (Ahmed et al., 2008). In contrast, prostate cancer cells 
lacking PAK4 are less responsive to HGF stimulation with the significantly reduced level of 
cell migration observed (Wells et al., 2010a). In addition, constitutively active PAK4 
increases the invasiveness of pancreatic ductal cells, whereas the knockdown of PAK4 
decreases growth and reduces the migratory capacity of a highly invasive pancreatic cell line 
(Kimmelman et al., 2008). 
 
Others have shown that PAK5, downstream of active Rac/Cdc42, colocalises and binds to 
both actin and microtubule structures in Xenopus. Within the Xenopus model, X-PAK5 is 
expressed early on during development, particularly within the regions where morphogenetic 
movements are induced during the onset of gastrulation (Cau et al., 2001, Faure et al., 2005). 
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All these studies indicate a role of PAK5 in cell migration. In addition, PAK5 has been 
linked to filopodial formation during neurite outgrowth. The overexpression of PAK5 in 
N1E-115 neuroblastoma cells induces outgrowth as well as filopodia formation (Dan et al., 
2002). Moreover, overexpressed PAK5 in colorectal carcinoma cell lines localises to focal 
adhesions and the leading edge (Gong et al., 2009) and can reduce adhesion and increase the 
migratory response on collagen I (Gong et al., 2009). These studies on PAK5 are similar to 




It has been shown that the PAK5-Egr1-MMP2 signalling pathway could be crucial in breast 
cancer cell migration and invasion in both BT549 and MDA-MB-231 cells (Wang et al., 
2013). Here silencing PAK5 reduced breast cancer cell line proliferation, promoted 
apoptosis, and decreased cell migration in wound-healing and matrigel transwell invasion 
assay. Depletion of PAK5 expression in BT549 and MDA-MB-231 cells was associated with 
a decreased level of cleaved MMP2 and increased level of Egr1 expression. Egr1 is a 
transcription factor which can bind to the MMP2 promoter and inhibit its activity (Zcharia et 
al., 2012), and MMP2 is one of the proteases involved in breast cancer invasion, associated 
with poor prognosis (Talvensaari-Mattila et al., 2001, Talvensaari-Mattila et al., 2003). These 
results suggest a mechanism through which PAK5 could play a significant role in cancer cell 
migration and invasion.  
 
 
In contrast to the other Group II PAKs, there is much less known about the interaction 
between PAK6 and changes in cytoskeletal dynamics. However, it has been reported that 
PAK6 interacts with IQGAP1 and protein phosphatase 1B in breast cancer cells (Kaur et al., 
2008b). This binding was confirmed by our group in prostate cancer cells demonstrating that 
PAK6 and IQGAP1 can function to induce cell:cell dissociation downstream of HGF in 
DU145 cells. Furthermore, it has been shown that E-cadherin, IQGAP1 and PAK6 are 
present in a protein complex (Fram et al., 2014). While group I and II PAKs interact with the 
same Rho GTPases, the interaction with specific Rho family members might direct the 
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specific downstream signalling of individual PAK isoforms (Figure 1.9). Although an 
overview of all PAK members has been provided, PAK6 serves as the main focus of the 
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Figure 1.9: Group II PAK mediated signalling pathways. The group II PAKs, PAK4 
(purple), PAK5 (yellow) and PAK6 (red), mediate signalling cascades that influence 
cytoskeletal reorganization, neuronal development, cell survival and hormone signalling. 
PAK-mediated substrate phosphorylation is shown using the letter P. Abbreviations: 
AR, androgen receptor; BAD, Bcl-2 agonist of cell death; ER, oestrogen receptor; FA, 
focal adhesion; JNK, c-Jun N-terminal kinase; MKK, MAP kinase kinase 6; MT, 
microtubule; PDZ, post-synaptic density protein (PSD95), Drosophila disc large tumour 
suppressor (DlgA), and zonula occludins-1 protein (zo-1); SF, stress fibres. Adopted 
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1.5.6. PAK6  	  
PAK6 was detected in a screen to identify proteins that interact with the androgen receptor 
(AR) (Yang et al., 2001). PAK6 binds to the ligand-binding domain (LBD) of the AR and 
triggers suppression of AR signalling. The ability of PAK6 to bind to steroid hormone 
receptors suggest that it could contribute to the hormonal independence that is representative 
of many aggressive tumours (Schrantz et al., 2004). In support of this notion, PAK6 
expression is increased in both prostate and breast cancer cell lines (Kaur et al., 2008b). 
Reduced PAK6 expression combined with irradiation can decrease the survival of prostate 
cancer cells (Zhang et al., 2010) and PAK6 may protect these cells from apoptosis by 
phosphorylating the proapoptotic protein BAD on Ser112 (Zhang et al., 2010). Consistent with 
this observation, a combination of PAK6 inhibition and 5-fluorouracil (5-FU) treatment 
causes significantly decreased survival of colon cancer cells, and this result has been 
reproduced in vivo (Chen et al., 2014).  
In prostate cancer, cell growth was inhibited upon PAK6 knockdown and this effect was 
enhanced in the presence of the anti-tumour compound, docetaxel (Wen et al., 2009). 
Furthermore, the depletion of PAK6 in prostate cancer cells resulted in impaired PC3 cell 
migration and reduced expression of matrix metalloproteinase 9 (Goc et al., 2013). Notably, 
in some prostate cancer cells, the PAK6 gene is hypermethylated, and this would ordinarily 
lead to downregulation of expression.  
Our group found that knockdown of PAK6 expression in DU145 prostate cancer cells 
inhibited HGF induced cell:cell junction dissociation and cell scattering. In contrast, 
overexpression of PAK6 caused cell dissemination (Fram et al., 2014). It is known that 
PAK6 shows abundant localisation in the mitochondria (Cotteret et al., 2003). In addition, 
PAK6 has been detected in the cytoplasm and at the plasma membrane of HeLa cells (Lee et 
al., 2002), as well as in the nucleus of prostate cells (Yang et al., 2001). Overexpressed 
PAK6 can also localise to punctate cytoplasmic structures in HeLa and NCI-H1299 lung 
cancer cells (Shepelev and Korobko, 2012). Despite these investigations of PAK6 function in 
prostate cancer, the involvement of PAK6 in the development of breast cancer has not been 
studied previously. 
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1.6.   FilaminA 
 
Of particular interest in this thesis is FilaminA, which has been identified as a novel PAK6 
binding protein that has also been previously linked to the PAK family. The up-regulation of 
phosphorylated PAK1 leads to increased breast cancer cell motility by FilaminA (Hammer et 
al., 2013). In addition, the interaction between PAK1 and FilaminA could contribute to the 
stimulation of PAK1 activity and its targets in cytoskeletal structures (Vadlamudi et al., 
2002b). Clinical studies have shown that FilaminA is overexpressed in metastatic breast 
cancer (Jiang et al., 2013, Alper et al., 2009, Tian et al., 2013). It is reported that the 
overexpression of cytoplasmic FilaminA is linked with advanced stage, lymph node 
metastasis and vascular or neural invasion of breast cancer (Tian et al., 2013).  
In addition, low levels of FilaminA expression are associated with a better distant metastasis-
free survival compared to patients with normal levels of FilaminA (Jiang et al., 2013). The 
circulating levels of FilaminA in patient’s plasma are higher in cases with metastatic breast 
cancer (Alper et al., 2009).  
FilaminA is also referred to as actin-binding protein 280 (ABP 280), and this protein was 
first identified as a non-muscle actin filament cross-linking protein. It is a cytoskeletal 
protein that cross-links F-actin into either networks or stress fibres, (Niedeman, 1983, 
Hartwig and Stossel, 1975). The name Filamin refers to its filamentous colocalisation with 
actin stress fibres (Wang et al., 1975). In mammals, there are three highly homologous 
filamins; Filamins A, B and C. The full-length FilaminA consists of an N-terminal, which 
contains an actin-binding domain (ABD), and a C-terminal end followed by 24 
immunoglobulin (Ig)-like repeat domains, which are folded into β-sheets and together, form 
a rod structure as illustrated in Figure 1.10 (Ruskamo et al., 2012). The ABD of FilaminA 
contains two-calponin homology domain (CH1 and CH2). Calponin homology domains 
have been shown to facilitate the actin-binding properties of multiple proteins, including 
dystrophin, utrophin, α-actinin and β-spectrin (Gimona et al., 2002, Ruskamo and Ylanne, 
2009). FilaminA cross-link F-actin through ABD, and therefore interact with a multiplicity 
of other transmembrane and peripheral membrane proteins. Furthermore, FilaminA also 
contains nuclear localisation signals (NLS) in the ABD in repeat 14 and repeat 20. Two 
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hinge regions are located between repeats 15 and 16 and between repeats 23 and 24, which 
allow the protein to bend when, the molecules homodimerise through repeat 24. This occurs 
when the protein dimerises and the structure is similar to a Y, with dimerization occurring at 
the 24th repeat (van der Flier and Sonnenberg, 2001, Robertson, 2005). Dimerisation 



























Figure 1.10: The structure of FilaminA. The amino-terminal actin-binding domain is 
represented in orange and the chain of 24 filamin repeats in purple. Two hinge regions are 
located between repeats 15 and 16 and between repeats 23 and 24. Dimerization happens 
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1.6.1. Biological function of Filamins 
 
FilaminA function is regulated at many levels by phosphorylation, proteolysis, the binding of 
phospholipids, as well as organellar compartmentalisation (Gorlin J, 1990, Liu et al., 1997, 
Woo et al., 2004). Filamins act as scaffolding molecules, facilitating protein–protein 
interactions and influencing protein cellular localisation. Over 90 binding partners, including 
receptors, intracellular signalling molecules, and transcription factors have been identified 
(Nakamura et al., 2011). FilaminA binds to functionally diverse proteins through repeats 14–
24, as shown in Figure 1.11. It is reported that FilaminA can bind to the Rac-specific GTPase 
binding protein FilGAP, and FilGAP localises to sites of membrane protrusion where it is 
involved in lamellipodia formation. Moreover, cell spreading is disturbed by this interaction 
through mutations at the FilGAP binding site in Filamin (Nakamura et al., 2009, Ohta et al., 
2006b, MacPherson and Fagerholm, 2010). Subsequent reports revealed the importance of 
this protein in the cytoplasm, cell contraction, and cell spreading (Hartwig and Stossel, 
1975). Therefore, these results have highlighted the importance of FilaminA in regulating 
cell migration (Price et al., 1994, de Wit et al., 2009). FilaminA is necessary in cell migration 
to recruit proteins to the sites of migration, such as filopodia and lamellipodia, and these 
proteins can then function to the cell surface to allow cell movement (Nakamura et al., 2011). 
On the other hand, overexpression of wild type FilaminA can inhibit neuronal migration, 
thereby demonstrating that optimum levels of FilaminA are required for appropriate 
development  (Sarkisian et al. 2006).  
 
The exact role of Filamin during migration and whether its mechanosensing activities are 
essential remains unclear. It is has been shown that cells deficient in Filamins are impaired in 
initiation of migration but are nevertheless capable of migrating at normal speeds 
(Baldassarre et al., 2009). This finding suggests that Filamins are not essential for migration 
processes but they could contribute to its regulation, possibly through the formation of 
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Mutations in the FilaminA gene are detected in a wide range of disease phenotypes, 
involving, cardiovascular malformations, terminal osseous dysplasia, and neural defects 
(Robertson, 2005, Nakamura et al., 2011, Stossel et al., 2001). It is reported that the loss of 
FilaminA is also embryonically lethal (Feng et al., 2006). Furthermore, the lack of FilaminA 
results in male lethality due to incomplete separation of the outflow tract of the heart, which 
produces common arterial trunk and midline fusion, defects manifesting as sternum and 




















Figure 1.11: Diagram illustrating Filamin interactions. The ABD at the N-terminal of 
filamin includes two-calponin homology domain. The 24 repeats that follow the ABD most 
probably fold into antiparallel β-sheets and function as interfaces for protein-protein 
interaction. These repeats not only mediate the dimerization of filamin through C- terminal 
repeat 24, but also allow filamin to interact with different proteins. Figure is adapted from 
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1.6.2. FilaminA in Cancer Invasion and Metastasis  	  
FilaminA is expressed in many human cancers. It can act as a cancer-promoting protein 
and is likely to be of fundamental importance in cell migration and metastasis (Zhou et 
al., 2011). However, recent reports have also found that it prevents tumour progression, 
indicating that FilaminA could have a dual role in cancer (Savoy and Ghosh, 2013b). 
FilaminA may likely play a role in cancer metastasis due to the fact of its involvement in 
multiple associated regulatory pathways (Zhou et al., 2010). The association between R-
Ras and FilaminA can significantly enhance melanoma migration (Gawecka et al., 
2010). Moreover, the inhibition of FilaminA significantly reduces the migration and 
invasion of cancer cells (Jiang et al., 2013). Targeting FilaminA through depletion 
experiments has helped investigators understand the role of FilaminA in cancer progress 
and its importance in cancer cell growth and metastasis (Savoy and Ghosh, 2013a). 
Many studies have indicated that although full-length FilaminA is generally localised to 
the cytoplasm, or plasma membrane, it has a tumour-promoting effect due to its 
interaction with signalling molecules (Savoy and Ghosh, 2013b). On the other hand, if 
FilaminA is localised to the nucleus, then it may act to suppress tumour growth and 
inhibit metastasis by interacting with transcription factors (Ozanne et al., 2000, Loy et 
al., 2003, Bedolla et al., 2009, Wang et al., 2007). It is reported that in the cytoplasm, 
full-length FilaminA stimulates the development of metastasis. This hypothesis is based 
on immunohistochemistry studies of a human prostate tissue microarray; they found that 
FilaminA proteolysis is associated with a decrease of metastatic potential of prostate 
cancer. Prostate cancer metastasis correlates with cytoplasmic localization of full-length 
FilaminA but not nuclear FilaminA fragments (Yue et al., 2013, Bedolla et al., 2009). It 
was also suggested that metastasis may be prevented by cleavage and subsequent 
nuclear translocation of this protein, where nuclear FilaminA was exhibited to be 
essential for inhibition of transcription and susceptibility to therapeutic interventions 
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FilaminA function in the cell depends on the binding partners and acts to bring proteins 
together and promote the interaction of these proteins to either promote or prevent 
cancer (Savoy and Ghosh, 2013a). Pre-clinical studies show that FilaminA has a dual 
role in breast cancer metastasis. In MCF-7 human breast cancer cells stably expressing 
caveolin-1 (MCF-7/Cav1cells), FilaminA expression is upregulated and is 
phosphorylated on Ser-2152 in response to IGF-I stimulation, likely mediated by the 
PI3K/Akt pathway. It was further demonstrated that MCF-7/Cav1 cells exhibit 
substantially higher migration rates when compared with control MCF-7 cells (Xu et al., 
2010, Ravid et al., 2008, Ravid et al., 2005). Cyclin D1 is also known to bind to 
FilaminA, furthermore the level of two phosphorylated forms of FilaminA S2152 and 
S1459 is reduced in cyclin D1 siRNA treated cells (Zhong et al., 2010, Jiang et al., 2013, 
Tian et al., 2013). Interestingly, cyclin D1 knockdown and inhibition resulted in 
decreased motility and an impaired wound healing response in MDA-MB-231 breast 
cancer cell lines, which maybe correlated with the changes in FilaminA phosphorylation 
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1.7. Aims of the project  
 
The aim was to characterise the role of PAK6 in breast cancer cells and to investigate PAK6 
binding partners that may affect cell migration. More specifically:  
• Characterise the expression of PAK6 in a panel of breast cancer cell lines and to investigate 
the effect on cellular behaviour of PAK6 overexpression in breast cancer cells 
• Investigate the effect of PAK6 specific knockdown on cell morphology and associated 
pathways. 
• Identify breast cancer relevant PAK6 binding partners by immunoprecipitation and mass 
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2. Chapter 2: Materials and Methods 
 
2.1. Materials 
2.1.1. General Materials 
 
 




GIBCO®, Invitrogen, UK 
4ʹ′, 6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich, UK 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT) Sigma- Aldrich, UK 
96-well, U-bottomed, suspension culture plate Greiner, UK 
Acetic acid Sigma-Aldrich, UK 
Agarose Invitrogen. UK 
Ammonium persulfate (APS) Sigma-Aldrich, UK 
Acrylamide (30%) Severn Biotech Ltd, UK 
Alexa Fluor 488 Goat anti Mouse antibody  Invitrogen, UK 
Ampicillin Sigma Aldrich. UK 
Aprotinin Sigma-Aldrich, UK 
Beta- mercaptoethanol Sigma-Aldrich, UK 
Bromophenol Blue Bio-Rad, UK 
Bovine serum albumin (BSA) (VWR International,UK) 
Blebstatin inhibitor  Calbiochem 
Calcium phosphate transfection kit Sigma-Aldrich, UK 
Control siRNA oligonucleotide (non-silencing) Qiagen Ltd, UK 
Concentrated rat tail collagen, type I BD Biosciences, UK 
Coomassie brilliant blue (Thermo Scientific, USA) 
Dulbecco's Modified Eagle Medium (DMEM) Invitrogen. UK 
DMEM (1x) Powder, High Glucose PAA, UK 
DH5αTM Competent Escherichia coli (E. coli) Cells
  Invitrogen, UK 
Dithiothreitol (DTT) Sigma-Aldrich, UK 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich. UK 
Dulbecco's Phosphate buffered saline (PBS) without 
Calcium & Magnesium PAA, UK 




EGF (Recombinant Human) (R&D system, USA) GIBCO® 
Ethanol (BDH Laboratory Supplies, UK) 
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Ethylenediaminetetraacetic acid (EDTA) Gibco. UK 
Flbronectin  Sigma-Aldrich. UK 
Foetal Bovine Serum (FBS) Gibco. UK 
Fluorasave reagent Calbiochem, UK 
HGF (Recombinant Human)  (R&D system, USA) 
Isopropanol (VWR International, UK) 
Glycerol Sigma-Aldrich, UK 
Glycine Sigma-Aldrich, UK 
HiPerfect transfection reagent Qiagen Ltd, UK 
Kanamycin Invitrogen, UK 
Leupeptin Sigma-Aldrich. UK 
Luria-Bertani agar (LB-agar) Sigma-Aldrich, UK 
Luria-Bertani broth (LB-broth) Invitrogen. UK 
Lipofectaminew 2000 Invitrogen. UK 
Lithium chloride (LiCl) Fisons Scientific Apparatus, UK 
Magnesium chloride (MgCl2) Sigma-Aldrich, UK 
Methylcellulose Sigma-Aldrich,UK 
Methanol  (VWR International, UK) 
Non-fat milk powder Marvel, UK 
Nitrocellulose membrane Perkin Elmer 
Octylphenoxypolyethoxyethanol/NonidetTM P40 
substitute (NP-40) Sigma-Aldrich,UK 
PAK6 siRNA Oligo 1 Ambion 
PAK6 siRNA Oligo 2 Thermo scientific 
OptiMEM GIBCO®, Invitrogen, UK 
Panobinostat (LBH) BioVision 
Paraformaldehyde (PFA) Sigma-Aldrich, UK 
Penicillin & Streptomycin Sigma-Aldrich, UK 
Pierce® ECL western blotting substrate Thermo Scientific, USA 
Protein G SepharoseTM 4 Fast Flow beads Amersham Biosciences, UK 
Precision Plus Protein Marker Bio-Rad, UK 
Phosphate Buffered Saline (PBS) Tablets Oxoid Ltd. UK 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich. UK 
Fibronectin QIAGEN Plasmid maxi-prep kit Qiagen Ltd, UK 
RhoA Inhibitor  Cytoskeleton 
ROCK Inhibitor Calbiochem 
Sodium chloride (NaCl) Sigma-Aldrich, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, UK 
Sodium fluoride (NaF) Alfa Aesar, UK 
Sodium hydroxide (NaOH) Sigma-Aldrich, UK 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, UK 
	   62	  
 
 
           Table 2.2: Buffers and solutions. 
Buffer Composition Blocking	  solution	   5%	  w/v	  milk	  powder	  or	  5%	  w/v	  bovine	  serum	  albumin	  in	  TBS-­‐Tween	  Coomassie	  blue	  stain	   50%	  v/v	  methanol,	  10%	  v/v	  acetic	  acid,	  0.025%	  w/v	  coomassie	  blue	  Collagen	  I	  matrix	   1.617mg/mL	  Purecol	  collagen	  type	  I,	  3mM	  NaOH,	  10%	  FBS	  in	  DMEM	  
GFP Trap Lysis buffer 10 mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 
0.5% NP-40 
 
GFP-TRAP wash buffer 10 mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA 




250mM Tris-base, 1.92M Glycine, 1% w/v SDS. Dilute 
to 1X with distilled water  
SDS-PAGE transfer 250mM Tris-base, 1.92M Glycine. Dilute to 1X with 
Sodium pyrophosphate BDH Chemicals, UK 
Tetramethylrhodamine isothiocyanate (TRITC)- 
Phalloidin 
Sigma-Aldrich, UK 
Tetramethylethylenediamine (TEMED) (Sigma-Aldrich, UK) 
Triton X-100 VWR International, UK 
Tris Base Sigma-Aldrich, UK 
Trypsin/EDTA GIBCO®, Invitrogen, UK 
Tween 20 VWR International, UK 
Whatman PROTRAN nitrocellulose membrane (Perkin Elmer, USA) 
X ray film Scientific Laboratory Supplies 
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buffer (10X) distilled water and methanol (to a final concentration of 
20% v/v) TBS-­‐Tween	   25mM	  Tris-­‐HCl	  pH7.6,	  50mM	  NaCl,	  0.1%	  v/v	  Tween	  20	  Stripping	  buffer	   25mM	  glycine	  pH2	  +	  1%	  SDS	  in	  H2O	  
2.1.2. Primary Antibodies 	  
Table 2.3: Primary Antibodies 
Antibody Company Species Dilution for WB 
Dilution 
for IF 
β-actin Sigma-Aldrich Mouse 1:5000 - 
PAK4 Cell Signalling Technology  Rabbit 1:500 
- 
c-Met Santa Cruz Rabbit 1:500 - 
c-Myc (9E10) Santa Cruz Mouse 1:1000 1:500 
ERK1/2 Cell Signalling Technology Rabbit 1:2000 
- 
FilaminA Gentex  Rabbit 1:1000 - 
GAPDH Millipore Mouse 1:10,000 - 












EGFR Cell Signalling Technology Rabbit 1:500 
- 
PAK4 Cell Signalling Technology Rabbit 1:500 
- 
PAK4/6 Cell Signalling Technology Rabbit 1:1000 
- 
PAK6 Calbiochem Rabbit 1:500 - 
PAK6 Gnentex Rabbit 1:2000 
- 
pFilaminA Cell Signalling Technology Rabbit 1:1000 
- 







Technology Rabbit 1:500 
- 
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2.1.3. Secondary Antibodies 	  
Table 2.4: Primary Antibodies 




(HRP)-conjugated anti mouse Dako Goat 1:2000 
- 
Horseradish peroxidase 
(HRP)-conjugated anti rabbit Dako Goat 1:2000 
- 
AlexaFluor® 488 anti mouse Invitrogen Goat - 1:200 
AlexaFluor® 488 anti rabbit Invitrogen Goat - 1:200 
AlexaFluor® Rhodamine 
Phalloidin Invitrogen  1:500 
- 
 
2.1.4. Plasmids 	  
Table 2.5: Plasmid Constructs. 
Construct Source 
c-Myc FilaminA  Dr. Mark Dodding, KCL, UK  
c-Myc RhoV Dr. Mark Dodding, KCL, UK 
c-Myc RhoU Dr. Pontus Aspenstrom 
c-Myc RhoG  Dr. Pontus Aspenstrom 
GFP-MyosinIIA Dr. Michelle Peckham, Leeds, UK 
GFP-FilaminA Dr. David Calderwood, Yale, UK 
GFP-RhoA (WT) Prof. Anne Ridley, KCL, UK 
GFP-RhoD  Prof. Anne Ridley, KCL, UK 
GFP-PAK6 (WT) Dr.Sally Fram, KCL, UK 
RFP-PAK6  Dr.Sally Fram, KCL, UK 
Myc-PAK6  Dr.Sally Fram, KCL, UK 
Myosin IIA  Dr.Michelle Peckham, Leeds 
GFP-PAK6 Kinase active (S531N) Dr.Sally Fram, KCL, UK 
GFP-PAK6 Kinase dead (K436A) Dr.Sally Fram, KCL, UK 
GFP Cdc42  Dr. Maddy Parsons, KCL, UK 
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2.2. Methods: Molecular Biology 	  
2.2.1. Transformation of Escherichia coli cells 
 
The heat shock method was used to transform E.coli  (DH5α strain) bacteria. The strain used 
varied between different assays. Competent E.coli cells stored at -80ºC were thawed out on 
ice prior to transformation. 2 µl of plasmid DNA was added to 50 µL of the bacterial 
competent cells. These cells were then incubated on ice for 30 minutes followed by 
incubation at 42ºC for exactly 20 seconds. The reaction mix was then placed on ice for 5 
minutes. 950 µL L-broth was then added to the reaction mix and then vials were incubated at 
37ºC in a shaking incubator for one hour at approximately 225rpm. Subsequently, 200 µL of 
the transformation reaction was plated onto pre-warmed LB plates containing the appropriate 
antibiotic for plasmid selection (100 µg/mL ampicillin or 30 µg/mL kanamycin). The plates 
were inverted and incubated at 37ºC overnight. The following day, colonies were picked and 
grown in L-broth containing the appropriate selection antibiotic. 
2.2.2. Purification of plasmid DNA 
 
Plasmid DNA was isolated and purified from E.coli cells using either the Invitrogen 
PurelinkTM HiPure plasmid DNA purification maxiprep kit, or the PurelinkTM HiPure 
Plasmid Filter Mini- prep kit, dependent on the DNA yield required. L-broth supplement 
with the appropriate antibiotic added was inoculated with transformed bacteria and incubated 
at 37°C overnight with shaking. The concentrations of antibiotic used were 30 µg/mL for 
kanamycin and 100 µg/mL for ampicillin. The plasmid DNA eluted in TE buffer and stored 
at -20°C. DNA was purified as per the manufacturer’s protocol and resulting DNA 
resuspended in TE buffer was stored at -20°C for future use. 
2.2.3. Determination of DNA concentration 
DNA concentration was determined using a Nano-Drop system. A 1µl sample was pipetted 
onto the end of a fibre optic cable and the optical density (OD) was measured at 260 nm. The 
DNA concentration in ng/µL was automatically determined 
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2.3. Methods: cell biology 
2.3.1. Cell culture  	  
The breast cancer cell lines MDA-MB-231 (kind gift from Prof.Anne Ridley), MCF-7 
(ATCC), HT29 human colon cancer and HEK 293 (ATCC) cells were grown in Dulbecco’s 
modified eagles medium DMEM containing 10% foetal bovine serum (FBS) and 100U/mL 
penicillin and 100 µg /mL streptomycin (Gibco). MCF10A (ATCC) were grown in 
DMEM/F12 containing 5% foetal bovine serum (FBS) and 100U/mL penicillin and 100 
µg/mL streptomycin with 100µL EGF, 250µL Hydrocortizone, 50µL CholeraToxin and 
500µL Insulin. DU145 and PC3 prostate cancer cells (obtained from Claire Wells, King’s 
College London) were cultured in in RPMI-1640 media supplemented with 10% foetal 
bovine serum (FBS) and 100U/mL penicillin/streptomycin. A375 melanoma cell lines were 
in cultured Dulbecco’s modified eagle’s medium: nutrient F-12 ham (DMEM F-12) 
containing 2.5mM L-glutamine. 
All media were warmed before use to 37°C. Cells were maintained in humidified incubator at 
37°C with 5% CO2 and passaged at 80% confluent levels. During cell passaging the growth 
medium was removed and the cells were washed with sterile phosphate buffered saline (PBS) 
and trypsinised with 0.5% Trypsin/Ethylenediaminetetraacetic acid (EDTA). The cell pellet 
resuspended in growth media and suspended cells were placed in new tissue culture flask at 
appropriate dilution.  	  
2.3.2. Thawing and freezing cells 
To thaw cells, a cryovial was taken from liquid nitrogen and thawed rapidly at 37°C in a 
water bath. The cells were then transferred to 5 mL (T25 flask) of cell specific medium in a 
tissue culture flask. The medium was changed the next day and cells were cultured using the 
method illustrated in 2.3.1 
To freeze cell lines, cells were detached using trypsin and transferred into cryovials in a 90% 
FBS, 10% DMSO solution. Cryovials were placed in a cryo-freezing container and stored at -
80ºC to allow slow freezing overnight. The cells were then transferred to liquid nitrogen for 
long-term storage. 
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2.3.3. Lipofectamine transfection 	  
The Lipofectamine was used to transfect MDA-MB-231 and MCF-7 Cells. The cells were 
seeded at density 1x10
5 
/mL then incubated at 37° for 24 hours. On the day of 
transfection, the medium was aspirated from the cells and replaced with serum free 
OptiMEM medium, free from antibiotics. The transfection mixture was then made up in 
OptiMEM serum free media, details of which are outline in Table 2.6. 
 
Table 2.6: Lipofectamine transfection reaction mix. 
 
The mixtures were left at room temperature for 5 minutes. Next this, the contents of tube A 
added to the tube B mix and then incubated at room temperature for 15 minutes. The cells 
were then incubated with the transfection reagents and maintained at 37ºC for 6 hours. Then, 
optimum media replaced with growth media.  	  	  	  	  	  	  	  	  	  
 2cm tissue culture plate (2 mL) 10cm tissue culture plate (10 mL) 
Tube A 3µl of lipofectamine 
100µl serum-free OptiMEM 
media 
15µl of lipofectamine  
100µl serum-free OptiMEM media 
Tube B 3 µg of DNA 
100 µl serum-free OptiMEM 
media 
 
15 µg DNA 
500 µl OptiMEM media 
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2.3.4. Calcium Phosphate Transfection 	  
The calcium phosphate transfection kit was used to transfect HEK293 cells. Cells were 
seeded at a density of 1x105/mL and incubated at 37ºC overnight. On the day of transfection, 
3-4 hours prior to the addition of the reaction mix, the media was aspirated and replaced with 
fresh medium. The reaction mix was set up using the conditions described in Table 2.7. 
Table 2.7: Calcium phosphate transfection reaction mix. 
 2cm tissue culture plate (2 mL) 10cm tissue culture plate (10 mL) 
Tube A 7.2µL 2M CaCl2  
4µg DNA  
Make up to 60µL with sterile 
water 
30µL 2M CaCl2  
20µg DNA  
Make up to 300µL with sterile water 
Tube B 60µL 2x Hepes buffered saline 300µL 2x Hepes buffered saline 
 
The contents of tube A added to the tube B, with aeration. This transfection mixture was then 
incubated at room temperature for 30 minutes, before being added dropwise to the cells. 
2.3.5. HiPerfect siRNA transfection 
Cells were plated at density 1x10
4 
/mL the day before transfection in full growth media. The 
following day, 60nM short interfering RNA (siRNA) oligonucleotides and 12µL HiPerfect 
transfection reagent were added to 97µL optiMEM and incubated at room temperature for 20 
mins before being added dropwise to the cells. Cells were then incubated at 37ºC for 
different time frames depending on the assay. Equal concentrations of a control siRNA were 
used in each experiment. The siRNA oligonucleotides used in this study (including the target 
sequence) are shown in Table 2.8. 
 
Table 2.8: The Sequences of siRNAs used in this study. 
Oligo Name Target sequence 
Control siRNA AAT TCT CCG AAC GTG TCA CGT 
PAK6 Oligo 1 GGCUAUUCCGAAGCAUGUTT 
PAK6 Oligo 2 GCACCAAUAGGCAUGGAAU 
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2.3.6. Inhibitors 
Panobinstat LBH-589 (molecular formula: C₂₁H₂₃N₃O₂) is known to be a highly selective 
inhibitor of histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, 
which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M 
phase and apoptosis and has been shown to inhibit tumour cell proliferation in vitro. 
Blebbistatin (molecular formula: C₁₈H₁₆N₂O₂) is identified as high affinity and selectivity 
small molecule inhibitor myosin II. 
RhoA (C3) is known to inhibits RhoA by ADP-ribosylation on asparagine 41 in the effector 
binding domain of the GTPase. ROCK   H-1152 (molecular formula: C₁₆H₂₁N₃O₂S • 2HCl) 
is known to be more specific, potent and membrane-permeable inhibitor of Rho-kinase.  A 
stock solution, at a concentration of 10µM, was made by diluting in DMSO for panobinstat 
and blebbistatin and in distilled water for ROCK and RhoA inhibitors. Aliquots were stored 
at -20 ºC until required. For use in all assays the stock solution was diluted further in culture 
medium to establish a working concentration of 5µM. An equal volume of DMSO and water 
was used as a control in all experimental procedures. 
 
2.3.7. MTT Proliferation Assay 
Cells were seeded onto plastic or matrix-coated 96 well plates at a cell density of 3×103/mL 
in DMEM media. Media was aspirated from each well and washed once with sterile PBS 
and   replaced with 50µl(5mg/mL) methyl thiazolyldiphenyl tetrazolium bromide  (MTT) 
diluted in serum free DMEM media.  Cells were incubated in the presence of the MTT at 
37ºC, in 5% CO2 for 3 hours. Following this incubation, the MTT solution was carefully 
removed and   50µL DMSO was added.  The cells were mixed thoroughly and the 
absorbance at 540 nm was   measured using an Alpha-Fusion plate reader.    
2.3.8. 3D Spheroid Invasion Assay       
To form spheroids, MDA-MB-231 cells were seeded into a 96-well U-
bottomed   suspension   culture   plate at density of 2.5x102-10x102 in 100 of DMEM media, 
containing   5% FBS   and   0.32% methylcellulose. Cells were incubated at 37°C in 5% 
	   70	  
CO2, for three days to enable a spheroid mass to form.  On the third day, collagen I 
matrix  (from bovine) was prepared on ice and 400µL was added to a 24 well plate   and 
allowed to polymerise for 2 hours at 37°C in 5% CO2. Following this, another 400µL of 
collagen I matrix was added on to the polymerized collagen I layer 
and   the   spheroid   was   transferred   directly into this layer.    Images were taken at day 0 
and after 17-24 hours using an Olympus Ix71 microscope with Image-Pro Plus 7.0 
software  (x10 objective).     
2.3.9. Preparation of coverslips for Immunofluorescence  
13 mm round glass coverslips (VWR, UK) were placed in a solution containing 40% of 1 M 
hydrochloric acid (HCL) and 60% of 70% ethanol at room temperature overnight in the fume 
hood. Following this, the coverslips were rinsed three times in distilled water and boiled. 
Then, rinsed a further six times with distilled water and then autoclaved.  
 Rat tail collagen type I coated coverslips 2.3.9.1.
Type I rat tail collagen was diluted to 50µg/mL in 0.02M glacial acetic acid, which had been 
filter sterilized. The dilute collagen solution was added and incubated at room temperature 
for one hour. The collagen was then aspirated and washed twice with sterile PBS before cells 
were seeded. 
 Fibronectin coated coverslips 2.3.9.2.
The fibronectin was diluted to a final concentration of 10µg/mL in sterile PBS was then 
added and incubated at room temperature for 45 minutes. The fibronectin was then aspirated 
and washed twice with sterile PBS before cells were seeded. 
2.3.10.  Immunofluorescent labelling 
Cells were seeded onto sterilise coverslips at appropriate density. The following day, cells 
were fixed with 4% paraformaldehyde (PFA) for 20 minutes at room temperature. Coverslips 
were washed three times with phosphate buffer saline (PBS) plus calcium and maganesium 
(Oxoid,UK) before being permeabilised with 0.2% Triton X-100 for 5 minutes. Cells were 
then washed three times with PBS. For F-actin staining cells were incubated at room 
temperature for 1 hour with TRITC-Phalloidin or Alexa Fluor 488 conjuated phalloidin. For 
nuclei staining were stained by adding DAPI. Coverslips were then washed twice with PBS 
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and once with dH2O. Then, cells fixed to microscope slide and mounted in 10 µl 
FluorSaveTM Reagent.  
For Myc-PAK6 and Myc-Filamin, cells were blocked in 3% BSA-PBS for 30 minutes and 
incubated in primary antibody, diluted in 3% BSA for 2 hours at room temperature in the 
dark. Then, washed three times in PBS and incubated with the appropriate secondary 
antibody and DAPI diluted in 3% BSA-PBS for one hour at room temperature in the dark. 
Coverslips were then mounted onto microscope slides using FluorSave, left at room 
temperature in the dark overnight and stored at -20oC until being imaged. The fluorescence 
was visualized using on Olympus IX71 microscope with Image-Pro Plus 7.0 software. 	  
2.3.11. Growth factor stimulation 	  
 Stimulation of cells on 6-wells plates 2.3.11.1.
MDA-MB-231 and MCF-7 cells were seeded	  onto	  a	  6-­‐well	  plate	  at	  a	  density	  of	  1x105	  in	  2	  mL	  of	   growth	  media	   and	   incubated	   at	   37°c	   overnight.	   Cells	  were	   then	   incubated	   for	   24	   hours	   in	  starve	  media;	   Dulbecco’s	  modified	   eagles	  medium	  DMEM	  containing	   0.5%	  FBS	   and	   100U/mL	  penicillin	  and	  100	  µg/mL	  streptomycin.	  Then,	  starved	  cells	  stimulate	  with	  (10ng/mL)	  HGF	  or	  (100ng/mL)	  EGF	  at	  designed	  time	  points.	  Cells	  were	   lysed	   in	   lysis	  buffer	  NP40	  supplemented	  with	  protease	  inhibitors	  on	  ice	  for	  10	  minutes	  and	  centrifuged	  at	  13000	  rpm	  for	  10	  minutes	  to	  remove	  cell	  debris.	  Lysates	  were	  immunoblotted	  for	  the	  desired	  protein	  to	  quantify	  the	  changes	  in	   phosphorylation	   levels	   of	   PAK6	   following	   HGF	   or	   EGF	   stimulation.	   The	   intensity	   of	   each	  phospho-­‐protein	  and	  loading	  band	  was	  determined	  using	  Image	  J.	  	  
. 	  
 Stimulation of cells on coverslips 2.3.11.2.
MDA-MB-231 and MCF-7 cells were seeded onto coverslips at density of 2x104 /mL in 1mL 
of growth media and incubated at 37°c overnight. Cells were then incubated for 24 hours in 
starve media; Dulbecco’s modified eagles medium DMEM containing 0.5% FBS and 
100U/mL penicillin and 100 µg /mL streptomycin. Then, starved cells stimulate with (10 
ng/mL) HGF or (100 ng/mL) EGF For 15 minutes. Moreover, MCF-7 stimulated for 24 hour. 
Then, cells washed twice with PBS before being fixed with 4% PFA and immunostained as 
described in section 2.3.10. 
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2.3.12. Image processing and Cell shape analysis 
Coverslips were viewed on Olympus IX71 microscope with Image-Pro Plus 7.0 software. 
Image J software was used to determine the morphology of each cell by drawing around 
individual cell.  The data were then processed to measure the area, elongation ratio. The cell 
elongation was calculated as a relative value of the longest axis to the shortest axis of a cell, 
subtracted from 1 reference. The average value (mean) and standard error were calculated. 
This process was repeated for 90 cells over three experiments. 
 
2.4. Methods: Cell Biochemistry 
 
2.4.1. Preparation of cell lysates 
When cells were approximately 70% confluent, they were washed twice in PBS and lysed for 
10 minutes on ice in 100 µl 0.5% NP-40 lysis buffer supplemented with 1mM DTT, 1µg/mL 
aprotinin, 10µg/mL leupeptin, 1mM PMSF, 50mM sodium fluoride and 1mM sodium 
orthovanadate for six well plates and 1000 µl for 10 CM plates. Cells were scraped and 
transferred to eppendorf tubes and centrifuge at 13,000g for 10 minutes at 4ºC to remove cell 
debris. The supernatant was transferred to a fresh eppendorf and samples prepared through 
the addition of a 6x Laemmli buffer (diluted to 1x) before samples were boiled for 3 minutes. 
Whole cell lysate samples were then subsequently stored at -20 ºC until use. 
2.4.2. Gel electrophoresis and immunoblotting 
Cellular proteins were separated on 6.5-12.5% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) gels at 125 V in running buffer for 1-2 hour. Proteins were 
electroblotted onto nitrocellulose membrane at 70-100 volts for 1-2 hours (dependent on the 
percentage gels used) in transfer buffer. The membrane was then blocked in 5% skimmed 
milk powder in 0.1% TBS-Tween20 or 5% BSA in 0.1% TBS-Tween20, for one hour at 
room temperature to block non specific binding.  The membrane was incubated in primary 
antibody overnight at 4 °C. The membrane was washed three times for 10 minutes each in 
TBST to remove unbound primary antibody. Following this, membrane was incubated with 
secondary antibody conjugated with horseradish peroxidase at double the dilution of primary 
antibody in TBST with milk for one hour at room temperature. Proteins were detected using 
Pierce enhance chemiluminscence (ECL) kit. 
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2.4.3. Stripping of Nitrocellulose Membranes 
To allow reprobing, the nitrocellulose membranes were incubated in stripping buffer twice 
for 15 minutes each at room temperature. Membranes were then washed twice for 10 minutes 
in TBS-T Tween20. Consequently, the blots were blocked for 1 hour in 5% milk and 
incubated overnight with primary antibodies at 4 °C. Following day, the blot was incubated 
for secondary antibody as previously stated. 
2.4.4. Immunoprecipitation 
Lysates of HEK 293 and MDA-MB-231 cells were prepared using IP lysis buffer with 
inhibitors. 50 µl each lysate was kept for immunoblotting as a loading control. 3 µl of 
appropriate IP antibody was added to the lysis supernatant and incubated on a rotating wheel 
overnight at 4 °C. Following day, protein A or G beads (depend on the antibody) were 
washed three times in appropriate volume lysis buffer with inhibitors, before to adding 30 µl 
of beads to each IP sample. The samples were then incubated for 1 hour on a rotating wheel 
at 4 °C. Each samples following incubation, washed three times with lysis buffer with 
inhibitors. Gel sample buffer was added to each sample and boiled at 90 °C for 3 minutes. 
2.4.5. GFP-TRAP 
 
Lysates of HEK 293 and MDA-MB-231cells were prepared using GFP-TRAP lysis buffer 
with inhibitors. Prior to the adding the GFP-TRAP, 10 µl of beads were washed three times 
and centrifuge at 2500xg for two minutes. Following that, the supernatant added to the beads 
and incubated for 2 h rotating at 4°C. 50 µl of each lysate was kept for immunoblotting as a 
loading control. After the incubation, the beads were washed three times with 1 mL of GFP 
TRAP wash buffer, at 4°C. The supernatant was aspirated very carefully using a pipette. 
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2.4.6. Densitometry 
For western blotting, densitometric analysis of specific bands was performed using ImageJ 
software. In order to obtain a semi-quantitative measurement of the level of total protein, all 
band densities were normalised to a loading control. In most circumstances, ß-actin was used 
as a loading control and was detected on the same membrane as the protein of interest. 
 
2.4.7. Statistics 
Statistical analysis was carried out where indicated using data of three independent 
experiments. Statistical significance was calculated using an unpaired Student’s t-test, or 
where specified using one-way ANOVA (analysis of variance). Values were considered 
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3. Chapter 3: Investigation the role of PAK6 in Breast cancer  	  
3.1. Introduction 	  
Our group published that HGF stimulation increases PAK6 autophosphorylation and an 
increase in PAK6 expression also leads to cell-cell dissociation in response to HGF. 
Moreover, overexpression of PAK6 induces morphological changes when compared to 
control cells (Fram et al., 2014). Tumour metastasis involves multiple steps, and cell 
migration is one of the key steps in the development of this complex process (Spano et al., 
2012). Growth factors can promote cell migration; both in vivo and in vitro. HGF or EGF are 
known to activate a variety of intracellular signalling cascades via stimulation of c-Met and 
EGFR receptors, respectively. Many of these downstream signalling cascades participate in 
the regulation of pathways related to actin cytoskeletal reorganization (Ridley et al., 1995), 
cell motility and/or invasive growth of tumour cells, which provide the hallmarks of 
metastatic cancer (Maulik et al., 2002). HGF or EGF signalling pathways have been shown 
to be involved in the spread of prostate cancer or breast cancer, respectively (Kim and 
Muller, 1999). HGF induces invasiveness of prostate cancer cells in vitro (Parr et al., 2010), 
and increased expression of c-Met/HGF in breast carcinoma have been correlated with poor 
prognosis and increased cell proliferation (Taniguchi et al., 1994). HGF also increases the 
invasiveness of breast cancer cells (Woodbury et al., 2002) and the serum levels of HGF are 
elevated in breast cancer patients. The elimination of malignant breast tumours also results in 
a reduction in serum HGF levels (Woodbury et al., 2002, Yamashita et al., 1994). 
Furthermore, HGF can drive cell migration and invasion in breast cancer cell lines (Mine, 
2003). 
PAK family proteins can be activated downstream of HGF or EGF, and are known effectors 
of Rho Family GTPases (Wells, 2002, Yang et al., 2011). Indeed, both PAK1 and PAK4 are 
required for the HGF-induced migration of prostate cancer cells (Ahmed et al., 2008, Bright 
et al., 2009), and activated PAK4 induces cell rounding following the HGF stimulation of 
MDCK cells (Wells, 2002). EGFR also plays a role in the activation of PAK1 and PAK4 
(Beier et al., 2008, Siu et al., 2010) and EGF stimulates MDA-MB-231 cell migration in vitro 
via activation of PAK1 (Yang et al., 2011).  
	   77	  
PAK6 was first detected in a screen to identify proteins that interact with the androgen 
receptor (AR) (Yang et al., 2001). It is known that endogenous PAK6 is expressed in DU145 
prostate cancer cells (Fram et al., 2014, Wells and Jones, 2010, Yang et al., 2001). The 
overexpression of wild type PAK6 cells were significantly elongated and highly expressing 
cells became rounded in prostate cells. In addition, the overexpression of activated PAK6 
also induced cell elongation, although not to the same degree as that observed in cells 
overexpressing wild type PAK6. Again highly expressing cells become rounded (Fram et al., 
2014). This is unusual as the majority of PAK induced cell morphological changes have been 
detected only when the constitutively active forms of PAK1, PAK2 or PAK4 are utilized 
(Wells, 2002, Manser et al., 1997, Zeng et al., 2000, Qu et al., 2001).  
PAK6 interacts with the active form of Cdc42, but this does not enhance the kinase activity 
of PAK6 (Schrantz et al., 2004). PAK6 kinase activity can be regulated by the MAPK 
signalling pathway (Kaur et al., 2005). Phosphorylation by p38 MAPK and mitogen activated 
protein kinase kinase 6 (MKK6) can stimulate PAK6 (Kaur et al., 2005). Furthermore, the 
autophosphorylation of PAK6 at serine 560 in the activation loop is required for MKK6-
facilitated activation. The AR may also play a part in regulating PAK6 kinase activity in 
prostate cancer cells (Lee et al., 2002). However, there is much less known about the 
regulation and activation of PAK6 in breast cancer.  
In this chapter, the expression level of PAK6 in breast cancer cell lines was analysed, and the 
possibility that PAK6 might be activated downstream of HGF or EGF was tested using 
MDA-MB-231 and MCF-7 breast cancer cells. The morphological impact of PAK6 
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3.2. Results 
3.2.1. PAK6 is endogenously expressed in MDA-MB-231 and MCF-
7 cells 	  
PAK6 expression has been linked to prostate cancer invasiveness (Wen et al., 2009). In this 
study, they also demonstrated that the depletion of PAK6 expression inhibited the growth of 
the prostate cancer cells. Consequently, PAK6 expression was tested in a panel of breast cell 
lines, as illustrated in the  (Table 3.2); a non-tumorigenic epithelial cell line (MCF10A), non-
invasive breast cancer cells (MCF-7), invasive human breast cancer cells (MDA-MB-231) 
and (HCC1954), poorly differentiated breast cancer cells (HCC1143) and DU145 prostate 
cancer cells were used as a positive control. In these cell lines, PAK6 was found to be present 
at 75 kDa using specific PAK6 antibody from Gentex (Figure 3.3). This antibody detected a 
single protein band at the correct size for PAK6. The Gentex antibody did not appear to 
cross-react with PAK4 or PAK5, which run with a different apparent molecular weight. This 
antibody was therefore selected for future studies, and PAK6 expression was detected in all 
of the cell lines, both colony and single cells (Figure 3.3). Although not statistically 
significant, there appeared to be potential and slightly higher expression in MDA-MB-231 
cells.  










HCC1954 Epithelial mammary gland; 
breast/duct 
TNM stage IIA, grade 3, 
ductal carcinoma 
DU145 Epithelial prostate; derived from 




Epithelial mammary gland/breast; 
derived from metastatic 
site: pleural effusion 
Adenocarcinoma 
MCF-7 Epithelial mammary gland, breast; 
derived from metastatic 




Epithelial mammary gland/breast fibrocystic disease 
HCC1143 Epithelial breast; mammary 
gland/duct 
TNM stage IIA, grade 3, 
primary ductal carcinoma 
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Figure 3.1: PAK6 expression in breast and prostate cell lines. A) Western blotting was 
used to analyze the expression of PAK6 in a panel of cell lines. Cell lysate were 
immunoblotted for PAK6 expression using Gentex PAK6 antibody or probed for β-actin as a 
loading control. B) The blot shown is representative of three independent experiments, which 
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3.2.2. Expression of growth factor receptors in panel of cancer cell 
lines 	  
HGF and EGF signalling pathways have both been implicated in breast cancer progression ( 
Harrison et al., 2013, Natan et al., 2014). Furthermore, previous work has suggested that 
PAK family kinases can be activated downstream of growth factor stimulation (Bright et al., 
2009, Wells, 2002). Initial experiment analysed the endogenous expression of the receptors 
for Hepatocyte Growth Factor (HGF)/c-Met and Epidermal Growth Factor (EGF)/EGFR in 
selected cell lines. Cell lines were selected that were known to be positive for PAK6 
expression as a positive control. Detectable c-Met protein expression was observed in PC3, 
HT29 and MDA-MB-231 malignant cell lysates cells. In contrast, MCF-7 cells appeared to 
express c-Met at much lower levels (Figure 3.4).  
Additional imunoblotting experiments showed that EGFR was expressed in all of the cell 
lines analysed and the highest levels of expression were detected in MDA-MB-231 cells. In 
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Figure 3.2: c-Met expression in panel of cancer cell lines. A) Western blotting was used to 
analyze the expression of c-Met in a panel of cell lines as indicated. Cell lysates were 
immunoblotted for c-Met expression or β-actin as loading control. B) The blot shown is 
representative of three independent experiments, which were quantified through densitometry. The 
molecular weight of c-Met is 140 kDa and β-actin 42 kDa. Statistical significance was calculated 

















































Figure 3.3: EGFR expression in panel of cancer cell lines. A) Western blotting was used to 
analyze the expression of EGFR in a panel of cell lines as indicated. Cell lysates were 
immunoblotted for EGFR expression or β-actin as loading control. B) The blot shown is 
represent of three independent experiments, which were quantified through densitometry. 
The molecular weight of EGFR is 175kDa and β-actin 42 kDa. Statistical significance was 
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3.2.3. Growth factor stimulation did not modify PAK6      
autophosphorylation 	  
Having established that the MDA-MB-231 and MCF-7 cell lines selected for this project 
express PAK6, c-Met and EGFR, these two cell lines were selected to test the ability of HGF 
and EGF to activate PAK6. The effect of HGF or EGF stimulation on PAK6 
autophosphorylation levels was therefore investigated using a phospho-specific antibody 
from Cell Signalling Technology. This antibody detects phosphorylated PAK4 on serine 474, 
phosphorylated PAK5 on serine 602 and phosphorylated PAK6 on serine 560 within the 
kinase domain. This residue in PAK6 is thought to be an autophosphorylation site 
homologous to threonine 423 (T423) in PAK1 (Schrantz et al., 2004) and serine 474 (S474) 
in PAK4 (Abo et al., 1998).  
In MDA-MB-231 cells, the level of PAK6 phosphorylation decreased when the cells were 
serum starved and appeared to increase slightly following 5 minutes of HGF stimulation, 
when compared to the starved cells (Figure 3.6 A). However, this change in PAK6 
phosphorylation levels was not significant (Figure 3.6 B). The blot was also probed for 
phospho-ERK to confirm efficient c-Met signalling downstream of HGF. Analysis beyond 5 
minutes suggested that there was no significant increase in the PAK6 phosphorylation levels 
upon HGF stimulation (Figure 3.6). With regards to EGF stimulation, results show that there 
is no significant difference in the PAK6 phosphorylation level following EGF stimulation 
(Figure 3.7) in MDA-MB-231 cells despite a robust phosphoERK response.  
Consistent with the results from the MDA-MB-231 cells, no change in PAK6 
phosphorylation levels were detected in MCF-7 cells following stimulation with either HGF 

























Figure 3.4: HGF stimulation has no effect on PAK6 autophosphorylation levels in 
MDA-MB-231 cell line. A) MDA-MB-231 cells were seeded and were serum-starved 
overnight after plating for 24 hours. Cells were then left unstimulated (starve) or stimulated 
with HGF (10 ng/mL) for 5, 15, 30 and 60 minutes prior to lysis. Lysates were 
immunoblotted for levels of PAK6 autophosphorylation at serine 560 using a phospho-
PAK4/PAK5/PAK6 antibody or probed for phospho ERK using an anti-pERK antibody.  
Blots were re-probed for β-actin. The molecular weight for pPAK6 is 75 kDa, pERK 24/44 
kDa and β-actin 42 kDa. B) Changes in PAK6 autophosphorylation levels at serine 560 were 
























































Figure 3.5: EGF stimulation has no effect on PAK6 autophosphorylation levels in 
MDA-MB-231 cell lines. A) MDA-MB-231 cells were seeded and were serum-starved 
overnight after plating for 24 hours. Cells were then left unstimulated (starve) or stimulated 
with EGF (100 ng/mL) for 5, 15, 30 and 60 minutes prior to lysis. Lysates were 
immunoblotted for levels of PAK6 autophosphorylation at serine 560 using a phospho-
PAK4/PAK5/PAK6 antibody and probed for phospho ERK using an anti-pERK antibody. 
Blots were re-probed for β-actin. The molecular weight for pPAK6 is 75 kDa, pERK 24/44 
kDa and β-actin 42 kDa. B) Changes in PAK6 autophosphorylation levels at serine 560 were 




















































Figure 3.6: HGF stimulation has no effect on PAK6 autophosphorylation levels in 
MCF-7 cell line. A) MCF-7 cells were seeded and were serum-starved overnight after 
plating for 24 hours. Cells were then left unstimulated (starve) or stimulated with HGF (10 
ng/mL) for 5, 15, 30 and 60 minutes prior to lysis. Lysates were immunoblotted for levels of 
PAK6 autophosphorylation at serine 560 using a phospho-PAK4/PAK5/PAK6 antibody and 
probed for phospho ERK using an anti-pERK antibody.  Blots were re-probed for β-actin. 
The molecular weight for pPAK6 is 75 kDa, pERK 24/44 kDa and β-actin 42 kDa. B) 
Changes in PAK6 autophosphorylation levels at serine 560 were quantified. Bars represent 
























































Figure 3.7: EGF stimulation has no effect on PAK6 autophosphorylation levels in MCF-7. A) 
MCF-7 cells were seeded and were serum-starved overnight after plating for 24 hours. Cells were 
then left unstimulated (starve) or stimulated with EGF (100 ng/mL) for 5, 15, 30 and 60 minutes 
prior to lysis. Lysates were immunoblotted for levels of PAK6 autophosphorylation at serine 560 
using a phospho-PAK4/PAK5/PAK6 antibody and probed for phospho ERK using an anti-pERK 
antibody.  Blots were re-probed for β-actin. The molecular weight for pPAK6 is 75 kDa, pERK 
24/44 kDa and β-actin 42 kDa. B) Changes in PAK6 autophosphorylation levels at serine 560 were 
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3.2.4. Cell morphology of breast cancer cell lines 	  
To complement the protein expression studies, the impact of PAK6 overexpression on cell 
morphology was investigated. Prior to initiating PAK6 overexpression experiments, the cell 
morphology of MDA-MB-231 and MCF-7 cells was characterised under basal and growth 
factor stimulated conditions. Cells were stained for F-actin using phalloidin and morphology 
analysed using Image J software. Illustrative staining of each cell line under basal conditions 
is represented in Figure 3.10 A. The cell area and cell elongation were calculated for both 
cell lines, and they were found to differ in both cell area and cell shape (Figure 3.10 B). 
Elongation values were found to be higher in MDA-MB-231 cells compared to MCF-7 cells. 
However, MCF-7 cells exhibited a larger area than MDA-MB-231 (Figure 3.10). 
3.2.5. Growth factor mediated cell morphology changes 	  
Both the MDA-MB-231 and MCF-7 cell lines express HGF and EGF receptors (Figure 3.4 
and 3.5) and demonstrate a biochemical response to stimulation with the appropriate ligand. 
However, the morphological response to HGF or EGF stimulation has not been reported. 
MCF-7 cells stimulated with HGF for 15 minutes exhibit significantly higher cell elongation, 
when compared to serum starved cells (Figure 3.11). MCF-7 cells stimulated with EGF for 
15 minutes also trended towards increased elongation, but this did not reach significance in 
this data set (Figure 3.11). In contrast to MCF-7 cells, EGF stimulation of MDA-MB-231 
cells resulted in a significant decrease in elongation (Figure 3.12), whilst cells stimulated 












Figure 3.8: MCF-7 and MDA-MB-231 cell morphology. Both cell lines were examined by 
immunofluorescence staining to characterise their cellular morphology. (A) MCF-7 or MDA-
MB-231 cells were seeded on glass coverslips and actin stained using TRITC conjugated 
phalloidin (Red) and stained with DAPI (blue). B) Cell shape analysis of breast cancer cell 
lines. The cell elongation or areas were measured using Image J. The standard error of the 
mean was calculated for 90 cells in three independent experiments. Bars represents the mean 

















Figure 3.9: Changes in cell morphology in MCF-7 cells downstream HGF but not EGF 
stimulation. A) MCF-7 cells were seeded onto glass coverslips and serum starved for 24 
hours. HGF (10 ng/mL) or EGF (100 ng/mL) were added for 15 min, then fixed and stained 
for F-actin (red) and DAPI (blue). Images were taken using an Olympus IX71 inverted time-
lapse microscope with 40x magnification. Shape analysis was preformed on the cells using 
Image J. The standard error of the mean was calculated for 90 cells in three independent 
experiments to determine the elongation ratio. B) Statistical significance was calculated using 






















Figure 3.10: Changes in cell morphology in MDA-MB-231 cells downstream EGF but 
not HGF stimulation. A) MDA-MB-231 cells were seeded onto glass Coverslips and serum 
starved 24 hours. HGF (10ng/mL) or EGF (100ng/mL) were added for 15 min, then fixed 
and stained for F-actin (red) and DAPI (blue). Images were taken using an Olympus IX71 
inverted time-lapse microscope with 40x magnification. Shape analysis was preformed on the 
cells using Image J. The standard error of the mean was calculated for 90 cells in three 
independent experiments to determine the elongation ratio. B) Statistical significance was 
calculated using t-test, **P<0.005, n.s=not significant. Bars represent the mean  ± S.E.M. 
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3.2.6. PAK6 induces cell elongation in MCF-7 cells but not in MDA-
MB-231 cells  	  
Previous work in the Wells Lab had established that overexpression of PAK6 can induce cell 
shape changes in prostate cancer cells. The initial aim of this project was to establish whether 
PAK6 overexpression could also regulate the cell shape of selected breast cancer cell lines. 
Given that neither HGF nor EGF treatment of the cells lines delivered a robust change in the 
level of phosphorylated PAK6 (Figure 3.6-3.9), it was decided that further experiments 
should investigate the impact of PAK6 overexpression in cells under basal conditions. RFP-
PAK6 was initially expressed in MDA-MB-231 cells, and the full-length protein was 
detected by western blot to confirm that expression could be maintained for at least 48 hours, 
post transfection (Figure 3.13). Overexpression of wild type full-length PAK6 (referred to as 
PAK6 in all figures) in MDA-MB-231 did not significantly affect cell shape or cell area 
(Figure 3.14). This result is consistent with previous work that reported that the 
overexpression of wild type PAK4 in MDCK cells had no effect on cell morphology (Wells 
et al., 2002). Moreover, cell shape changes were not observed when wild type PAK4 was 
overexpressed in C2C12 mouse myoblast cells or NIH3T3 mouse embryo fibroblast cells 
(Qu et al., 2001, Dan et al., 2001b). However, MCF-7 cells expressing RFP-PAK6 shows 
significantly higher elongation when compared to control cells expressing RFP alone or 
untransfected cells (Figure 3.15). This result is consistent with previous work from the lab 
which demonstrated that overexpression of PAK6 can induce cell elongation in the DU145 
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Figure 3.11: PAK6 overexpression in MDA-MB-231 cells. MDA-MB-231 cells were 
transfected with RFP or RFP-PAK6 for 24 hours or 48 hours. Cell lysates were prepared 
immunoblotted for RFP expression using anti-RFP antibody and for PAK6 using anti-PAK6 
antibody. The molecular weight for PAK6 is 75 kDa and ß-actin 42 kDa. Lysates were also 
immunoblotted for ß-actin to provide a loading control. The blots shown are representative of 
































Figure 3.12: Overexpression wild type PAK6 does not induce changes in cell 
morphology in MDA-MB-231 cells. A) MDA-MB-231 cells were seeded onto glass 
coverslips and transfected with RFP-PAK6 or RFP alone using lipofectamine 2000. 
Untransfected (UT) or RFP cells were used as a control cells. Cells were then fixed after 24 
hours and stain with TRITC-phalloidin for actin or DAPI. Shape analysis was performed on 
the cells using Image J to determine the elongation. B) The standard error of the mean was 
calculated for 90 cells in three independent experiments. Statistical significance was 
determined by using t-test, n.s.=not significant. Bars represent the mean  ± S.E.M.  Scale bar 






























Figure 3.13: overexpression wild type PAK6 induces changes in cell morphology in 
MCF-7 cells. A) MCF-7 cells were seeded onto glass coverslips and transfected with RFP-
PAK6 and RFP alone using lipofectamine. Untransfected cells and RFP were used as a 
control. Cells were then fixed after 24 hours and stained with TRITC-phalloidin (actin) or 
DAPI. Shape analysis was performed on the cells using Image J to determine the elongation. 
B) The standard error of the mean was calculated for 90 cells in three independent 
experiments. Statistical analysis was calculated using t-test, ***P<0.0005 n.s.=not 
significant. Bars represent the mean  ± S.E.M. Scale bar 10µm. 
A) 
B) 
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3.2.7. Overexpressing active form of PAK6 (S531N) induces cell 
rounding in MDA-MB-231 cells 
 
 
Since the morphological response of MCF-7 cells phenocopies the morphological effect that 
exhibited by DU145 prostate cells (Fram et al., 2014), which has already been extensively 
explored, this project was directed to better understand the role of PAK6 in the non-colony 
forming MDA-MB-231 cells. It has previously been shown that whilst wild type PAK4 did 
not induce cell morphology changes, the overexpression of activated PAK4 could induce cell 
rounding (Wells, 2002). Thus, the overexpression of activated PAK6 was tested here and a 
number of PAK6 mutant constructs were used (Fram et al., 2014). GFP-PAK6 (K436A) has 
a lysine to alanine mutation at amino acid 436 in the activation loop, and the mutation of this 
residue is proposed to inhibit ATP binding and thereby inhibit PAK6 kinase activity 
(Schrantz et al., 2004), thus rendering a kinase dead PAK6. GFP-PAK6 (S531N) has a serine 
to asparagine mutation at amino acid 531 in the catalytic loop to render PAK6 constitutively 
activated. Mutation of this residue is thought to stabilize the catalytic loop region in the 
kinase domain of PAK6 and is analogous to the PAK4 activation site (S445N) (Schrantz et 
al., 2004, Qu et al., 2001) and the kinase domain alone located between amino acids 368–
682. 
Initially, the PAK6 kinase domain alone, kinase dead or active forms were transfected into 
MDA-MB-231 cells to confirm the correct expression size of PAK6 constructs. Western blot 
analysis of transfected cell lysates shows that the exogenous expression of PAK6 kinase dead 
or kinase active PAK6 was detected at the correct size for full-length proteins  (Figure 3.16), 
whilst PAK6 kinase domain alone was detected at the correct size for a truncated protein 
(Figure 3.16). I acknowledge there is a variation in the expression of wild type PAK6 and 
active PAK6. Subsequently, wild type PAK6, Active PAK6 (S531N), PAK6 kinase domain 
alone or PAK6 kinase dead (K436A) were transfected into MDA-MB-231 cells to monitor 
the effect on cell morphology. Twenty-four hours following transfection, cells expressing 
wild type PAK6, kinase dead PAK6 or PAK6 kinase domain alone expressing cells were not 
significantly different in morphology when compared to cells expressing GFP alone (Figure 
3.17).  
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          Interestingly, active PAK6 (S531N) expressing cells were significantly more rounded cells 
compared with cells expressing the GFP alone (Figure 3.18). It should be noted that when I 
conducted the shape analysis I excluded highly expressed cells from the analysis, which is 
more than 2x brighter than WT signal. Moreover, the morphological effect of PAK6 
overexpression can be recapitulated when cells are seeded on collagen and fibronectin, 






















Figure 3.14: Overexpressing PAK6 mutants in MDA-MB-231 cell. MDA-MB-231 cells 
were transfected with PAK6 kinase domain alone, active PAK6 (S531N) or PAK6 dead 
(K436A). After 24 hours, cells lysates immunobloted with anti-GFP or anti β-actin antibody, 
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Figure 3.15: Overexpressing the active form of PAK6 (S531N) induces cell rounding in 
MDA-MB-231 cells. MDA-MB-231 cells were seeded on glass coverslips and transfected 
with GFP control vector or GFP-PAK6 mutants as indicated. After 24 hours, cells were fixed 
and stained with TRITC-phalloidin for actin or DAPI. 90 cells over three independent 




















Figure 3.16: Overexpressing the active form of PAK6 (S531N) induces cell rounding in 
MDA-MB-231 cells. Shape analysis was performed on the cells using Image J to determine 
the elongation ratio. 90 cells over three independent experiments were analysed. Statistical 
significance compared with GFP expressing control cells was calculated using t-test, 
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Figure 3.17: Overexpressing the active form of PAK6 (S531N) in MDA-MB-231 cells 
seeded on collagen and fibronectin. MDA-MB-231 cells were seeded on collagen and 
fibronectin and transfected with GFP or GFP Active PAK6 (S531N). After 24 hours, cells 
were then fixed and stained with TRIC-phalloidin for actin and DAPI. Shape analysis was 
performed on the cells using Image J to determine the elongation ratio as indicated. 
Representative image are shown three independent experiments. 
 













Figure 3.18: Overexpressing the active form of PAK6 (S531N) in MDA-MB-231 cells 
seeded on collagen and fibronectin. Quantification results represents three independent 
experiments. Bars are standard error of mean value. Statistical significance compared with 
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3.3. Discussion: 	  
In this chapter, the PAK6 protein expression levels in breast cancer cell lines have been 
investigated. Regarding PAK expression, there has been widely research into how they 
contribute to disease progression and cancer (King et al., 2014). However, there are very few 
studies on PAK6 expression levels and in particular in breast cancer. A panel of breast cell 
lines were therefore investigated for PAK6 protein expression, in order to determine the most 
appropriate cell lines to use going forward within the project investigation and test whether 
the level of expression is correlated with invasive potential. Northern blot analysis has shown 
that PAK6 is expressed in the testis and prostate tissues (Yang et al., 2001). In addition, it is 
reported that PAK6 expressed in two breast cancer cell lines MDA-MB-231 and MCF-7 
(Kaur et al., 2008a). Previous work from our laboratory, demonstrated links between PAK6 
expression and cancer cell invasiveness in the prostate cancer cell line DU145, with 
overexpression of PAK6 leading to colony dissemination (Fram et al., 2014). In my study, 
PAK6 was found to be expressed in both single cells and colony forming breast cancer cell 
lines MDA-MB-231and MCF-7 respectively, with higher expression trending in invasive 
breast cancer cells, although these results did not reach significance. Overall, the results 
indicate that PAK6 plays roles in breast cancer cells in addition to those previously assigned 
to function at cell:cell junctions (Fram et al., 2014).  
To facilitate PAK6 studies, efforts were made to develop an in-house-PAK6 antibody. 
However, although this in-house antibody could specifically detect overexpressed PAK6, the 
antibody did not recognize the expression of endogenous PAK6 at the correct size. The 
antibody was not used further as a new commercial antibody became available that did detect 
endogenous PAK6 at correct size and this reagent was used for the remainder of the project. 
Little was known about the regulation of PAK6 at the start of this project. The 
phosphorylation of PAK6 on a specific serine residue Ser560 was thought a sign of its 
activation (Kaur et al., 2005). PAK6 had also been shown to be activated downstream HGF 
in prostate cancer cells by other members of our laboratory (Fram et al., 2014). Therefore, 
the level of PAK6 autophosphorylation following growth factor stimulation (EGF and HGF) 
was investigated in breast cancer cells. Two breast cancer cell lines were selected, MDA-
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MB-231 and MCF-7; both express PAK6, and represent single cell and colony forming cells 
respectively. In both tested cell lines, it is known that the activation of the receptors for HGF 
and EGF results in the phosphorylation of many downstream effectors. MEK-dependent 
phosphorylation of the MAP kinases ERK1 and ERK2 is the best-studied pathway, and this 
was used as a positive control for HGF or EGF stimulation. Both MDA-MB-231 cells and 
MCF-7 cells showed an increase in the phosphorylation of ERK, with the response being 
evident after only 5 minutes. This observation confirmed that HGF/c-Met and EGF/EGFR 
signalling is highly active within these cell lines. However, with regards to PAK6, the results 
suggest that PAK6 autophosporylation levels do not increase upon HGF or EGF stimulation 
in either MDA-MB-231 or MCF-7 cells (Figure 3.6-3.9). This could be due to the efficiency 
of the phospho-serine 560 antibody, or it is possible that PAK6 is phosphorylated 
downstream of HGF or EGF on residues other than serine 560, and this has been shown for 
other PAK family members including PAK1 where multiple autophosphorylation sites have 
been observed (Chong et al., 2001).  In addition, it is known that whilst the activation of 
PAK6 via MKK6 requires serine 560 phosphorylation, PAK6 is also directly activated by 
phosphorylation on tyrosine 566 by MKK6 (Kaur et al., 2005). This supports a hypothesis 
that phosphorylation of other residues on PAK6 may be important for PAK6 activation. This 
could be investigated more by designing in-house antibodies to different serine, threonine or 
tyrosine sites on PAK6. Furthermore, recent publications have suggested that group II PAKs 
may in fact be constitutively phosphorylated at this site and that their regulation is controlled 
either by the release of an autoinhibitory domain, or a pseudosubstrate region within the N-
terminal (Baskaran et al., 2012, Ha et al., 2012). Thus, from these studies it was concluded 
that at least in these two breast cancer cell lines, HGF/EGF might not play a prominent role 
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Generally, when PAK family proteins are overexpressed in cells, morphological changes are 
only detected when activated mutants are expressed (King et al., 2014). Indeed, wild type 
PAK4 overexpression demonstrates no effects on MDCK cell morphology (Wells, 2002). In 
addition to PAK4, overexpression of wild type PAK1 has no affect on cell morphology, 
while the constitutively active forms of PAK1 induces loss of intracellular stress fibres 
(Manser et al., 1997). However, previous work in our laboratory has indicated that 
overexpression of wild type PAK6 could induce cell morphology changes, with 
overexpression of wild type PAK6 inducing cell elongation in DU145 prostate cancer cell 
lines (Fram et al., 2014). Here, in MCF-7 cells, the overexpression of wild type PAK6 was 
again found to induce cell elongation (Figure 3.15). The elongation phenotype observed 
when wild type PAK6 is overexpressed in MCF-7 cells is likely due to a decrease in cell:cell 
adhesion. This has not been reported before for MCF-7 cells and suggests that PAK6 may 
also play a role in cell:cell adhesion beyond DU145 cells. Thus further investigation of 
PAK6 function in the cell:cell adhesion of MCF-7 cells is warranted. The ability of wild type 
PAK6 expressing cells to prompt a morphological change could be related to the 
phosphorylation status of wild type PAK6 and thus activity levels. Wild type PAK6 may be 
autophosphorylated under basal conditions, as has been speculated in the literature for group 
II PAKs (Pandey et al., 2002, Xu et al., 2010, Fram et al., 2014).  
In contrast, the overexpression of wild type PAK6 in MDA-MB-231 cells does not induce 
significant differences in cell shape. However, it might be that for MDA-MB-231 cells, the 
PAK6 needs to be an activated version. Indeed, the majority of PAK induced cell shape 
changes reported previously have been detected when constitutively active forms of PAK1, 2 
and 4 were used (Wells, 2002, Manser et al., 1997, Qu et al., 2001, Zeng et al., 2000). 
Consistent with this hypothesis, cell shape does not change when wild type PAK4 was 
overexpressed in C2C12 mouse myoblast cells or NIH3T3 mouse embryo fibroblast cells 
(Dan et al., 2001b, Qu et al., 2001). The lack of cell shape change might indicate that PAK6 
has a different functional role in MDA-MB-231 cells compared to MCF-7 cells; indeed, 
MDA-MB-231 cells do not form cell:cell adhesions. Results reported here found that the 
overexpression of the active PAK6 (S531N) induces cell rounding, whereas overexpression 
of PAK6 (K436A) or the PAK6 kinase domain alone had no impact on cell shape (Figure 
3.18).  
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The PAK6 kinase domain alone construct is thought to be constitutively activate (Yang et al., 
2001). However, in this assay it did not induce a rounding phenotype (Figure 3.18). This 
observation may be due to incorrect localisation of the protein indeed; PAK6 kinase domain 
alone was not routinely detected at the cell periphery, but rather exhibited a diffuse 
cytoplasmic localisation.  The cell rounding morphology induced by active PAK6 (S531N) is 
reminiscent of that induced by the expression of activated PAK4 in mouse embryo fibroblast 
cells, C2C12 mouse myoblast cells or NIH3T3 cells (Qu et al., 2001, Dan et al., 2001b), and 
it was suggested that cells may become rounded due to loss of adhesion. The cell rounding 
phenotype observed following expression of active PAK6 in MDA-MB-231 cells might be 
due to a number of different mechanisms. It could also be due to a defect in cell spreading. 
Indeed, studies have shown that Rat1 fibroblast cells expressing active PAK4 exhibited a 
diminished ability in cell spreading on a fibronectin-coated substratum (Qu et al., 2001). 
Furthermore, evidence suggests that PAK family member play a role in cell-substratum 
adhesion turnover (Manser et al., 1997, Wells, 2002, Whale, 2011). Alternatively, cell 
rounding may be the result of increased actomyosin contractility (Sahai and Marshall, 2003). 
Work in this chapter has confirmed that there was a high level of PAK6 expression in MDA-
MB-231 cells. Moreover, the overexpression of activated PAK6 was able to induce cell 
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3.4. Future Work 	  
Based on the activation of PAK6 data in this chapter, it would be interesting to test the 
phosphorylation by performing in vitro kinase assay by overexpressed PAK6 and 
immunopurified from stimulated and unstimulated cell lysates. Moreover, another PAK6 
phosphorylation antibody could be tested. Breast cancer PAK6 mutations are reported in the 
COSMIC database, and it would be interesting to see if these mutations also impact on cell 
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4. Chapter 4: Characterisation of cell morphology in PAK6 modulated 
cells 	  
4.1. Introduction 	  
Cell migration and invasion play a key role in metastasis and are considered hallmarks of 
cancer. To metastasize, tumour cells must move through and across boundaries, and this 
process requires cell motility, remodelling of cell-cell contacts and additional interactions 
with the extra cellular matrix (Fidler, 1999). Tumour cells can move as an individual or as a 
collective group (Wolf et al., 2007). Others have demonstrated that individual tumour cells 
can display two different types of movement: an amoeboid mode, with a rounded 
morphology and no obvious polarity, or alternatively a mesenchymal mode, characterised by 
an elongated morphology that requires extracellular proteolysis which occurs at cellular 
protrusions (Friedl and Wolf, 2003). Previous studies have shown that amoeboid or 
mesenchymal modes of movement are distinguished and regulated by different signalling 
pathways (Sahai and Marshall, 2003). The amoeboid phenotype is characterised by high 
levels of actomyosin contractility driven by ROCK (Wilkinson et al., 2005a), whereas the 
mesenchymal mode of movement requires extracellular proteolysis (Sahai and Marshall, 
2003).  
The processes of cell polarity, cell shape, cell adhesion, motility and/or cytokinesis each 
require reorganization of the actin cytoskeleton. Cell motility is determined by the cycles of 
actin polymerization, cell adhesion and actomyosin contractility (Sahai et al., 2007). The 
purification of motile cells from living tumours has shown that the actin polymerization 
machinery is more active in these cells when compared with non-motile cancer cells 
extracted from the same tumour. Therefore, it is important to identify the mechanisms by 
which cytoskeletal regulatory proteins control polymerized actin structures. The RhoGTPase 
family has been implicated in multiple cellular responses, including the regulation of the 
actin cytoskeleton, cell adhesion, motility, the activation of signal transduction pathways, the 
control of cell proliferation, oncogenic transformation and/or invasiveness (Vega and Ridley, 
2008, Yilmaz and Christofori, 2010).  
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The best characterised RhoGTPases are Rho, Rac1 and Cdc42, which have been shown to 
regulate cell shape, migration and invasion primarily by actin 
polymerization/depolymerization and the branching of actin filaments. Rac1 drives motility 
by promoting lamellipodia formation (Ridley, 1992b), while RhoA signalling occurs via 
Rock I and II kinases, and subsequent phosphorylation and activation of myosin light chain 2 
(MLC2), thereby promoting the formation of actin stress fibres and the generation of the 
actomyosin contractile force required for cell movement (Riento and Ridley, 2003, Sanz-
Moreno et al., 2008). 
The most well-characterised downstream effectors of Cdc42 and Rac are the PAK family of 
protein kinases (Bishop and Hall, 2000). However, whilst Group I PAKs have been 
extensively studied, PAK6 is relatively uncharacterised. There are no studies on the 
morphological impact of PAK6 knockdown in breast cancer cells. 
Traditionally, cell migration studies have focused on 2D migration assays however, it is 
becoming evident that 3D assays provide a better and more relevant system is better to study 
cell invasion (Friedl and Wolf, 2003, Wolf et al., 2003). Indeed, it has been shown that cells 
can demonstrate phenotypic differences in a 2D environment, when compared to 3D studies. 
Therefore, to complement 2D experiments, many recent studies have employed 3D assays to 
investigate invasion in an environment that more closely resembles that seen in vivo (Blacher 
et al., 2014). The role of PAK6 in 3D cell invasion has not been investigated. 
In this chapter, the modulation of PAK6 expression levels will be used to further characterise 
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4.2. Results: 	  
4.2.1. PAK6 knockdown in MDA-MB-231 cells  	  
In the previous chapter, the overexpression of activated PAK6 (S531N) was shown to induce 
cell rounding in MDA-MB-231 cells (Figure 3.17). To further explore the relationship 
between PAK6 and cell shape, a PAK6 knockdown strategy was employed. Two different 
PAK6 specific siRNA oligonucleotides were tested in MDA-MB-231 cells, alongside a non-
targeting control siRNA or untransfected (mock) cells. The level of PAK6 expression was 
significantly reduced 24 hours after siRNA transfection when compared with PAK6 levels in 
cells treated with control siRNA. No significant difference in PAK6 expression levels was 
detected between untransfected mock and control siRNA-treated MDA-MB-231 cells (Figure 
4.1). However, there were no differences in PAK6 expression after 48 and 72 hours (Figure 
4.2). Suggesting that the PAK6 depletion is a transient event. Whilst PAK6 knockdown was 
achieved, this was a challenging process that required optimization of the siRNA 
concentrations, the cell seeding densities used and the time point of detection. This could be 
due to the fact that PAK6 was identified as a ‘difficult to silence’ gene in an siRNA screen 
where the central region of PAK6 mRNA was found to be highly difficult to target using 
siRNA knockdown (Bergauer et al., 2009). Additional experiments using a shRNA vector to 
generate a stable PAK6 knockdown cell line were conducted; however, after the antibiotic 
selection, it was not possible to achieve significant reductions in PAK6 expression in the 
selected cell lines. 
4.2.2. Depletion of PAK6 has no significant impact on MDA-MB-
231 cell proliferation 
Previous studies have reported that PAK6 knockdown using siRNA can significantly inhibit in vivo 
and in vitro cell growth in prostate cancer cells (Wen et al., 2009). Knockdown of PAK6 using 
shRNA technology has also demonstrated a significant reduction of cell viability following 
irradiation, when compared to the control cells expressing normal PAK6 levels in prostate cancer 
cells (Zhang et al., 2010).  
 















Figure 4.1: PAK6 knockdown in MDA-MB-231 cells. MDA-MB-231 cells were seeded and 
transfected with PAK6 siRNA (Oligo 1 or 2) or control siRNA or untransfected mock. Cells lysed 
after 24 hours and immunoblotted for PAK6 using a PAK6 specific antibody and for β-actin as a 
loading control. Quantification of blots representative of three independent experiments, which 
were quantified using densitometry. Bars represent the mean  ± S.E.M. Statistical significance was 








































Figure 4.2: PAK6 knockdown does not effect MDA-MB-231 cells after 48 and 72 hours. 
MDA-MB-231 cells were seeded and transfected with PAK6 siRNA (Oligo 1 or 2) or control 
siRNA or untransfected mock. Cells lysed after 48 and 72 hours and immunoblotted for 
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Moreover, PAK6 depletion also reduces the rate of PC3 (prostate) cell proliferation compared to 
the control cells (Goc et al., 2013). Thus, it was decided to investigate whether MDA-MB-231 cell 
proliferation was also effected by PAK6 depletion over the time frame of our assay. Control or 
PAK6 specific siRNA treated cells were replated onto plastic and collagen coated tissue culture 
plates. Cells were incubated for 72 or 96 hours and an MTT assay conducted to determine the cell 
proliferation. Different matrixes were used because studies have shown that matrixes can influence 
the proliferative response of cells in colon cancer (Ohtaka et al., 1996). However, the results 
suggest that there was no significant difference in cellular proliferation was observed in PAK6 
knockdown MDA-MB-231 cells, when compared to control and wild type cells (Figure 4.3). Given 
that PAK6 knockdown is very transient and is only sustained for 24 hours, it would be optimal to 

































Figure 4.3: Depletion of PAK6 has no significant impact on MDA-MB-231 cell 
proliferation. After siRNA-mediated depletion of PAK6, MDA-MB-231 cells were 
subjected to an MTT assay to look at the effect of PAK6 knockdown on cellular 
proliferation. PAK6 knockdown cells were compared with both untransfected (Mock) or 
control siRNA cells after 72 or 96 hours. There was no significant difference observed in 
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4.2.3. PAK6 depletion induces cell elongation  	  
Optimal PAK6 knockdown was observed 24 hours after siRNA transfection, and 
morphological characterisation studies of MDA-MB-231 cells after PAK6 depletion were 
therefore performed at this time point (Figure 4.4). Control or PAK6 knockdown cells were 
seeded onto glass coverslips, and PAK6 depleted cells appeared to exhibit a more elongated 
morphology. Following quantification, cells transfected with PAK6 siRNA oligo1 or oligo2 
were significantly elongated compared with untransfected (mock) or control cells (Figure 
4.5).  Furthermore, similar elongated phenotypes were observed when cells depleted of 
PAK6 were seeded on collagen or fibronectin coated coverslips. This morphological change 
does not depend on the extracellular matrix composition, as observed with overexpression 
studies (Figure 3.19). In addition, PAK6 knockdown cells also exhibited a significantly 
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Figure 4.4: PAK6 knockdown in MDA-MB-231 cells. MDA-MB-231 cells were        
subjected to siRNA knockdown of PAK6 using two pre-validated siRNAs. In addition both a 
control siRNA and mock cells were used in these morphological studies. Cells were seeded 
onto glass, collagen and fibronectin coated coverslips and stained for actin. Images are 































Figure 4.5: PAK6 knockdown induce cell elongation in MDA-MB-231 cells. The cell 
elongation and area were calculated using ImageJ and results quantified. Statistical 
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4.2.4. LBH inhibitor reduces PAK6 expression 	  
PAK6 siRNA studies were limited to a twenty-four hour knockdown window. However, 
during these studies, it was reported that the pan-deacetylase inhibitor Panobinstat 
(LBH) can lead to a decrease in PAK6 expression in a hepatocellular carcinoma cell line 
(Henrici et al., 2013). This observation raised the possibility that LBH could be used to 
achieve an extended period of PAK6 depletion in the MDA-MB-231 cells. LBH 
selectively inhibits histone deacetylase (HDAC) and induces the hyperacetylation of 
core histone proteins, which may result in the modulation of cell cycle protein 
expression, cell cycle arrest in G2/M phase and apoptosis. Panobinostat induces growth 
inhibition and cytotoxicity across, breast, colon, prostate, pancreatic and prostate cancer 
cell lines and acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), 
Hodgkin lymphoma (Shao et al., 2014). Many of the genes altered by panobinostat have 
roles in cell invasion and metastasis involving CDH1, CLDN7, FOSL1, PLAU, STC2, 
and TGFA (Tate et al., 2012). In addition, HDAC inhibitors stimulate transcription of 
proapoptotic genes such as Bax, Bak and Apaf1 (Marchion and Münster, 2007). Studies 
demonstrated that following HDAC inhibitor application, various TNF receptor super 
family members and their ligands are transcriptionally activated (Johnstone, 2002, 
Minucci and Pelicci, 2006). Moreover, Panobinostat mediated apoptotic pathways and 
induced cellular differentiation, this effect is associated with cell-cycle arrest at the G1/S 
boundary mediated by the retinoblastoma protein (pRb) and related proteins (Gabrielli et 
al., 2002). 
 
 The effect of using the inhibitor on PAK6 expression in the MDA-MB-231 cells was 
investigated first (Figure 4.6). MDA-MB-231 cells were subjected to the treatment for 
24 or 48 hours with 5 nM LBH or with DMSO as a control. The results showed that the 
expression of PAK6 was significantly decreased after the addition of the LBH and there 
was some indication that actin expression was also suppressed following LBH treatment 
(Figure 4.6). Previous studies have shown that triple negative breast cancer cells, but not 
ER-positive cell lines, treated with LBH have significantly reduced cell proliferation 
(Tate et al., 2012), and the impact of LBH inhibitor on MDA-MB-231 proliferation was 
therefore examined. Cells were treated with the LBH inhibitor and incubated for 24, 48 
	   120	  
or 72 hours, and an MTT assay was carried out to measure the cell proliferation. The 
result shows that there was no significant difference in cellular proliferation observed 
after 24 and 48 hours treatment. A significant decrease in the MDA-MB-231 cell 
proliferation was however observed after 72 hours post LBH inhibitor treatment (Figure 
4.7).  
4.2.5. LBH treatment phenocopies PAK6 knockdown cell 
morphology 	  
Having established that the LBH treatment depletes PAK6 expression, the effect of adding 
LBH on MDA-MB-231 cell morphology was investigated. In a time frame 24/48 hours 
before significantly drop proliferation, the results demonstrated that there was a significant 
cell elongation upon the LBH inhibitor after 24 or 48hours (Figure 4.8). This result is 
consistent with the knockdown results (Figure 4.4), which show that the depletion of PAK6 























Figure 4.6: LBH inhibitor reduces PAK6 expression. The Histone deacetylase inhibitor 
can reduce the PAK6 expression. MDA-MB-231 cells were treated with 5nM LBH or DMSO 
as control for 24 or 48 hours. Quantified data represents three independent experiments. 
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Figure 4.7: The effect of LBH inhibitor on MDA-MB-231 cell proliferation. MDA-MB-231 
cells were treated with LBH for the indicated times and then subjected to an MTT assay to measure 
cell proliferation. LBH treated cells were compared with DMSO control cells after 24, 48 and 72 
hours. There was no significant difference observed after 24 hours. However, after 72 hours upon 
treatment there is significant decrease on cellular proliferation. Results represent three independent 
experiments. Bars represent the mean  ± S.E.M.  Statistical significance was calculated using 




















































































Figure 4.8: LBH inhibitor phenocopies PAK6 knockdown cell morphology. MDA-MB-
231 cells were seeded on glass coverslips and treated with 5nM LBH or DMSO as a control 
for 24 and 48 hours. Quantified results represent three independent experiments. Bars are the 
standard error of the mean. Statistical significance was calculated using Student’s t-test. 
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4.2.6. Active PAK6 can revert the LBH phenotype  	  
In these studies, the reduction of PAK6 expression either by siRNA or LBH treatment   
induced cell elongation. In contrast, the expression of active PAK6 (S531N) induced cell 
rounding. It was therefore reasoned that the expression of active PAK6 (S531N) might be 
able to rescue the morphological response to LBH. MDA-MB-231 cells were transfected 
with active PAK6 (S531N), wild type PAK6 and GFP alone for 24 hours to allow protein 
expression to occur and then treated with LBH inhibitor for 24 hours. Subsequently, the cells 
were fixed and stained for F-actin. The morphology of cells in all conditions was then 
analysed. LBH was able to induce cell elongation in both cells expressing GFP alone and 
PAK6. However, where cells were expressing active PAK6 (S531N), LBH treatment did not 
induce a significant level of cell elongation (Figure 4.9). Thus, active PAK6 (S531N) can 






























Figure 4.9: Overexpress active PAK6 can revert the effect of LBH inhibitor. MDA-MB-
231 cells were seeded on coverslips and transfected with GFP as control, PAK6 WT, active 
PAK6 S531N and untransfected (UT) for 24 hours and then treated with LBH (5nM). 
Quantified data represents three independent experiments.  Statistical significance was 
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4.2.7. RhoA and ROCK but not Blebbistatin inhibitors prevent 
active PAK6 induced cell rounding 
 
It is known that group I PAKs regulate myosin II contractility (Bokoch, 2003) and that PAK1 
acts to coordinate the interplay between F-actin, myosin II and focal adhesion dynamics for 
efficient cell migration (Delorme-Walker et al., 2011). Here, the overexpression of PAK6 
induces cell rounding (Figure 3.18), and therefore, PAK6 could be mediating cell 
contractility. Signalling via the Rho-ROCK pathway has been shown to be a key determinant 
of actomyosin contractility and is associated with rounded-amoeboid cell (Wilkinson et al., 
2005b, Wolf et al., 2003). To explore further whether there is a mechanistic link between 
PAK6 and the Rho-ROCK pathway, a number of specific inhibitors were exploited. RhoA 
signalling was inhibited using the Rho specific inhibitor (C3), ROCK was inhibited using 
H1152 and Myosin II was inhibited by blebbistatin. It was decided to express active PAK6 in 
cells and then treat them with specific inhibitors to test for the ability of active PAK6 to 
induce cell rounding.  Prior to the application of the inhibitors, the time point of cell rounding 
was determined. MDA-MB-231 cells were transfected with active PAK6 for 6, 17 or 24 
hours. Studies suggest that cells were expressing active PAK6 6 hours following transfection 
but that cell rounding occurred between 6 and 17 hours post transfection (Figure 4.10). Thus, 
MDA-MB-231 cells were transfected with active PAK6, incubated for 6 hours and then 
treated with inhibitors or vehicle control.  The results show that whilst treatment with vehicle 
control did not prevent active PAK6 induced rounding, treatment with C3 was able to 
prevent active PAK6 induced rounding and the cells remained significantly more elongated 
than vehicle control (Figure 4.11).  Consistent with a Rho:ROCK pathway, the inhibition of 
active PAK6 expressing cells with H1152 also prevented cell rounding, and treated cells 
were again significantly more elongated than vehicle control (Figure 4.12). Interestingly, 
treatment with blebbistatin inhibitors whilst trending towards increased elongation at early 
time points was unable to significantly prevent active PAK6 induced cell rounding as seen 
with C3 and H1152 (Figure 4.13). Taken together, these data suggest that the active PAK6 
induced rounded morphology is dependent on the Rho:ROCK pathway. However it is less 
clear how the cell rounding signal is transduced downstream of ROCK.  
 
 


















Figure 4.10: PAK6 overexpression at different time points. MDA-MB-231 cells were 
seeded onto glass coverslips and transfected with active GFP-PAK6 at different time points. 





















Figure 4.11: RhoA inhibitor prevents active PAK6 induce cell rounding. The effect of 
using 5µM RhoA inhibitor (C3) on cell morphology in MDA-MB-231 cells after 2,4 and 16 
hours were investigated. MDA-MB-231 cells were seeded on coverslips; following day the 
cells transfected with Active PAK6 and treated with RhoA inhibitor at different time points. 
Quantification results represents three independent experiments. Bars represent the mean  ± 
S.E.M. Statistical significance was calculated using Student’s t-test where P****<0.0001. 
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Figure 4.12: ROCK inhibitor prevents active PAK6 induce cell rounding. The effect of 
using 5µM ROCK inhibitor (H1152) on cell morphology in MDA-MB-231 cells after 2,4 and 
16 hours were investigated. MDA-MB-231 cells were seeded on coverslips; following day 
the cells transfected with Active PAK6 and treated with ROCK inhibitor for different time 
points. Quantification results represents three independent experiments. Bars represent the 
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Figure 4.13: Blebbistatin does not prevent active PAK6 induce cell rounding. The effect 
of using 5µM Blebbistatin (MyosinII inhibitor) on cell morphology in MDA-MB-231 cells 
after 2,4 and 16 hours were investigated. MDA-MB-231 cells were seeded on coverslips; 
following day the cells transfected with Active PAK6 and treated with Blebbistatin and 
vehicle control and incubated at different time points. Quantification results represents three 
independent experiments. Bars represent the mean  ± S.E.M. Statistical significance was 
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4.2.8. Optimization the 3D spheroid invasion assay using MDA-
MB-231 cells 	  
It is becoming increasingly apparent that the behaviour of cells in a 2D environment does not 
always reflect their 3D behaviour. Therefore, in parallel with 2D cell morphology studies, it 
was decided to employ 3D spheroid invasion assays. It was originally anticipated that this 
assay could be used to assess the effect of PAK6 knockdown on invasive migration. Prior to 
the use of PAK6 depleted cells, the assay was optimized for use with MDA-MB-231 cells, as 
this was a new technique introduced into the laboratory.  In the spheroid assay, the spheroid 
tumour masses are created and encapsulated by a 3D matrix, such as collagen I, to represent 
the primary tumour mass and the surrounding tissue. Over time, the tumour cells invade 
away from the spheroid mass, and this invasion can be quantified. 
To form the spheroid mass, cells were submerged in methylcellulose media for 3 days. The 
cell mass was then transferred into the collagen I matrix, where the level of invasion was 
quantified. Cell invasion was measured as the number of cells that had migrated further than 
100 µm from the spheroid edge. MDA-MB-231 cells were observed to invade relatively 
quickly compared to melanoma cells in our laboratory; whereas melanoma cells require 2-3 
days embedding to deliver a quantifiable invasion, MDA-MB-231 cell invasion was visible 
17 hours post embedding, as illustrated in Figure 4.14. Thus, the end point was modified for 
MDA-MB-231 cells. Unfortunately, it was not possible to test PAK6 depleted cells in the 
spheroid assay as the time frame for PAK6 knockdown was limited to 24 hours (Figure 4.1) 
and did not facilitate a long-term assay.  However, it was decided to test the impact of LBH 
inhibitor treatment, as there was a slightly longer window of PAK6 depletion. MDA-MB-231 
cells were treated with the LBH inhibitor and allowed to form a spheroid and the cells were 
then tested for invasion into the collagen matrix. Whilst DMSO treated control cells were 
able to successfully invade the collagen, and more than 40 single cells on average could be 
detected beyond 100um from the spheroid center, LBH treatment had a significant inhibitory 
effect on the ability of these cells to invade (Figure 4.15).  
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Figure 4.14: Optimization of a 3D spheroid invasion assay using MDA-MB-231 cells. 
Representative phase contrast images of the 3D spheroid invasion assay are shown. 
Spheroids were produced in media containing methylcellulose for 3 days, then submerged in 
collagen type I matrix. Phase contrast images were taken at day 0 and 96, 24 and 17 hours. 
The cell invasion was measured after 96, 24 and 17 hours commencing when the spheroids 
were placed in collagen type I. 
 








Figure 4.15: 3D spheroid invasion assay. Representative image at day 0 and 17 hours of the 
3D invasion assay in MDA-MB-231 cells in which the cells treated with DMSO as control 
and LBH. Spheroids were produces in media containing methylcellulose for 3 days, then 
submerged in collagen type I matrix. Phase contrast images were taken at day 0 and 17 hours. 
The cell invasion was measured after 17 hours commencing when the spheroids were placed 
in collagen type I. Bars represent the mean  ± S.E.M. Statistical significance was calculated 
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4.2.9. PAK6 is localised at the cell periphery in MDA-MB-231 cells 	  	  
The work presented here has identified a putative role for PAK6 in cell rounding mediated by 
the Rho:ROCK signalling pathway. Such a role might suggest a peripheral or cell adhesion 
localisation. However, very little is known about subcellular localisation of PAK6. It has 
been speculated that PAK6 is localized at the cell periphery in androgen expressing cells and 
subsequently translocates to the nucleus upon receptor stimulation (Yang et al., 2001). In 
contrast, previous work in our laboratory demonstrated that in colony forming prostate 
cancer cells, PAK6 localized at cell-cell boundaries (Fram et al., 2014). The localisation of 
PAK6 in MDA-MB-231 cells has not been previously investigated. Ideally, localisation 
would be established using an antibody to endogenous PAK6, however, no such antibody is 
available for Immunofluorescence. Thus, GFP-tagged PAK6 was utilized. GFP-PAK6 was 
transiently expressed in MDA-MB-231 cells, and the subcellular localisation observed by 
confocal microscopy. The F-actin staining revealed that GFP localizes to the cytoplasm and 
GFP-PAK6 localizes predominantly in the cytoplasm, however it was also possible to detect 
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Figure 4.16: Localisation of exogenous PAK6 in MDA-MB-231 cells. MDA-MB-231 cells 
were transfected with GFP alone as a control and GFP-PAK6 wild type. After 24 hours cells 
were fixed and stained with TRITC-phalloidin to detect F-actin. Confocal images were taken. 
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4.3. Discussion 	  
In this chapter, the potential role of the PAK family member PAK6 on cell morphology has 
been further investigated. Complementary to Chapter 3, it has now been demonstrated that 
cells induce the opposing morphological change when PAK6 expression is depleted. 
Interestingly, the reduction of PAK6 expression using LBH inhibitor treatment phenocopies 
the morphology of PAK6 knockdown. Moreover, the expression of active PAK6 can prevent 
the LBH inhibitor induced cell morphology changes, whilst inhibition of the RhoA:ROCK 
pathway prevented active PAK6 induced morphologies. These results suggest that PAK6 
may play an important role in the regulation of cell contractility and the cytoskeleton. 
 
It is known that PAK6 is up regulated in various cancer cell lines and tissue samples (Chen et 
al., 2014, Liu et al., 2014, Kaur et al., 2008b). PAK6 depletion is known to inhibit cell 
growth, invasion and the ability to disassemble junctions in response to HGF in prostate 
cancer cells (Goc et al., 2013, Fram et al., 2014). However, there is no study addressing the 
effect of PAK6 knockdown in breast cancer cells. The level of PAK6 in MDA-MB-231 cells 
was significantly reduced when compared to PAK6 levels in control siRNA and 
untransfected (mock) samples. No significant difference in PAK6 expression levels were 
detected between mock and control siRNA in MDA-MB-231 cells.  However, whilst PAK6 
knockdown was achieved, this was a challenging process that required a series of 
experiments, using a range of siRNAs from different companies in order to obtain optimal 
knockdown efficiencies. PAK6 levels were significantly decreased after 24 hours siRNA 
treatment but started to recover after 48 and 72 hours of treatment. There are a number of 
reasons that could account for this relatively short period of PAK6 depletion. PAK6 was 
classed as a ‘difficult to silence’ gene in a siRNA screen where the central region of PAK6 
mRNA was found to be highly difficult to target using siRNA knockdown (Bergauer et al., 
2009). Conversely, it has been reported that PAK6 has anti apoptotic functions in prostate 
cancer cells (Zhang et al., 2010), perhaps MDA-MB-231 cells with a high level of PAK6 
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In hepatocellular carcinoma (HCC) samples, PAK6 was overexpressed compared with non-
cancerous liver tissue, and PAK6 was positively correlated with proliferation and poor 
prognosis (Chen et al., 2014). Moreover, in colon cancer PAK6 promotes tumour progression 
and chemoresistance, both in vivo and in vitro (Chen et al., 2015). However, a difference in 
cell proliferation rate was not observed in the PAK6 siRNA treated cells (Figure 4.3). Since a 
stable PAK6 knockdown cell line could not be generated there could be a long-term cell 
viability issue or alternatively, the case that PAK6 protein turnover occurs very quickly. 
 
Despite the technical difficulties of working with PAK6 siRNA treated cells it was possible 
to conduct cell morphology assays by keeping to the small reduced expression window. The 
results show that in direct contrast to the overexpression of the active form of PAK6 
(Figure3.19), depletion of PAK6 significantly induces cell elongation in MDA-MB-231 cells 
(Figure 4.5). Interestingly, cells became much more elongated and larger in area following 
depletion of PAK6. The same phenotype was also observed in cells coated on collagen or 
fibronectin. This is confirming that the morphological changes observed are not dependent 
on matrix composition. It is known that cell spreading can be modulated by RhoGTPases and 
integrin-mediated signalling pathways (Herrera, 1998, Huttenlocher and Horwitz, 2011). 
RhoGTPases are necessary for the reorganization of the actin cytoskeleton during cell 
movement (Ridley et al., 1995), and integrins play an essential role in mediating the 
attachment of cells to the ECM (Herrera, 1998, Huttenlocher and Horwitz, 2011).  
It is well established that the Rho family GTPases Rho, Rac and Cdc42 organise cell 
adhesion, turnover and cell migration (Ridley et al., 2003). High levels of Rho-ROCK 
signalling in tumour cells drive high levels of actomyosin contractility and are associated 
with the movement of individual cells in a rounded phenotype whereas lower levels of 
contractility are associated with Rac-dependent elongated movement. Having looked at the 
effect of PAK6 knockdown on cell morphology, the involvement of PAK6 in the Rho-ROCK 
pathway was investigated. The results show that cells expressing active PAK6 remain 
elongated in the presence of ROCK (H1152) and RhoA (C3) inhibitors but not blebbistatin. 
These data suggest that PAK6 could be involved in RhoA signalling pathways. Since PAK6 
binds to Cdc42, but not RhoA (Schrantz et al., 2004), these data raise the question as to 
whether the relationship between PAK6 and RhoA is direct or is mediated via other 
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mechanisms or other proteins. Interestingly the silencing of RhoA expression in MDA-MB-
231 cells also induced cell elongation similar to PAK6 (Vega et al., 2012). It might be 
speculated that overexpression PAK6 activates a RhoA pathway, which leads to increased 
MLC2 phosphorylation, whereas the knockdown of PAK6 results in reduced activation of 
RhoA and phosphorylation of MLC2. However, the results from blebbistatin inhibition 
suggest that PAK6 induced cell rounding does not require the activity of Myosin II. PAK6 
may be involved in other pathways downstream of ROCK. It is known that ROCK 
phosphorylates and activates LIMK, which in turn phosphorylates cofilin (Riento and Ridley, 
2003). 
It is possible that the cell rounding phenotype observed with PAK6 could also be the result of 
a loss of cell adhesion, as has been previously reported for PAK4 (Wells et al., 2010a). 
Perhaps, PAK6 links Cdc42 activation to integrin signalling. Whether PAK6 is involved in 
integrin signalling remains to be determined. However, it should be noted that the phenotype 
observed following the PAK6 depletion is not the same as the PAK4 depletion phenotype in 
MDA-MB-231 cells, suggesting a differential mechanistic pathway (Dart et al., 2015). It is 
reported that the rounded amoeboid cell movement is less dependent on integrin signalling 
than the mesenchymal type cell movement, and this might be relevant to the PAK6 induced 
phenotype (Wolf et al., 2003).  
While the work presented here was being carried out, a new study was published 
demonstrating that the pan-deacetylase inhibitor Panobinostat (LBH) could suppress the 
expression of PAK6 in hepatocellular carcinoma cells (Henrici et al., 2013). Therefore, the 
effect of the LBH inhibitor on PAK6 expression and cell morphology was investigated. 
Consistent with PAK6 knockdown results, the inhibition of PAK6 expression leads to 
significantly elongated cells following LBH inhibitor treatment (Figure 4.8). In addition, 
active PAK6 overexpression can invert the LBH inhibitor cell phenotype. However, it should 
be considered that this inhibitor may not be specific for PAK6 and it is not really known how 
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Down regulation of PAK6 in the presence of the inhibitor could be the direct result of histone 
acetylation. Alternatively, hyperacetylation could result in the transcription of regulatory 
factors that negatively regulates gene transcription. It has been reported that in some prostate 
cancer cells the PAK6 gene is hypermethylated (Wen et al., 2009), which would ordinarily 
lead to down regulation of PAK6 expression. Nevertheless, the combined LBH and 
knockdown data strongly validate the cell elongation phenotype. 
 
In addition to cell morphology studies, the LBH inhibitor was also utilized in 3D spheroid 
assays, as PAK6 knockdown cells could not be used. LBH treatment (including the depletion 
of PAK6 expression) leads to a significant decrease in cell invasion. This is an interesting 
observation that requires more investigation. Consistent with this observation, it has 
previously been shown that PAK6 knockdown in prostate cancer cells had a significant 
reduction in invasion when compared to control cells (Wen et al., 2009). Furthermore, 
knockdown of PAK6 in PC3 prostate cancer cells results in reduced expression of MMP9 
(Goc et al., 2013). Interestingly, recent studies suggest that histone deacytlase inhibitors (like 
LBH) could limit the expression of the matrix metalloproteinase MMP9 (Bolden et al., 
2006). Thus, it cannot be ruled out that the inhibition of invasion delivered by LBH could be 
an indirect effect on the MMP, which may or may not be mediated by PAK6. It is interesting 
to note that in a panel of twelve melanoma cell lines, a higher secretion of several MMPs was 
observed including MMP9, MMP2 and MMP13, which were associated with rounded cell 
morphology when compared with elongated cells. MMP9 acted as a signalling intermediate 
to activate MLC2 phosphorylation and resulted in efficient rounded 3D cell migration (Orgaz 
et al., 2014). Thus, perhaps there is an intrinsic link between cell rounding, PAK6, ROCK, 
MMP expression and invasion.  
 
Results presented here suggest that PAK6 can act as a cytoskeletal regulator and may be 
active in the cytoplasm and/or near to the plasma membrane. However, very little is known 
about PAK6 localisation in breast cancer cells. In non-colony forming fibroblastic CV-1 
cells, the full-length PAK6 was found to be localized predominantly in the cytoplasm. PAK6 
can also translocate to the nucleus with AR stimulation (Yang et al., 2001) in prostate cancer 
cells. PAK6 is also found localized at the plasma membrane in HeLa cells (Lee et al., 2002), 
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although in an independent study,  PAK6 frequently localized to punctate formations in the 
cytoplasm of HeLa cells and NCI-H1299 lung cancer cells (Shepelev and Korobko, 2012). 
Our laboratory has previously reported that in colony forming prostate cancer cells, PAK6 
localizes to cell-cell junctions (Fram et al., 2014). Since a PAK6 antibody that could be used 
for immunofluoresence experiments could not be generated, the localisation of exogenous 
tagged PAK6 was investigated. The localisation of PAK6 was in agreement with previous 
studies being mainly cytoplasmic, however, a distinct localisation at the cell periphery could 
be detected. This peripheral localisation might represent the active pool of PAK6 however 
without specific probes to localise active PAK6, this remains to be determined. It might be 
speculated that the induction of cell rounding could be delivered by modifications to the 
peripheral actin cytoskeleton.  
 
In summary, it has been determined that there is an important specific role for PAK6 in 
mediating cell morphological changes using overexpression or knockdown strategies. Indeed, 
the work presented here suggests that PAK6 may mediate cell cytoskeleton reorganization. 
These PAK6 functions may be the result of interaction with other binding proteins. Further 















	   141	  
4.4. Future works 
 
One major challenge with the work performed in this chapter was the time point of the 
knockdown and the transient nature of that knockdown. It would be interesting to explore 
the PAK6 lifetime cells through pulse-chase experiments. The knockdown PAK6 cells did 
show a clear phenotype; however, ideally, it would be better to produce a stable 
knockdown cell line, which was the original experimental plan to work with 3D and in vivo 
experiments. Given that attempts with shRNA did not yield successful long-term 
knockdown, it might be advantageous to exploit a newer technology, CRISPR. Although it 
cannot be assumed that a complete loss of PAK6 might be deleterious to the cells. CRISPR 
would also permit the re-expression of tagged PAK6 at endogenous levels (knock-in), which 
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5. Chapter 5: Identification PAK6 binding partners 	  
5.1. Introduction 	  
The work in Chapter 3 and 4 suggests that PAK6 interacts with actin cytoskeletal signalling 
pathways, which are recognised to be regulated by Rho family GTPases, such as Rho, Rac 
and Cdc42. It is widely established that Rac and Cdc42 bind to PAK family proteins. Indeed, 
for Group I PAKs, binding stimulates their kinase activity (Eswaran et al., 2008). The Group 
II PAKs are thought to preferentially bind to Cdc42, however, whether this Cdc42 interaction 
increases kinase activity is controversial (Schrantz et al., 2004). Thus, the differential 
preference for Cdc42 and the controversy over activation suggest that the two groups of 
PAKs are regulated in fundamentally different ways (Abo et al., 1998, Arpino et al., 2004, 
Cotteret and Chernoff, 2006, Ha et al., 2012). Whilst binding to Rac and Cdc42 has been 
extensively explored, other RhoGTPases have been less studied, including the atypical 
RhoGTPases, such as RhoU and RhoV. These GTPases are of particular interest, as RhoU is 
reported to bind to PAK1 (Fort et al., 2011b), PAK4 (Dart et al., 2015) and PAK6 (Shepelev 
et al., 2011). The PAK6 interaction with RhoV is only reported in one study of human 
embryonic kidney (HEK) 293 cells, whilst in the same study RhoU was also reported to bind 
to PAK6 (Shepelev and Korobko, 2012). Moreover, it is reported that the overexpression of 
active RhoU can induce cell rounding in NIH3T3 cells (Chuang et al., 2007). In contrast, the 
overexpression of RhoV leads to lamellipodia formation, focal adhesion assembly and 
oncogenic transformation in NIH3T3 cells (Aronheim et al., 1998).  
As downstream effectors of RhoGTPases Cdc42 and Rac1, PAK signalling is known to 
mediate multiple pathways, including cell movement. In the majority of cases, PAK drives 
these responses via substrate phosphorylation, and a number of PAK substrates have been 
identified (Chapter1, Table 1.1). In the context of migration it is reported that PAKs are 
linked to the regulation of actin cytoskeletal reorganization via phosphorylation of LIMK, 
GEF-H1 and MARK2 (Van Troys et al., 2008, Callow et al., 2005a, Zenke et al., 2004b, 
Matenia et al., 2005).  
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An interesting downstream target of PAK1 is the actin-binding protein FilaminA. FilaminA 
has been implicated in the regulation of cell migration, integrin-mediated adhesion, cell–cell 
adhesion and signal transduction (Chen et al., 2009, Zhou et al., 2010). The relationship 
between FilaminA and PAK is complex, with both upstream and downstream interactions 
reported, both from a single study (Vadlamudi et al., 2002b). On the one hand, FilaminA 
binds PAK1 in the CRIB domain, releasing autoinhibition and thereby stimulating PAK1 
activity, on the other hand, PAK1 can phosphorylate FilaminA at serine 2152, which appears 
to drive the formation of dorsal membrane ruffles (Vadlamudi et al., 2002b). In contrast to 
the other PAK members, there is much less known about the interaction between PAK6 and 
the proteins controlling cytoskeletal dynamics. PAK6 can interact with IQGAP1, but this 
interaction was detected in the junction of colony forming cells (Fram et al., 2014, Kaur et 
al., 2008b). 
The work presented in this chapter sought to further explore the interaction between PAK6 
and the wider RhoGTPase family as well as to identify novel PAK6 binding partners that 
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5.2. Results: 	  
5.2.1. PAK6 interacts with RhoV, RhoU and RhoD 	  
To explore the interaction between PAK6 and Rho Family GTPases in more detail, 
interaction studies were conducted in HEK293 cells. This system was adopted, as it yields 
high levels of protein expression and facilitates the detection of protein:protein interaction by 
immunoprecipitation. Initially, cells were co-transfected with GFP-Cdc42 and RFP-PAK6 as 
a positive control, as this was tested against Myc-RhoV, which is already published to 
interact, and Myc-RhoG, which as a close relative of Rac would be predicted not to bind 
PAK6. In this experiment, RFP-PAK6 was immunoprecipitated with anti-RFP antibodies, 
and the immune complexes were then analysed by western blotting for the expression of 
RFP-PAK6 (anti-PAK6) and RhoGTPases using anti-GFP (Figure 5.1 A) and anti-Myc 
antibodies (Figure 5.1 B). The results show as expected, Cdc42 bound to PAK6, confirming 
the validity of the assay (Figure 5.1 A). Moreover, in agreement with the previous study 
(Shepelev and Korobko, 2012), PAK6 interacted with RhoV (Figure 5.1 B), and as predicted 
did not interact with RhoG (Figure 5.1 B). These findings suggest that PAK6 might indeed 
be an effector of RhoV.  
To further validate this result, an alternative strategy was employed using GFP-TRAP.  Cells 
were transfected with GFP-PAK6 alone or co-transfected with GFP-PAK6 and Myc-RhoV. 
In addition, Myc-RhoU was also co-transfected with GFP-PAK6 to test this reported 
interaction (Shepelev and Korobko, 2012). The results confirm the interaction between 
PAK6 and RhoV or RhoU (Figure 5.2). However, despite an equal amount of overexpressed 
RhoV and RhoU in the cell lysates in the TRAP experiment, GFP-PAK6 appears able to 
complex with RhoV more efficiently than RhoU.  This suggests that the interaction between 
RhoU and PAK6 may be weaker.  
Having established PAK6 binding of Cdc42, RhoV and RhoU, an additional Rho family 
GTPase was tested, RhoD. RhoD has been linked to FilaminA activity (Gad et al., 2012) and 
is also thought to be related to Cdc42 at the cell response level (Ridley, 2006), playing a role 
in cell protrusion. Cells were co-transfected with GFP-RhoD and RFP-PAK6 and 
immunoprecipitated using an anti-RFP antibody. The complex was analysed by western 
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blotting using anti-PAK6 and anti-GFP antibodies (Figure 5.3), and GFP-RhoD was clearly 
detected in the PAK6 immunoprecipitation. To further validate this result, GFP-TRAP 
experiment was employed. Cells were co-transfected with GFP-RhoD and Myc-PAK6 or 




































Figure 5.1: Co-immunoprecipitation of PAK6 with Cdc42, RhoV and RhoG. A) 
HEK293 cells were transfected with RFP-PAK6, and GFP-Cdc42 as indicated as positive 
control and untransfected as negative control. The cells were lysed and RFP-PAK6 was 
immunoprecipitated using an anti-RFP antibody (IP) from cell lysates. The samples were 
immunoblotted for overexpressed GFP-Cdc42 using an anti-GFP antibody, for RFP-PAK6 
using an anti-PAK6. Whole cell lysates (WCL) were immunoblotted using anti-PAK6 and 
anti-GFP antibodies. B) The samples were immunoblotted for over- expressed c-Myc RhoV 
and c-Myc RhoG using an anti-c-Myc antibody, for RFP-PAK6 using an anti-PAK6. Whole 
cell lysates (WCL) were immunoblotted using anti-PAK6 and anti-c-Myc antibodies. The 
molecular weight for Cdc42 21kDa, RhoV 29 kDa and PAK6 75 kDa. The blots shown are 































Figure 5.2: RhoV and RhoU binds to PAK6.  A) HEK293 cells were transfected with GFP-
PAK6 alone, GFP-PAK6 and Myc-RhoU or GFP-PAK6 and RhoV. The cells were lysed and GFP-
TRAP used. The samples were immunoblotted for over- expressed PAK6 using an anti-GFP 
antibody, for RhoU and RhoV using anti-Myc. B) Whole cell lysates (WCL) were immunoblotted 
using anti-GFP and anti-Myc antibodies. The molecular weight for PAK6 is 75 kDa, RhoU 28 kDa 
and RhoV 29 kDa. The blots shown are representative of three independent experiments. 	  	  	  
 	  	  
A) 
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Figure 5.3: Co-immunoprecipitation of PAK6 with RhoD. HEK293 cells were transfected 
with RFP-PAK6 alone, or RFP-PAK6 with RhoD. The cells were lysed and RFP-PAK6 was 
immunoprecipitated using an anti-RFP antibody (IP) from cell lysates. The samples were 
immunoblotted for overexpressed RhoD using an anti-GFP antibody, for RFP-PAK6 using 
an anti-PAK6. Whole cell lysates (WCL) were immunoblotted using anti-PAK6 and anti-
GFP antibodies. The molecular weight for RhoD is 23 kDa and PAK6 75 kDa. The blots 
shown are representative of three independent experiments. 	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Figure 5.4: RhoD binds to PAK6.  HEK293 cells were transfected with Myc-PAK6 alone, Myc-
PAK6 and GFP-RhoD. The cells were lysed and GFP-TRAP used. The samples were 
immunoblotted for over-expressed PAK6 using using an anti-Myc antibody, for RhoD using anti-
GFP. Whole cell lysates (WCL) were immunoblotted using anti-GFP and anti-Myc antibodies. The 
blots shown are representative of three independent experiments. 
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5.2.2. MDA-MB-231 cell morphology is affected by RhoV and 
RhoD   	  
It was already established that the overexpression of active PAK6 could induce cell rounding 
(Chapter 3, Figure 3.19). PAK6 is not thought to be activated by Cdc42 (Schrantz et al., 
2004), but it may be that other RhoGTPases act to stimulate PAK6.   Having established that 
PAK6 also interacts with RhoU, RhoV and RhoD, the impact of GTPase expression was 
tested to elucidate any commonality with activated PAK6. Overexpression of RhoU did not 
phenocopy active PAK6 overexpression; in contrast, overexpression of RhoV and RhoD 
induced a rounded phenotype when compared with    GFP or untransfected control cells 



































Figure 5.5: RhoD and RhoV overexpression induces morphological changes in MDA-MB-231 
cells. MDA-MB-231 cells were transfected with GFP (control) or GFP-RhoU, GFP-RhoD, GFP-
RhoV or active PAK6 S531N. After 24 hours, cells were fixed and stained with TRITC-phalloidin 
for F-actin. Shape analysis was performed on the cells using Image J to determine the elongation 
ratio. The quantification results over three independent experiments. Bars represent the mean  ± 
S.E.M. Statistical significance where compared with GFP control cells was calculated using 
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5.2.3. Identification of novel PAK6 binding partners by mass 
spectrometry  	  	  
In parallel to identifying RhoGTPase family members that can interact with PAK6, 
additional novel PAK6 binding partners were sought, with a specific aim is to identify breast 
cancer relevant interactions. To achieve this objective, PAK6 was isolated from breast cancer 
cells for interaction analysis. Initial work focused on developing good transfection and 
expression of PAK6 in selected breast cancer cells, and the testing whether PAK6 could be 
successfully isolated from lysates. RFP and RFP-PAK6 were transfected into MDA-MB-231 
cells, immuopreciptated using RFP antibody and PAK6 immunobloted using anti-RFP 
antibody. The results show that PAK6 can be immunoprecitated from MDA-MB-231 cells 
(Figure 5.6) with no band detected it in untransfected and RFP control lane. The expression 
of PAK6 in the whole cell lysates consistently revealed a double band, which might be due to 
non-specific binding or degradation. The amount of PAK6 immunoprecipitated from cell 
lysates was not considered optimal for mass spectrometry analysis and the presence of a 
doublet was also troubling. Therefore it was decided to use GFP-TRAP beads as an 
alternative strategy as good yields had been achieved in HEK293 cells (Figure 5.3). Western 
blot analysis suggests that there was a good yield of GFP-PAK6 (single band) and very little 
background contamination. Moreover, unlike immunopreciptation, the bound fraction of the 
GFP-TRAP does not contain contaminating polypeptide chains (antibodies). Thus GFP-
TRAP was used for the mass spectrometry experiments. 
To identify novel proteins that interact with PAK6, MDA-MB-231 cells were transfected 
with wild type GFP-PAK6, GFP-PAK6 kinase domain or GFP alone to provide a control. 
This approach allowed detection of proteins that bind to the PAK6 kinase domain, which 
could represent a substrate or detection of proteins that bind outside the kinase domain, 
which could represent regulators. The isolated protein complexes were first resolved using 
SDS-PAGE gel and stained with Coomassie blue (Figure 5.6).  
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Protein bands were excised, digested with trypsin and proteins identified by Liquid 
chromatography–mass spectrometry (LC/MS). The mass spectrometry was performed by 
Malcolm Ward’s group based at King’s College London. The criteria applied were to exclude 
the PAK6 overexpression protein band and proteins at the level of RhoGTPases as this would 
skew the analysis towards known interactions. Analysis was restricted to the protein bands in 




















Figure 5.6: PAK6 immuoprecipitated from MDA-MB-231 cells. MDA-MB-231 cells 
were transfected with RFP-PAK6 and RFP as control untransfected (UT). The cells were 
lysed and overexpressed PAK6 was immunoprecipated using anti-RFP antibody (IP). IPs was 
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Figure 5.7: Identification of novel PAK6 binding partners expressed in MDA-MB-231 
cells by mass spectrometry. MDA-MB-231 cells were transfected with GFP as control, 
GFP-PAK6 or GFP-PAK6 Kinase domain. Cells were lysed and add GFP-TRAP beads. The 
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5.2.4. FilaminA, MyosinIIA and 14-3-3 proteins interact with PAK6  	  
The results from mass spectrometry analysis indicate some novel proteins that bind to PAK6 
(Table 5.1) but not to GFP alone. Interestingly, the experiments also revealed some proteins 
that bind to wild type full-length PAK6 but not to the PAK6 kinase domain and vice versa. 
FilaminA, Myosin IIA and 14-3-3 proteins were found to bind to the wild type PAK6. Others 
have shown recently shown that 14-3-3 can also bind to PAK6 in HEK293 cells (Tinti et al., 
2014). Any putative interaction partner identified either through affinity purification or 
biochemical fractionation must be validated to confirm its physiological relevance. The 
interaction between PAK6 and Myosin IIA could not be confirmed. Given that the interaction 
between PAK6 and 14-3-3 had already been reported (Tinti et al., 2014), and that GEF-H1 
has already been extensively characterised with respect to PAK (Callow et al., 2005a, Zenke 
et al., 2004b), it was decided to focus on the FilaminA and PAK6 interaction.  
Table 5.1: The results from mass spectrometry. 




FilaminA NO Yes NO 
Myosin IIA NO Yes NO 
14-3-3 
protein 
NO Yes NO 
GEF H1 NO NO Yes 
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5.2.5. Full-length PAK6 interacts with FilaminA 	  
For initial validation of a specific interaction between PAK6 and FilaminA, HEK293 cells 
were used. FilaminA is a large (approximately 280 kDa) multi-domain scaffold protein that is 
known to have multiple binding partners (van der Flier and Sonnenberg, 2001). HEK293 
cells were transfected with full-length GFP-PAK6 and Myc-FilaminA, GFP-PAK6 kinase 
domain and Myc-FilaminA, GFP-PAK6 full-length alone or Myc-FilaminA alone. Consistent 
with the mass spectrometry predictions FilaminA was isolated with full-length PAK6 but not 
the kinase domain (Figure 5.8 A). To confirm this result, an alternative protocol was used to 
test the specificity of this interaction. HEK293 cells were transfected with Myc-FilaminA 
and either full-length GFP-PAK6 or GFP alone. Myc beads were then added to pull down 
Myc-FilaminA and western blot analysis revealed that full-length PAK6 was also present in 























Figure 5.8: PAK6 interacts with FilaminA in HEK293 cells. A) HEK293 cells were transfected 
with GFP-PAK6 full-length and Myc-FilaminA, GFP-PAK6 kinase domain and Myc-FilaminA, 
Myc FilaminA and GFP-PAK6 full-length. The cells were lysed and GFP-TRAP used and 
immunoblotted for FilaminA using anti-Myc and for PAK6 using anti GFP. Whole cell lysate was 
immunoblotted for FilaminA using anti-Myc and for PAK6 using anti GFP. The blots are 
representative of three independent experiments. B) HEK293 cells were transfected with GFP-
PAK6 full-length and Myc-FilaminA and GFP alone. The cells were lysed and Myc beads used 
and immunoblotted for FilaminA using anti-Myc and PAK6 using GFP antibody representative of 
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5.2.6. FilaminA is expressed endogenously in breast cancer cell lines 	  
Although PAK1 has been reported previously to interact with FilaminA (Vadlamudi et al., 
2002b), this finding is a novel interaction for PAK6. An anti-FilaminA antibody was 
obtained from Gentex and detected band at the correct size for Myc-tagged FilaminA when 
overexpressed in MDA-MB-231 cells (Figure 5.9). Subsequently the antibody was tested for 
efficient detection of endogenous FilaminA in our chosen cells line (MDA-MB-231) and 
expression levels of FilaminA compared to normal non-tumorigenic MCF10A and MCF-7 
non-invasive breast cancer cells. The antibody was able to detect endogenous FilaminA 
expression in all three cell lines. Quantification results revealed no significant difference in 
the FilaminA expression levels between theses three cell lines (Figure 5.10). Having 
established the anti-FilaminA antibody works well in the MDA-MB-231 cell line, the 
interaction between PAK6 and FilaminA was explored further. MDA-MB-231 cells were 
transfected with full-length GFP-PAK6 and GFP-PAK6 kinase domain, proteins were 
isolated using GFP-TRAP beads and lysates were probed for the presence of endogenous 
FilaminA. Again endogenous FilaminA could be detected when full-length PAK6 was 
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Figure 5.9: Testing of FilaminA antibodies for detecting exogenous FilaminA. MDA-
MB-231cells were transfected with Myc-FilaminA and detected the expression of FilaminA 
using anti-FilaminA from Gentex and an anti-Myc antibody. Lysates were immunoblotted for 
β-actin as a loading control.  
 	   	  





















Figure 5.10: FilaminA expression in panel of breast cell lines. MCF-10A, MCF-7 or 
MDA-MB-231 whole cell lysates were immunoblotted for FilaminA expression using the 
anti-FilaminA antibody Gentex or the β-actin antibody, which was used as a loading control. 
Quantification results are representative of three independent experiments. Bars represent the 


































Figure 5.11: PAK6 interacts with FilaminA in MDA-MB-231 cells. A) MDA-MB-231 
cells were transfected with GFP-PAK6 full-length and GFP-PAK6 kinase domain. The cells 
were lysed and GFP-TRAP used. The samples were immunoblotted for endogenous 
FilaminA using FilaminA specific antibody and GFP antibody for exogenous PAK6. B) 
MDA-MB-231 whole cell lysate (WCL) was immunoblotted for endogenous FilaminA using 
FilaminA specific antibody and GFP for exogenous PAK6. The blots are representative of 
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5.2.7. Co-expression of FilaminA and PAK6 induces morphological 
changes in MDA-MB-231 cells  	  	  
In chapter 3, wild type full-length PAK6 overexpression did not induce cell morphology 
changes in MDA-MB-231 cells (Figure 3.18). Given that an interaction between FilaminA 
and PAK6 was observed in these cells (Figure 5.8), the effect of overexpressing wild type 
FilaminA alone or in combination with overexpressed PAK6 on cell morphology was 
investigated. Overexpression of GFP-FilaminA or GFP alone demonstrated that there is no 
difference in cell morphology in cell expressing GFP alone (control) or GFP FilaminA 
(Figure 5.12). In contrast, co-expression of wild type full-length PAK6 and wild type 
FilaminA can induce a cell morphology change in MDA-MB-231 cells (Figure 5.13) which 
is reminiscent of that induced by overexpressing active PAK6 alone (Figure 3.18). Indeed, 
overexpression of wild type full-length PAK6 alone does not induce cell rounding (Figure 































Figure 5.12: FilaminA overexpression does not induce morphological changes in MDA-
MB-231 cells. MDA-MB-231 cells were transfected with GFP control or GFP-FilaminA 
alone Cells were then fixed and stained TIRIC phalloidin for F-actin. Shape analysis was 
performed on the cells using Image J to determine the elongation ratio.  Quantification results 
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Figure 5.13: FilaminA co-expression with PAK6 induces morphological changes in 
MDA-MB-231 cells. MDA-MB-231 cells were transfected with GFP control or GFP-
FilaminA alone or co-transfected with wild type RFP-PAK6. Cells were then fixed and 
stained with TRIC phalloidin for F-actin. Shape analysis was performed on the cells using 
Image J to determine the elongation ratio. Quantification results perform over three 
independent experiments. Bars represent the mean  ± S.E.M. Statistical significance 
compared with GFP control cells was calculated using Student’s t- test; ****, P < 0.0005. 
Scale bar = 10 µm.  
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5.2.8. FilaminA phosphorylation levels are elevated in the presence 
of PAK6 in MDA-MB-231 cells  	  
Having established that FilaminA interacts only with full-length PAK6 (Figure 5.8) but not 
the kinase domain of PAK6 alone, and co-expression of FilaminA and PAK6 induces cell 
rounding (Figure 5.13), the interaction between FilaminA and PAK6 was further explored. It 
is possible that FilaminA directly activates PAK6 to induce rounding or that the association 
between FilaminA and PAK6 scaffolds a PAK6 activator to the complex. Indeed, FilaminA 
is known to bind to IQGAP1 (Jacquemet et al., 2013) which in turn binds Cdc42 a known 
activator of PAK6. It is also possible that PAK6 could mediate regulation of FilaminA, and 
indeed it was reported that serine 2152 could be phosphorylated by PAK1 (Vadlamudi et al., 
2002b). The phosphorylation status of the serine 2152 residue in the catalytic domain of 
FilaminA is thought to be an indicator of FilaminA activity (Vadlamudi et al., 2002b). 
Moreover, serine 2152 phosphorylation has been shown to be required for PAK1-mediated 
membrane ruffling and for regulation of cellular migration by Ribosomal S6 Kinase (RSK), a 
key kinase in the Ras-MAPK pathway (Vadlamudi et al., 2002a). The kinase domain of 
PAK6 did not bind to FilaminA; nevertheless PAK6 could still influence FilaminA activity 
indirectly. Thus, the effect of PAK6 overexpression on the phosphorylation status of 
endogenous FilaminA serine 2152 was tested. Cells were transfected with wildtype GFP-
PAK6, kinase dead GFP-PAK6, GFP-PAK6 kinase domain alone or active GFP-PAK6 and 
lysates were probed with the serine 2152 phosphorylation specific antibody. Whilst 
overexpression of wildtype GFP-PAK6, GFP-PAK6 kinase dead, GFP-PAK6 kinase domain 
alone did not significantly elevate the level of FilaminA serine 2152 phosphorylation, there 
was a significantly different increase in the level of endogenous FilaminA serine 2152 
phosphorylation when cells were overexpressing active PAK6 (Figure 5.14). This result 




















Figure 5.14: Active PAK6 expression significantly increases FilaminA phosphorylation 
levels. MDA-MB-231 cells were transfected with Myc-FilaminA, GFP-PAK6, GFP-PAK6 
kinase domain, GFP-PAK6 kinase dead and GFP-Active PAK6. The cells were 
immnunoblotted for levels of pFilaminA at serine 2152, FilaminA alone, H90 as a loading 
control and GFP for detect the expression of PAK6. Quantification results for the expression 
of pFilaminA are representative of three independent experiments. Bars represent the 
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5.3. Discussion: 	  
In this chapter, RhoV, RhoU and RhoD were identified as PAK6 binding partners. Moreover, 
a novel interaction between PAK6 and FilaminA has been established in MDA-MB-231 
cells. Furthermore, whilst expression of PAK6 or FilaminA alone has no impact on cellular 
morphology, co-overexpression of wild type full-length PAK6 and FilaminA could induce 
cell rounding in MDA-MB-231 cells. Indeed, PAK6 indicating that might be a potential 
regulator of FilaminA activity.   
PAKs are among the best-characterised effectors of Rac and/or Cdc42 and are considered to 
play a critical role in regulating actin dynamics and cell adhesion during cell migration. 
(Whale, 2011, Wells and Jones, 2010). However, a role for PAK6 in cytoskeletal 
reorganization has not been reported outside this study. Based on the findings reported in 
Chapter 3 and 4, PAK6 may also influence actin cytoskeletal dynamics either via interaction 
with Cdc42 or potentially via other GTPases. It is well established that RhoGTPases mediate 
the regulation of the actin cytoskeleton including the formation of filopodia (Cdc42, RhoD 
and RhoV) (Tapon and Hall, 1997, Gad et al., 2012, Aronheim et al., 1998, Gasman et al., 
2003) or lamellipodia (Rac, RhoG) (Parri and Chiarugi, 2010, Katoh et al., 2006). Whilst 
RhoA can stimulate the formation actomyosin–mediated cell contraction, focal adhesion and 
stress fibres (Karlsson et al., 2009, Jaffe and Hall, 2005). RhoV via an interaction with PAK2 
is implicated in the control of the mitogen activated protein kinase (MAP kinase), c-Jun N-
terminal kinase (JNK) and reorganization of the actin cytoskeleton (Aronheim et al., 1998). 
More recently, it has been shown that PAK6 interacts with the atypical RhoGTPase, RhoV 
and RhoU (Shepelev and Korobko, 2012), which shares close sequence homology with 
Cdc42.  
In this study, PAK6 interacts with RhoV and RhoU which is consistent with previous work 
(Shepelev and Korobko, 2012). However, results presented here suggest that the interaction 
between RhoU and PAK6 is less efficient (Figure 5.3). Additionally, the pull down work 
described here identified a novel interaction between PAK6 and RhoD (Figure 5.4).  
PAK6 is known to bind to Cdc42 (Schrantz et al., 2004) and overexpression of Cdc42 is 
already known to induce cell rounding (Calvo et al., 2011) thus, the impact of overexpression 
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of RhoV, RhoU and RhoD on cell morphology was tested in MDA-MB-231 cells. Whilst 
overexpression of RhoD and RhoV induced cell rounding, overexpression of RhoU did not 
induce cell rounding when compared to control cells (Figure 5.5). This observation may 
indicate that Cdc42, RhoV and /or RhoD are more likely to interact with PAK6 to induce the 
cell rounding phenotype. Indeed, the PAK6 interaction with RhoU was not as robust as 
RhoV, although overexpression of RhoU in NIH3T3 cells can reduce stress fibres formation 
and induces a rounded cell morphology (Saras et al., 2004).  
Much less is known about the activity of RhoD in cells.  It is reported that RhoD binds to a 
diaphanous-related formin splice variant of Dia2 known as hDia2C, which specifically binds 
RhoD and has been shown to play a key role in the motility of endosomal vesicles (Gasman 
et al., 2003). Moreover, RhoD has been found to interact with the Semaphorin receptors 
PlexinA1 and PlexinB1 and components of the TGF-β signalling pathway. However, the 
physiological significance of these interactions has not been established (Tong et al., 2007, 
Barrios-Rodiles et al., 2005, Hota and Buck, 2009, Zanata et al., 2002). In addition, RhoD 
has been shown to induce actin stress fibres and focal adhesion dissolution and this was 
explained to be caused by the ability of RhoD to counteract RhoA-dependent stress a fibres 
formation (Murphy et al., 1996, Tsubakimoto et al., 1999). Another identified RhoD effector 
is FILIP1, which is a filamin interacting protein that regulates actin cytoskeletal dynamics 
and cell migration via FilaminA mediated pathways (Gad et al., 2012). Thus, it could be 
speculated that PAK6 mediated cytokeletal changes may be mediated via a RhoD/FilaminA 
complex. In contrast to RhoD, RhoV has been linked to junctional dynamics through 
interactions with the Arhgef7b(β-Pix)/Pak complex and cadherin proteins. Moreover, RhoV 
is essential to stabilize the E-cadherin/β-catenin complex at adherens junctions (Fort et al., 
2011a, Tay et al., 2010).  
 
Furthermore, expression of RhoV induces focal adhesion assembly, lamellipodia formation 
and oncogenic transformation of mouse NIH3T3 fibroblasts (Aspenström et al., 2004, 
Chenette et al., 2005, Chenette et al., 2006). However, RhoV is not closely associated with 
cell rounding outside this study.  
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As well as Rho Family GTPases, FilaminA was also identified as an N-terminal binding 
protein via mass spectrometry (Figure 5.8). FilaminA is known to bind to Cdc42 (Ohta et al., 
1999), as well as the RhoD binding protein FILIP1 (Gad et al., 2012), thus, this protein could 
provide a platform for interaction between PAK6 and RhoFamily GTPases. In addition, it is 
also possible that FilaminA is a downstream effector of PAK6 or is acting via IQGAP1, 
which also binds to Cdc42 (Gad et al., 2012, Jacquemet et al., 2013). Studies here have 
demonstrated that PAK6 and FilaminA co-operate to drive cell rounding, moreover 
expression of PAK6 leads to increased levels of FilaminA phosphorylation at serine 2512.  
 
Filamins are a family of cytoskeletal proteins that organise actin filaments into networks and 
link these actin networks to cell membranes. These properties of Filamin support cell 
adhesion and promote signalling systems by providing a scaffold for cytoskeletal proteins 
and various signalling proteins (Stossel et al., 2001, Popowicz et al., 2006). It is already 
known that FilaminA interacts with PAK1 via the CRIB domain, which appears to be 
sufficient to release autoinhibition thereby stimulating PAK1 activity (Vadlamudi et al., 
2002b). Conversely, FilaminA has been placed downstream of PAK1 where PAK1 
phosphorylation of FilaminA at serine 2512 leads to actin cytoskeletal rearrangements 
(Vadlamudi et al., 2002b), thus although FilaminA did not bind to the kinase domain of 
PAK6, the increase of FilaminA serine 2512 phosphorylation in the presence of PAK6 could 
be significant in terms of the cell rounding phenotype. FilaminA also binds to IQGAP1 in a 
complex that acts downstream of β1 integrin activation following fibronectin integrin 
engagement, here FilaminA and IQGAP1 suppress Rac1 activity (Jacquemet et al., 2013). 
This interaction could account for the cell morphology changes observed when wild type 
PAK6 and FilaminA are co-expressed.  
 
 
In the co-expressing cells perhaps the complex is acting downstream of β1 integrin activation 
to suppress Rac and activate the RhoA pathway, which induces cell contractility and 
subsequent cell rounding. Alternatively, FilaminA binds to FilGAP, that is also reported to 
act downstream of ROCK to inactivates Rac. Thus, again an interaction with FilaminA could 
bring PAK6 and RhoD together to suppress Rac and activate RhoA pathways. Indeed, it is 
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suggested that FilGAP is a mediator of RhoA antagonism to; suppressing leading edge 
protrusion and promoting cell retraction to achieve cellular polarity (Ohta et al., 2006b, 
Nakamura et al., 2009).  
 
Supporting evidence for a functional interaction between PAK6 and FilaminA comes from 
androgen receptor studies. Both PAK6 and FilaminA directly interact with the androgen 
receptor (AR), regulating nuclear translocation and transcriptional action of AR in prostate 
cancer cells (Loy et al., 2003, Ozanne et al., 2000, Yang et al., 2001).   
The interaction between PAK6 and FilaminA could also have relevance in terms of c-Met 
signalling. Previous work has demonstrated that PAK6 autophosphorylation is elevated 
downstream of HGF in prostate cancer (Fram et al., 2014), and it has recently been reported 
that c-Met triggered FilaminA phosphorylation at serine 2152 in HEK293 cells, or gastric 
cancer cells MKN-45 or GTL-16 cells, and that phosphorylation is lost upon inhibition of c-
Met kinase activity. Moreover, the c-Met activation was correlated with cell rounding (Mai et 
al., 2014). However, in breast cancer cells no evidence of increased PAK6 
auotphosphoryaltion was detected following c-Met activation (Figure 3.6 and 3.8). Thus it 
will be interesting to further investigate the relationship between PAK6, FilaminA and c-Met 
signalling pathways.  
 
In summary, work here has demonstrated that there is a functional relationship between 
PAK6 and Filamin that cooperates to induce cell rounding. PAK6 binds to FilaminA and 
could be a potential regulator of FilaminA activity, given that PAK6 can drive Filamin 
phosphorylation. Alternatively, FilaminA through its interaction which potential regulators of 
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5.4. Future work  	  	  
It will be important to establish which, if any of the Rho family GTPases influences PAK6 
activity and induction of induced cell rounding. This could be investigated by reducing 
RhoGTPase expression in cells prior to overexpression of active PAK6. Additional 
experiments are required to establish if PAK6 binding to the Rho Family GTPases influences 
PAK6 localisation and activity. 
It would be interesting to further explore the interaction between PAK6, RhoD and 
FilaminA, including a consideration of FILIP1. The limitations of using co-
immunoprecipitation techniques to investigate protein-protein interactions do not confirm 
that the identified proteins pulled down together are in fact interacting directly. For example, 
PAK6 may be in a binary complex with other `proteins. Alternative approaches to establish 
direct protein-protein interactions and explore these interactions further would include yeast 
two-hybrid screening and fluorescence resonance energy transfer (FRET). 
Time constraints prevented the expansion of PAK6 studies to cell migration but future work 
could include an exploration of how the PAK6:FialminA functional interaction identified 
here could impact on cell migration or invasion  using techniques such as time-lapse 























Concluding Remarks  
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6. Chapter 6: Concluding Remarks  
 
The establishment of metastases in sites distant from the primary tumours is the leading 
cause of mortality in cancers (Valastyan and Weinberg, 2011), including breast cancer 
(Rahman and Mohammed, 2015). Indeed, although there are many effective treatments for 
breast cancer, a significant proportion of patients experience relapse and incurable metastatic 
disease (Higgins and Baselga, 2011). Therefore, identifying the proteins that regulate 
metastasis is crucial to designing therapeutic strategies that target this last stage of tumour 
progression. This study focused on invasive breast cancer and posed the question of whether 
PAK6 regulates cytoskeletal changes involved in breast cancer progression. Whilst there is 
already considerable evidence that PAK6 plays a role in prostate cancer progression, there is 
no study investigating PAK6 in breast cancer progression, with the exception of one study 
suggesting that there is a high level of PAK6 expression in breast cancer cell lines (Kaur et 
al., 2008b). This present study demonstrated that PAK6 is indeed expressed in a range of 
breast cancer cell lines, including cells derived from invasive breast cancer (Figure 3.3). 
Furthermore, using the highly invasive MDA-MB-231 cell line the study demonstrated that 
specifically overexpression of active PAK6 induced cell rounding (Figures 3.17 and 3.18). In 
direct contrast, siRNA-mediated depletion of PAK6 induced cell elongation (Figures 4.3 and 
4.4). These cell morphology data were also phenocopied using pharmacological inhibition of 
PAK6 expression with Panobinstat (Figure 4.8). This study clearly demonstrated the 
important and specific role of PAK6 in mediating cell morphological changes. 
The two cellular morphologies reported in this study: rounded and elongated. It is generally 
accepted that cancer cells have the potential to shift between an amoeboid (rounded) 
morphology and a mesenchymal (less-rounded) morphology during migration through 
matrix, and these two motility types are thought to allow cells to adapt to the environmental 
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Indeed, the amoeboid morphology is routinely linked to increased invasion potential (Gadea 
et al., 2008). Work presented here might suggest that PAK6 activity could promote a more 
rounded morphology. The rounded amoeboid mode of migration is characterised by high 
levels of actomyosin contractility (Wilkinson et al., 2005a) thought to be mediated through a 
Rho-ROCK pathway, and the more extended mesenchymal mode of migration is associated 
with increased levels of Rac signalling and a suppression of Rho (Friedl and Wolf, 2003, 
Wolf et al., 2003). This study speculates that PAK6 could be involved in the rounded 
morphology, thus supporting the Rho-ROCK pathway (Sahai et al., 2007, Sanz-Moreno et 
al., 2008, Friedl and Alexander, 2011). In support of this hypothesis, data presented here 
suggests that by inhibiting RhoA signalling, either directly, with the Rho-specific inhibitor 
C3, or indirectly by inhibiting the RhoA effector kinase, ROCK significantly impairs active 
PAK6 induced cell rounding and significantly induces cell elongation (Figures 4.10 and 
4.11). The Rho-ROCK pathway is thought to converge on Myosin II; however, using Myosin 
II inhibitors did not prevent active PAK6 induced cell rounding. Therefore, how PAK6 
drives contractility via Rho/ROCK remains to be elucidated.  
Interestingly, ROCK is not only involved in the activation of myosin II, but is also required 
for activation of FilGAP, which suppresses Rac activity (Ohta et al., 2006b). Therefore, it 
could be speculated that an alternative pathway downstream of PAK6 and ROCK, such as 
FilGAP, could promote cell rounding. FilGAP is phosphorylated by ROCK, and this 
phosphorylation stimulates its RacGAP activity (Ohta et al., 2006a, Nakamura, 2013). 
Overexpression of FilGAP induces cell rounded and blebbing amoeboid morphology, which 
requires Rho–ROCK-dependent phosphorylation of FilGAP (Nishi et al., 2015, Saito et al., 
2012), whereas depletion of endogenous FilGAP induces a Rac-driven elongated 
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It has been reported that FilGAP contributes to the regulation of the transition from 
mesenchymal to amoeboid (Saito et al., 2012). More importantly, it has been shown that 
FilGAP binds to the FilaminA, and this interaction is thought to promote GAP activity (Ohta 
et al., 2006a, Guilluy et al., 2011).  
This study used mass spectrometry analysis of breast cancer cell lysates to identify FilaminA 
as a novel PAK6 binding partner (Table 5.1). Subsequently, this binding was validated using 
GFP-TRAP (Figure 5.8). Interestingly, whilst expression of either wild type PAK6 or wild 
type FilaminA alone did not induce cell rounding, co-expression of the wild type proteins led 
to a significant increase in rounded cells (Figure 5.13), suggesting that PAK6 and FilaminA 
may co-operate to induce increased cellular contractility; indeed, FilaminA may activate 
PAK6 as it binds in the putative N-terminal regulatory region (Figure 6.1). Phosphorylation 
of FilaminA at serine 2512 by PAK1 is thought to promote functionality at membrane 
ruffles; however, this study confirmed that FilaminA does not bind to the kinase domain of 
PAK6. Although, there is no interaction between FilaminA and the PAK6 kinase domain, an 
increase in FilaminA serine 2512 phosphorylation was observed in the presence of active 
PAK6. Therefore, it is important to further elucidate the role of FilaminA serine 2512 
phosphorylation in the context of PAK6 activity.    
Interestingly, both PAK6 and FilaminA activity have been associated with c-Met signalling, 
in which overexpression of c-Met triggered FilaminA phosphorylation, which correlated with 
cell rounding (Mai et al., 2014). However, in breast cancer cells, no evidence of increased 
PAK6 autophosphorylation was detected following c-Met activation (Figure 3.7). 
Furthermore, using PAK6 serine 560 phosphorylation as a marker of activity is now disputed 
(Fram et al., 2014) and it might be prudent to revisit c-Met PAK6 signalling  in breast cancer 
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Previous work has suggested that PAK family kinase activity and/or localisation may be 
regulated via interaction with Rho family GTPases. Prior to this study PAK6 was known to 
interact with Cdc42 but not Rac or RhoA (Schrantz et al., 2004). Furthermore, a single study 
had suggested that PAK6 might also bind to RhoU and RhoV (Shepelev et al., 2011). This 
study confirmed here that PAK6 could bind to RhoV, RhoU and Cdc42. In addition, this 
study identified a novel interaction between RhoD and PAK6. Cdc42 overexpression has 
been reported to induce cell rounding (Gadea et al., 2008).  
Further experiments here suggest that RhoV and RhoD were also able to induce the cell 
rounding phenotype observed in cells overexpressing activated PAK6. At this stage, it is not 
possible to assign a specific PAK6 and RhoGTPase interaction with the cell rounding 
phenotype. However, It has been reported that RhoD, via binding to FILIP1, which is a 
protein that interacts with FilaminA, can control actin dynamics and, thus, cell attachment 
and cell migration (Gad et al., 2012). Therefore, it could be speculated that PAK6 mediated 
cytoskeletal changes may be mediated via a RhoD/FilaminA complex. 
In conclusion, a specific role for PAK6 in mediating cell morphological changes using 
overexpression and knockdown strategies has been identified. Evidence has been presented 
to support a hypothesis whereby PAK6 can mediate increased cell contractility (cell 
rounding) by modulating activation of the RhoA:ROCK pathway via a novel interaction with 

















Figure 6.1: Proposed model of PAK6 and FilaminA binding partner in regulation the 
change of cell morphology in breast cancer. Schematic illustrating data gathered 
throughout this study provides indication that PAK6 lies downstream of RhoA and ROCK to 
promote cell contractility. PAK6 has been shown to bind to FilaminA, which bind to FilGAP 
a suppresser of Rac activity and promote cell contractility. Overexpression active PAK6 
induced cell rounding. Moreover, inhibit the active PAK6 form significantly induce cell 
elongated upon ROCK and RhoA inhibitors. In direct contrast, siRNA-mediated depletion of 
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7. Chapter 7: Appendix 	  
7.1. Generation of PAK6 isoform specific rabbit polyclonal antibody 	  
PAK6 is one of the least characterised members of the PAK family. At the start of my 
project, a PAK6 specific antibody was commercially available from Calbiochem, and had 
been validated by our group (Fram et al., 2014), but unfortunately this PAK6 antibody was 
discontinued and no longer available. Consequently, a novel PAK6 antibody was made using 
human PAK6 sequences that might be exposed on the surface of the protein (Figure 7.1). 
This antibody is subsequently referred to as in-house PAK6 antibody. 
PAK6 contains 681 amino acids and the antibody was made to recognise a region of PAK6 
outside of the kinase domain. Potential PAK6 sequences were compared with the sequences 
of other group II PAKs and group I PAKs to identify regions in PAK6 that are unique. 
Protscale software (available on the Expasy website at http://web.expasy.org/protscale) was 
used to identify the suitable peptide sequence on PAK6 for antigen recognition. Two 
different scales (Hopp & Woods, and Kyte & Doolittle) were used to assess the 
hydrophobicity and the hydrophilicity profiles of PAK6 sequences (Figure 7.1). The most 
ideal antigenic epitopes are hydrophilic, as these regions tend to be found on the surface of 
proteins and are available for antibody recognition, whereas hydrophobic regions maybe 
hidden in the protein interior.  
 
Subsequently, amino acids sequences between 181-350 are the most suitable and are unique 
to PAK6 (Table 7.1). The ideal length of immunizing peptide sequence is 10-20 amino acids 
for antibody preparation (Hancock and OReilly, 2005). This reflects the fact that sequences 
above 20 amino acids in length might lose specificity and induce a secondary reaction, 
conversely if the peptide is too short, it could be non-specific and not recognise the protein 
with sufficient affinity. Four putative peptides were sent to the Custom peptide antibody 
production services at Eurogentec (Table 7.1). They recommended GRPGGEGSPSPKTRE 
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and QSKPNSSFRPPQKD. The peptide sequence QSKPNSSFRPPQKD was preferred to 
correspond and this chosen sequence to amino acid 284-298 of the PAK6 protein, located on 
the N-terminal regulatory domain. The Basic Local Alignment Search Tool (BLAST, 
http://blast.ncbi.nlm.nih.gov/) was used to check for all PAK and other proteins, which 
contain similar peptide sequence, and may also interact with the antibody designed. The 
search using protein BLAST indicated that this peptide sequence was specific for PAK6. The 
peptide identified was manufactured and inoculated into rabbit hosts for polyclonal antibody 
production by Eurogentec Ltd. 
 
 Table 7.1: The sequences of PAK6. Four sequences between 181-350 are the most suitable 
and are unique to PAK6 using two different scales (Hopp & Woods, and Kyte & Doolittle) to 





















Figure 7.1: Generation of the in-house PAK6 antibody. A) Hopp and Woods hydrophobicity 
/hydrophilicity profile of PAK6 protein was used for epitope selection (as indicated it in the box). 
B) Epitope used for antibody presentation (as indicated in the box) within the N-terminal 
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7.2. Validation of the in-house PAK6 antibody  	  
Previous studies have shown that endogenous PAK6 is expressed in DU145, HT29 and 
MDA-MB-231 cells (Fram et al., 2014, Kaur et al., 2008b). To validate the specificity of in-
house PAK6 antibody, lysates from cells overexpressing GFP-PAK4, GFP-PAK5 and GFP-
PAK6 were tested. The in-house PAK6 detected GFP-PAK6, but not GFP-PAK4 or GFP-
PAK5 (Figure 7.2). The whole cell lysates were also probed with a GFP-specific antibody to 
confirm that all three PAK proteins were expressed (Figure 7.2). The ability of the in-house 
PAK6 antibody to detect endogenous PAK6 was also tested, and western blotting 
experiments showed that the antibody was not able to detect an endogenous protein band at 
correct size. The PAK6 in-house antibody was therefore able to specifically detect 
transfected PAK6, but did not appear to detect endogenous PAK6 expression of the correct 
apparent size. During antibody development, a new commercial anti-PAK6 antibody became 




























Figure 7.2: Validation the PAK6 in-house antibody. Testing the in-house PAK6 antibody. 
HEK293 cells overexpressing GFP-PAK6, GFP PAK5 and GFP-PAK4 were lysed and 
immunoblotted for PAK6 expression using a PAK6 in-house antibody. PAK6 in-house 
antibody detects GFP-PAK6 but not GFP-PAK4 or GFP-PAK5. Lysates were also 
immunoblotted for β-actin as a loading control. The blot shown is representative of three 
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